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1. ABSTRACT 
Background: Disturbed endothelial barrier function is a hallmark of 
inflammation. Effusion of protein rich plasma fluid leading to edema formation 
and overshooting transmigration of leukocytes contribute to severe organ 
dysfunction under conditions of generalized inflammation, e.g. acute lung injury 
and sepsis. The peptide hormone Adrenomedullin (ADM) and its receptor 
(CRLR/RAMP2/3) constitute an important signaling system for the protection of 
endothelial barrier function. Although elevation of cAMP in endothelial cells was 
identified as signaling pathway of ADM responsible for barrier protection, it was 
speculated that other mechanisms are involved and precise intracellular 
signaling routes have not been explored, yet. 
Main findings and conclusions: ADM was confirmed to be a strong stabilizer 
of the endothelial barrier function in vitro, preventing and reversing 
hyperpermeability independent of the inflammatory stimulus (as determined by 
electrical impedance and FITC-dextran permeability measurements after 
stimulation with thrombin, TNFα, histamine, VEGF). Moreover, it was shown for 
the first time that ADM inhibited TNFα-induced granulocyte transmigration which 
was solely due to effects of ADM on endothelial cells. These in vitro-findings 
could be translated to animal models of vascular permeability and inflammation: 
ADM dose-dependently reduced vascular permeability in the skin of mice and 
rats (Miles assay; stimulus histamine). In a murine lipopolysaccharide (LPS)-
induced lung injury model, ADM reduced lung edema and leukocyte 
extravasation.  
In endothelial cells, barrier protection could solely be reduced to cAMP signaling 
via the protein kinase A (PKA) and Epac-Rap1 pathways (dose response 
comparison with Forskolin). Dissection of the downstream cascade by means of 
cAMP analogs, specific for PKA and Epac-Rap1 signaling (benz-cAMP and 
“007”, respectively), demonstrated that both pathways are with respect to their 
efficacy equally involved in effects on permeability probably addressing 
independent effector mechanisms as suggested by enhanced efficacy of 
combination of both. Consistently, both pathway activators prevented vascular 
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hyper-permeability in vivo. PKA activation and inhibition of MLC phosphorylation 
downstream of ADM diminish stimulus induced actin stressfiber formation and 
contraction of endothelial cells thus counteracting intercellular gap formation 
and hyperpermeability. Most notably, also effects independent of the contractile 
apparatus were demonstrated: ADM stabilized barrier function even in the 
absence of a functional actin cytosceletton after treatment with Cytochalasin D 
and knockdown of cortactin. ADM induced stabilization of VE-cadherin at the 
cell borders and increased the amount of detectable VE-cadherin/VE-PTP 
complex which is important for the regular function of VE-cadherin. 
In contrast, granulocyte transmigration was only reduced by PKA activation and 
ADM effects were lost after knockdown of cortactin. In line with this finding, a 
PKA inhibitor abolished the effect of ADM. As PKA activation reduces myosin 
light chain phosphorylation these data collectively link leukocyte extravasation 
to the contractile apparatus of the endothelial cell. As “007” was fully active with 
respect to TNFα induced hyperpermeability but had no effect with respect to 
granulocyte transmigration, endothelial hyperpermeability per se is not a 
prerequisite for granulocyte transmigration. 
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2. ZUSAMMENFASSUNG 
Hintergrund: Die Störung der endothelialen Schrankenfunktion ist ein 
Haupkennzeichen der Entzündung: Die Bildung von Ödemen durch den Austritt  
Protein-reicher Plasamaflüssigkeit und überschießende Auswanderung weißer 
Blutzellen ins Gewebe tragen zu schwerer Organfehlfunktion bei generalisierten 
Entzündungszuständen bei, wie z.B. im akuten Lungenversagen und der 
Sepsis. Das Peptidhormon Adrenomedullin (ADM) und sein Rezeptor 
(CRLR/RAMP2/3) stellen ein wichtiges Singalsystem dar, das die endotheliale 
Schrankenfunktion stabilisiert. Einer Erhöhung des cAMP-Spiegels wurde 
hierfür als Signalweg von ADM in Endothelzellen identifiziert. Daneben wurde 
aber auch die Existenz andere Mechanismen vermutet. Bislang sind die 
intrazellulären Signalwege von ADM in der endothelialen Schrankenfunktion 
noch nicht präzise untersucht worden. 
Hauptbefunde und Schlußfolgerungen: Es konnte bestätigt werden, dass 
ADM in vitro als starker Stabilisator der endothelialen Schrankenfunktion wirkt, 
indem es unabhängig vom verwendeten Entzündungsstimulus 
Hyperpemeabilität verhindert bzw. aufhebt (detektiert als elektrische Impedanz 
und Permeabilität für FITC-Dextran nach Stimulation mit Thrombin, TNFα, 
Histamin und VEGF). Darüber hinaus konnte erstmals gezeigt werden, dass 
ADM auch die durch TNFα-induzierte Transmigration von Granulozyten 
verhindert – ein Effekt der ausschließlich durch Wirkung von ADM auf das 
Endothel zustande kommt. Diese In vitro-Ergebnisse konnten auch in 
Tiermodellen für vaskuläre Permeabilität und Entzündung abgebildet werden. 
Mit ADM vorbehandelte Mäuse und Ratten zeigten dosisabhängig eine 
reduzierte Gefäßpermeabilität in der Haut (Miles-Assay mit Histamin als 
Stimulus). Darüber hinaus konnte eine Verringerung der Ödembildung und der 
Rekrutierung neutrophiler Granolozyten in der Lunge in einem murinen 
Lipopolysaccharid (LPS)-induzierten Lungenschädigungs-Modell gezeigt 
werden. 
In Endothelzellen konnte der die Schrankenfunktion steigernde Effekt von ADM 
ausschließlich auf den cAMP-Signalweg zurückgeführt werden, und gezeigt 
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werden, dass sowohl der Protein-Kinase A als auch der Epac/Rap1 Signalweg 
aktiviert werden (Dosis-Wirkungs-Vergleich mit Forskolin). Mit Hilfe von cAMP-
Analoga die spezifische Aktivatoren der Proteinkinase A (PKA) bzw. 
Epac/Rap1-Signalwege sind (benz-cAMP bzw. “007”) wurde die funktionelle 
Bedeutung der Signalwege analysiert. Die maximalen Effekte beider 
Signalwege in der Regulation der endothelialen Permeabilität sind zwar 
vergleichbar stark, laufen aber wahrscheinlich über unterschiedliche 
Effektormechanismen ab, da die Kombination beider Wege zur Verstärkung 
führt. Übereinstimmend mit dem in vitro-Befund verhinderten beide cAMP-
Analoga die Gefäß-Hyperpermeabilität in vivo. Durch Aktivierung des PKA 
Signalweges und Hemmung der MLC Phosphorylierung reduziert ADM die 
Stimulus-induzierte Bildung von Aktin Stressfibers und die Kontraktion von 
Endothelzellen und wirkt so der Bildung interzellulärer Lücken und der daraus 
folgenden Hyperpermeabilität entgegen. Bemerkenswerter Weise konnten auch 
Effekte, die unabhängig vom kontraktilen Apparat waren, gezeigt werden: ADM 
stabilisiert die Schrankenfunktion sogar in der Abwesenheit eines funktionellen 
Aktin-Cytoskeletts nach Behandlung mit Cytochalasin D und Knockdown von 
Cortactin. ADM induziert die Stabilisierung von VE-Cadherin an den Zell-Zell 
Kontakten und die Menge des nachweisbaren VE-cadherin/VE-PTP 
Komplexes, der wesentlich für die korrekte Funktion von VE-Cadherin ist. 
Im Gegensatz dazu wurde die Granulozytentransmigration nur durch die PKA-
Aktivierung gehemmt – ein Effekt der nach Knockdown von Cortactin 
aufgehoben war. Im Einklang mit diesem Befund hebt die Inhibition von PKA die 
Wirkung von ADM auf die Granulozytentransmigration auf. Da PKA-Aktivierung 
die Phosphorylierung der MLC hemmt, wird durch diese Befunde insgesamt die 
Abhängigkeit der Granulozytentransmigration vom kontraktilen Apparat der 
Endothelzelle deutlich. Da andererseits “007” die gestörte Schrankenfunktion 
aufhebt aber keinen Effekt auf die Transmigartion ausübt, ist eine gestörte 
Schrankenfunktion an sich (Hyperpermeabilitä) keine Voraussetzung für die 
Granulozytentransmigration. 
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3. INTRODUCTION 
The vascular endothelium represents a semipermeable barrier between blood 
and tissue which is important for tissue homeostasis by regulating the exchange 
of plasma fluid, electrolytes, proteins and cells. Endothelial barrier dysfunction is 
a hallmark of acute and severe inflammatory conditions associated with trauma, 
thrombosis, stroke, ischemia–reperfusion injury, sepsis, and acute lung injury 
(ALI/ARDS), but also relevant in the course of more chronic conditions such as 
diabetes and cancer. Increased microvascular permeability leads to plasma 
effusion and leukocyte extravasation, giving rise to tissue edema formation and 
eventually fatal organ dysfunction. Although the pathophysiology is well known 
for many years, a causative therapy to directly improve endothelial barrier 
function in inflammation is still not available (Temmesfeld-Wollbrück et al., 
2007).  
 
Adrenomedullin (ADM) was first discovered as a 52-amino-acid peptide from 
phaeochromocytoma that increased cAMP levels in a thrombocyte assay and 
was vasorelaxant when administered to rats (Kitamura et al., 1993). ADM is a 
multifunctional peptide which is able to act as an autocrine, paracrine, or 
endocrine mediator in many important and interrelated biological functions, such 
as in vascular tone regulation, fluid and electrolyte homeostasis and regulation 
of the reproductive system (Brain & Grant, 2004). More recent studies reveal 
the importance of ADM in systemic inflammatory response, particularly by 
improving endothelial barrier function thus establishing an organ protective 
effect in animal models of sepsis (Allaker et al. 2005; Zudaire et al., 2006). 
 
In the following three chapters, the present knowledge from literature is briefly 
summarized with respect to the biological function and regulatory effects of 
ADM in pathological conditions, particularly direct effects on endothelium in 
response to inflammation. Under this focus the knowledge is further reviewed 
with respect to the regulation of endothelial permeability as well as 
transendothelial migration of leukocytes. 
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3.1. Adrenomedullin (ADM) 
3.1.1. Structure and distribution of ADM 
Adrenomedullin was first discovered as a peptide from the lysate of an adrenal 
phaeochromocytoma that increased cyclic adenosine monophosphate (cAMP) 
levels in a thrombocyte assay and was vasorelaxant when administered to rats 
(Kitamura et al., 1993). The 52-amino-acid peptide belongs to the calcitonin 
superfamily of peptides, which also includes calcitonin, calcitonin gene-related 
peptide (CGRP), amylin, and intermedin (Muff et al., 1995; Wimalawansa, 
1997). The amidation at the C-terminus by peptidylglycine alpha-amidating 
monooxygenase (PAM) and the 6-amino acid ring structure formed by an 
intramolecular disulphide bond between residues 16 and 21 are essential for 
the receptor binding of ADM and for its biological activity (Eguchi et al., 1994). 
ADM22-52 lacking the intramolecular disulphide ring can only bind to ADM 
receptor without biological activity and is used as ADM receptor antagonist 
(Eguchi et al., 1994).  
 
The ADM gene encodes a 185-amino acid preproADM (Figure 1). After 
cleavage of a 21-residue N-terminal signaling peptide, preproADM is converted 
into a 164-amino acid proADM peptide, which is a precursor of two biologically 
active peptides, namely ADM and proADM N-terminal 20 peptide (PAMP) 
(Kitamura et al., 1994; Kitamura et al., 2002). Under normal healthy conditions, 
ADM circulates at low picomolar concentrations (2-10 pM) (Kitamura et al., 
1994; Suzuki et al., 2004) in the plasma in two forms, a mature 52-amino acid 
peptide (mADM) and an immature glycine-extended 53-amino acid peptide 
(iADM), which is subsequently converted to mADM after enzymatic amidation 
(Kitamura et al., 1998; Asakawa et al., 2001). ). iADM represents 85% of total 
plasma ADM (Yamaga et al., 2003).  
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Figure 1 Structure of ADM and post-translational processing of preproADM gene 
(Modified from Hamid & Baxter, 2005) 
After cleavage of a 21-residue N-terminal signaling peptide from the initial 185-amino acid 
preproADM peptide, the 164-amino acid proADM peptide is converted, which is a precursor of 
two biologically active peptides, namely ADM and PAMP. Further degradation products derived 
from the ADM precursor or ADM are also listed.  
 
 
In the blood circulation, ADM is bound to ADM binding protein 1 (AMBP-1; also 
called complement factor H) which stabilizes the peptide (Elsasser et al., 1999; 
Pio et al., 2001). It is also reported that via its binding to AMBP-1 the receptor-
mediated effects of ADM are increased, while its receptor-independent 
antimicrobial activity is suppressed (Beltoeski & Jamroz, 2004). In addition, the 
inhibitory effect of factor H in alternative pathway of complement activation is 
enhanced via its binding to ADM. It is noteworthy that, neither CGRP nor PAMP 
binds complement factor H from plasma (Beltoeski & Jamroz, 2004).  
 
In humans and rats, circulating ADM is rapidly metabolized with the elimination 
half-life (T1/2) of about 20 min. However, little is known about its precise 
metabolism and clearance. ADM is metabolized by neutral endopeptidase and 
cleared in the pulmonary circulation (Lisy et al., 1998; Dupuis et al., 2005). 
Studies using intravenous administration of radioactively labeled ADM 
derivatives demonstrate a high first pass effect during the passage through the 
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lung vasculature, where 36% of a bolus is captured in dogs (Dschietzig et al., 
2002; Dupuis et al., 2005). Studies in rats show that more than 25% of the lung 
bound ADM can be displaced by non-labeled ADM, which proportion is 
therefore likely to be receptor bound. Moreover, ADM is present in human urine 
with about six-fold higher concentration than in human plasma, suggesting that 
a renal clearance may be also relevant in addition to pulmonary clearance (Sato 
et al., 1995). However, circulating ADM is cleared by neutral endopeptidase in 
kidney, located in the tubular brush border system, and the subsequent urinary 
excretion of ADM may be derived from renal production rather than from 
glomerular filtration (Lisy et al. 1998, Nishikimi, 2007). 
3.1.2. Receptors and intracellular signalling of ADM 
ADM exerts its biological actions through binding to the heterodimeric G-protein 
coupled receptor complex (GPCR) composed of the calcitonin receptor-like 
receptor (CRLR) associated with RAMP-2 (ADM-1 receptor) or RAMP-3 (ADM-
2 receptor). RAMPs bind to the receptor molecule in the endoplasmic reticulum 
and facilitate their translocation to the plasma membrane. Additionally, RAMPs 
regulate the degree of receptor glycosylation and play an important role in 
receptor specificity, ligand affinity, and receptor desensitization (McLatchie et 
al., 1998). Although the three isoforms of RAMPs show a differential tissue 
distribution, a pharmacological difference of ADM-1 and-2 receptor is not 
established yet (Chakravarty et al., 2000; Hagner et al., 2002). Besides ADM-1 
and -2 receptors, ADM can also mediate its effects via CGRP-1 receptor, 
especially in the vascular system (Dennis et al., 1990; Chiba et al., 1989). 
Indeed, ADM can bind to some regions in the brain where actually CRLR is not 
expressed, suggesting the existence of specific ADM receptors with a different 
molecular structure (Hinson et al., 2000).  
 
The cellular signaling mechanisms through which ADM mediates its biological 
effects vary among species, vascular beds and cell types, but mainly involve 
cAMP, nitric oxide (NO) and calcium-dependent mechanisms (Lopez & 
Martinez., 2002). Moreover, activation of different kinases, such as protein 
kinase A (PKA), Src, protein kinase C (PKC), p38 mitogen-activated protein 
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kinase (MAPK), and extracellular-signal regulated kinases (ERK), have been 
reported to be involved in ADM signaling. The combinations of various signaling 
may be responsible for numerous biological functions of ADM in different cell 
types (reviewed by Gibbons et al., 2007). 
3.1.3. Biological actions of ADM in response to inflammation 
The ADM gene is broadly expressed throughout most organs during embryonic 
development and adulthood, especially in endothelial cells, vascular smooth 
muscle cells, cardiac myocytes, and human leucocytes (Garayoa et al., 2002; 
Hinson et al., 2000). Moreover, in highly vascularized tissues, such as placenta, 
lung, heart, and kidney, levels of ADM tend to be relatively higher. Experimental 
data from literature underscore a role of ADM in a variety of functions, including 
blood pressure regulation, broncho-dilatation, renal function, hormone 
secretion, cell growth, differentiation, neurotransmission, and modulation of the 
immune response. Moreover, ADM plays a crucial role as autocrine factor 
during proliferation and regeneration of endothelial cells (reviewed by Ishimitsu 
et al., 2006; Gibbons et al., 2007). However, data from targeted deletion in mice 
of ADM or its receptor gene, point to another dominant function of this peptide 
in regulating vascular permeability. While heterozygous littermates show a mild 
hypertension (Shindo et al., 2000) and exhibit a more pronounced inflammatory 
response to endotoxin-induced septic shock (Dackor and Caron, 2007), 
homozygous knockout mice develop a strong and lethal hydrops fetalis (Caron 
and Smithies, 2001). A similar phenotype is further substantiated by data from 
knockout mice lacking CRLR or PAM genes (Dackor et al., 2006; Czyzyk et al., 
2005). Conversely, mice overexpressing ADM show moderate hypotension and 
are largely resistant to LPS induced shock (Shindo et al., 2000). 
 
Transcription of the ADM gene is stress sensitive. A variety of stimuli such as 
hypoxia, inflammatory stimuli (e.g. LPS), as well as pro-inflammatory cytokines 
(e.g. IL-1α, IL-1β, TNFα, and TNFβ) are shown to induce the expression of 
ADM (reviewed by Tammesfeld-Wollbrück et al., 2007). Accordingly, elevated 
plasma ADM levels have been detected in a wide variety of physiological and 
pathological conditions, including normal pregnancy and pregnancy with 
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complications, cardiovascular and pulmonary diseases, diabetes, endocrine 
disorders, hepatic and renal failure, cancer, and sepsis (reviewed by Gibbons et 
al., 2007). In their analysis, based on published human clinical data, Gibbons 
and colleagues compared fold change of plasma ADM in a variety of human 
conditions. One of the highest increases in plasma ADM levels occurred during 
sepsis, which evidences the importance of ADM under inflammatory conditions. 
Moreover, in animal studies, high expression of ADM was observed in the lung 
in endotoxaemia (Cheung et al., 2004) and in acute lung injury induced by 
hyperoxia and LPS (Agorreta et al., 2005). In a model of cecal ligation and 
puncture in rats, the small intestine was demonstrated to be an important 
source of ADM release during polymicrobial sepsis (Zhou et al., 2001). These 
observations raised the question as to whether elevated ADM levels reflect a 
protective defense mechanism rather than being of pathological significance. 
 
Meanwhile, there is strong evidence from the literature that administration of 
ADM to supra-physiological levels exerts strong anti-edematous effects: 
 
In vitro, using measurement of physiological hydrostatic pressure as indictor of 
endothelial permeability, ADM was shown to dose-dependently reduce 
hyperpermeability induced by different stimuli, such as thrombin, hydrogen 
peroxide, E. coli hemolysin, or S. aureus alpha-toxin, in endothelial cells from 
different species (human, rat, porcine) and different vasculatures (umbilical 
vein, lung pulmonary artery) (Hippenstiel et al., 2002; Hocker et al., 2006). The 
measurable increase of intracellular cAMP levels was supposed to be the key 
mechanism of action of ADM signaling. Inhibition of MLC phosphorylation via 
PKA activation was hypothesized to counteract and reduce endothelial 
contractility and to further stabilize endothelial barrier function (Hippenstiel et 
al., 2002). Moreover, ADM was shown to tighten blood brain barrier in terms of 
increased transendothelial electrical resistance (Kis et al., 2001; Kis et al., 2003; 
Honda et al., 2006). In ex vivo-models using hydrogen peroxide-exposed rabbit 
lungs and S. aureus α-toxin-infused rat ileums, ADM showed protective effects 
in those isolated organs (Hippenstiel et al., 2002; Brell et al., 2005; Hocke et al., 
2006).  
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Further in vivo- studies were in line with the results obtained in vitro and in 
isolated organs. ADM reduced the ovalbumin-induced airway microvascular 
leakage in an ovalbumin-sensitized guinea pig model (Ohbayashi et al., 1999). 
Intravenous infusion of ADM in rats protected against endotoxemia induced 
lung injury (Itoh et al. 2007). In a sheep model of endotoxemia induced lung 
injury, ADM reduced pulmonary hypertension and prevented hypodynamic 
circulation (Ertmer et al., 2007). ADM was shown to protect lung function 
significantly in models of oxygen and ventilator induced lung injury (Müller et al., 
2010; Tao et al, 2012).  
 
In a rodent model of Gram positive sepsis and in the severe model of coecum 
ligation and puncture (CLP) induced polymicrobial sepsis, ADM reduced 
vascular leakage and secondary lung damage, and prolonged survival (Hocke, 
et al, 2006; Temmesfeld-Wollbrück et al., 2007; Wu et al, 2008). In further 
models of polymicrobial sepsis (Wang, 2001; Yang et al., 2010; Gonzalez-Rey 
et al., 2006), endotoxin-related shock (Gonzalez-Rey et al., 2006) and 
hemorrhage (Cui et al., 2005) ADM showed beneficial effects on survival. 
 
In severe sepsis a loss of plasma ADM coincides with loss of AMBP (the 
complement factor-H) at the transition from the phase of hyperdynamic to 
hypodynamic circulation due to increased consumption of components of the 
complement system (Yang et al., 2002). A decrease of ADM plasma level in 
sepsis was believed to facilitate generalized edema formation and deterioration 
of cardiac function (Westphal et al., 2006). In the CLP-induced sepsis model, 
administration of ADM together with human complement factor-H significantly 
could halt transition to hypodynamic circulatory failure (Yang et al., 2002), while 
infusion of ADM stabilized cardiac output in endotoxemic sheep (Ertmer et al., 
2007). 
3.2. Regulation of vascular permeability 
Endothelial permeability is described as a passage through either one of two 
different routes: one transcellular (cross cells), via caveolae-mediated vesicular 
transport, and the other paracellular (between cells), through interendothelial 
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junctions. Although transcytosis plays an important role in the basal 
permeability of the endothelium, paracellular flux of plasma fluid and proteins 
through endothelial cell–cell junction is more dominant in the development of 
vascular inflammation under pathophysiological conditions (Komarova & Malik, 
2010; Mehta & Malik, 2006).  
3.2.1. Endothelial cell-cell junctions and vascular integrity 
Although endothelial cell-cell junctions are differently structured in different 
organs, the general constituent of endothelial cell–cell junctional structures, with  
major impact on cell-to-cell adhesion and barrier properties, are tight junctions 
(TJs) and adherens junctions (AJs). AJs represent the predominant type of 
junctions within the endothelial barrier, whereas TJs predominate in the 
epithelium (Vandenbroucke et al., 2008). In the endothelium, the TJs are 
interwoven with AJs over the lateral intercellular space differing from the 
structure in epithelium (Figure 2). The molecular structure of AJ as well as TJ is 
based on the homophilic interaction of transmembrane proteins between two 
adjacent cells. Specific cytosolic proteins link to the adhesion proteins 
anchoring them to the cell cytoskeleton and transducing cellular signaling. By 
way of this protein complex, cell-cell junctions influence the important cellular 
process, such as proliferation, polarity, protein expression, and permeability 
(Bazzoni & Dejana, 2004).  
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Figure 2 Endothelial cell-cell junctions  
In the endothelium, the tight junctions and adherence junctions are interwoven with each other 
over the lateral intercellular space. The tight junction proteins, claudins, occludins and JAMs, 
are linked to the intracellular actin cytoskeleton via zonular occludins (ZOs). The primary 
molecular structure of adherence junction is VE-cadherin-catenin complex linking directly or 
indirectly to actin cytoskeleton. 
 
 
Tight junctions are primarily found in blood-brain, blood-retinal, or blood-testis 
barrier microvasculature (Mehta & Malik, 2006; Hawkins & Davis, 2005). Tight 
junction resembles a zipper-like structure formed by homophilic interactions of 
transmembrane proteins, including occludin, claudins, and junction adhesion 
molecule (JAMs). These three TJ proteins represent the backbone for TJs. 
They are intracellularly connected to the actin cytoskeleton via zonular 
occludins (ZO-1; 2) (Bazzoni, 2006). Complex tight junctions as found e.g. in 
the blood brain barrier are responsible for a high transendothelial electrical 
resistance and are exclusively impermeable to the passage of solutes (Crone & 
Olesen, 1982). Although TJs are well developed in large artery endothelial cells 
that are exposed to high flow rates, TJs are less complex in capillaries than in 
arterioles, and even less in venules within the microvasculature (Wallez & 
Huber, 2008). 
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Adherens Junctions have been recognized as a critical component in regulating 
paracellular permeability of microvascular endothelium, with the exception of 
blood-brain barrier and blood-retinal barrier endothelium (Mehta & Malik, 2006). 
AJs have been identified in nearly all types of vascular beds, especially in the 
peripheral microvasculature. In the postcapillary venules, where leukocyte 
adhesion and inflammatory hyperpermeability selectively occur, beside AJs 
other types of junctions are poorly developed. The primary molecular structure 
of AJ is based on homophilic interactions of vascular endothelial cadherin (VE-
cadherin) (Figure 3). VE-cadherin is a transmembrane protein composed of five 
extracellular calcium–binding domains, one transmembrane domain and a 
cytoplasmatic tail domain (Vestweber, 2008). The hemophilic interaction of 
extracellular domains is calcium dependent. The intracellular domain is 
anchored to the cell cytoskeleton through binding with catenins (α, β, γ and 
p120) (Djana, 2004; Vestweber, 2008). This cytosolic connection to the 
cytoskleton is of importance for maintaining junctional strength and for the 
regulation of paracellular permeability (Yuan, 2002). It is hypothesized that 
through these junction-cytoskeleton connections, endothelial cytoskeletal 
contractile forces can be transmitted to cell–cell junctions and thus dynamically 
regulate endothelial permeability. Antibodies that inhibit the adhesion function of 
VE-cadherin cause dissociation of endothelial cell layers in vitro, enhanced 
accumulation of neutrophils in a peritonitis mouse model and lead to 
subcutaneous hemorrhage and death of mice (Vestweber et al., 2009). 
  
The stability and composition of the VE-cadherin-catenin complex is dependent 
on the status of cell contacts and regulated by tyrosine phosphorylation 
(Vestweber, 2008). In subconfluent cell culture where the endothelial cells are 
weakly connected to each other, β-catenin and p120 are infirmly linked to VE-
cadherin, and the protein components of this complex are highly 
phosphorylated. In contrast, in confluent cell culture where endothelial cells are 
strongly connected to each other, γ-catenins are predominant over β-catenins in 
VE-cadherin-catenin complex, and the phosphorylation of the components is 
reduced (Lampugnani et al., 1997; Lampugnani et al., 1995). The 
destabilization of cell contacts is accompanied by a decreased association with 
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γ-catenin and increased association with β-catenin (Lampugnani et al., 1995). 
The underlying mechanism is still not fully understood (Vestweber, 2008).  
 
Furthermore, there is correlation between tyrosine phosphorylation of various 
components of the VE-cadherin-catenin complex and the decrease of VE-
cadherin-mediated adhesion. Many vasoactive stimuli, such as histamine, 
thrombin, VEGF and TNFα, have in common that they induce phosphorylation 
of the VE-cadherin-catenin components and thus destabilize the complex 
(Angelini et al., 2006; Vestweber, 2008).  Thrombin is shown to cause 
disassembly of AJs via PKC-induced modification of VE-cadherin and β-catenin 
phosphorylation (Konstantoulaki et al., 2003). Vascular endothelial growth factor 
(VEGF) stimulation induces activation of Src-kinase and thus phosphorylation of 
VE-cadherin on the residue Serine 665, leading to α-arrestin-2 regulated 
internalization and loss of endothelial barrier function (Gavard & Gutkind, 2006). 
 
An important counteracting regulator of this phosphorylation is the vascular 
endothelial protein tyrosine phosphatase (VE-PTP), which is associated with 
tyrosine kinase receptor (Tie 2) and VE-cadherin. Docking of neutrophil 
granulocytes or lymphocytes on tumor necrosis factor (TNFα)-stimulated 
endothelial cells leads to dissociation of VE-PTP from VE-cadherin, (Nottebaum 
et al., 2008). Down-regulation of VE-PTP expression increases endothelial cell 
permeability, enhances leukocyte transmigration, and inhibits VE-cadherin-
mediated adhesion (Nottebaum et al., 2008). 
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Figure 3 Structure of VE-cadherin-catenin complex in endothelial cells 
The primary molecular structure of adherence junction is based on the homophilic interactions of VE-
cadherin. This transmembrane protein VE-cadherin consists from five extracellular domains, one 
transmembrane domain and a cytoplasmatic tail domain interactingwith catenins (α, β, γ and p120). VE-
cadherin is anchored to the cell cytoskeleton, whereas through binding its extracellular domains, VE-
cadherin can interact with other binding partners, such as VE-PTP. 
. 
3.2.2. Endothelial cytoskeleton and vascular permeability 
3.2.2.1. Dynamic functions of cytoskeleton and vascular permeability 
Similar to smooth muscle cells vascular endothelial cells are contractile cells 
developing forces driven by a mechanochemical interaction between actin and 
myosin (Figure 4). The increased actomyosin contractility is characterized by 
the formation of stress fibers, which are bundles of actin filaments associated 
with nonmuscle myosin II (Wojciak-stothard & Ridley, 2002). The key signal to 
trigger endothelial contraction is the phosphorylation of the regulatory part of 
myosin, the myosin light chain (MLC) (Dudek & Garcia, 2001; Tiruppathi, 2002). 
Phosphorylation of MLC induces conformational change of myosin, interacting 
with actin, sliding along actin filaments, subsequently causing contraction 
(Tiruppathi, 2002; Sandoval et al., 2001). This myosin-actin cross-bridge cycling 
provides a mechanical basis to develop contractile force in response to 
physiological and pathological stimulation and is the cause for generating and 
maintaining a centripetal tension (Yuan, 2002).  
 
VE-cadherin
p120-catenin
α-catenin
β-catenin
actin
VE-PTP
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In vascular endothelial cells, the phosphorylation status of MLC results from the 
balance of MLC kinase (MLCK) and MLC phosphatase (MLCP) (Garcia et al., 
1995). Firstly, MLCK phosphorylates MLC at Ser-19 and subsequently at Thr-
18, starting actomyosin-interaction thus generating centripetal forces which 
ultimately may be responsible for dissociation of cell-cell contacts and formation 
of interendothelial gaps (Moy et al., 1996). MLCK is activated in a 
Ca2+/calmodulin dependent manner and by tyrosine kinase-mediated 
phosphorylation at Tyr-464 and Tyr-471 (Goeckeler & Wysolmerski, 1995; 
Garcia et al., 1995). Secondly, MLCP dephosphorylates MLC as opposed to 
MLCK, decreases contractile forces, and subsequently relaxes the endothelial 
cytoskeleton (Verin et al., 1995). Finally, small GTPases of the Rho family are 
also involved in regulating the phosphorylation status of MLC (van Nieuw 
Amerongen & van Hinsbergh, 2001). RhoA, a member of the Rho family of 
small GTPases, can increase MLC phosphorylation indirectly by activating its 
downstream effector, Rho C-terminal kinase (ROCK), which subsequently 
phosphorylates and inhibits MLCP (Noda et al., 1995; Yoshioka et al., 2007). 
Besides the formation of actin stress fibers and the induction of contractile 
forces, activation of Rho and ROCK directly affects the destabilization of cell 
contacts (Wojciak-Stozhard & Ridley, 2002). In addition to RhoA, additional 
small GTPases of the Rho superfamiliy, Rac and Cdc42, are also implicated in 
actomyosin contractility, since their downstream effector, p21-activated kinase 
(PAK), phosphorylates MLC on Ser-19 (Goeckeler et al., 2000). 
 
MLC phosphorylation is involved in modulating endothelial barrier dysfunction in 
response to cellular mediators (e.g. activated neutrophils), as well as 
inflammatory agonists (e.g. thrombin, histamine, cytokines, oxygen radicals). 
Inhibition of MLCK by specific inhibitors (ML7 and ML9), prevents 
phosphorylation of MLC and stabilizes vascular permeability. Using 
fluorescence microscopic approaches, endothelial cells exposed to 
inflammatory stimuli present a morphological change characterized by 
increased staining of MLC phosphorylation accompanied with formation of 
stress fiber and intercellular gaps (reviewed by Yuan, 2002). 
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Figure 4  Contractile machinery and actin cytoskeleton in endothelial cells 
In vascular endothelial cells, the balance of MLCK and MLCP results in the phosphorylation 
status of MLC, inducing conformational change of myosin, subsequently interacting with actin, 
sliding along actin filaments, and causing contractility. Ca2+/calmodulin dependent activation of 
MLCK, RhoA-ROCK dependent inactivation of MLCP, as well as the small GTPases (Rac, and 
Cdc42) are implicated in phosphorylation of MLC and acto-myosin based endothelial 
contractility. 
 
 
3.2.2.2. Static functions of cytoskeleton in vascular permeability 
Besides the role of actin in the active contractile apparatus, disruption and 
rearrangement of actin cytoskeleton are of equal importance in the development 
of endothelial gaps (Baldwin & Thurston, 2001; Schnittler et al., 1990). Upon 
stimulation by inflammatory mediators and neutrophils, as well as during 
ischemia–reperfusion injury, actin directly undergoes polymerization and 
redistribution to form stress fibers followed by the formation of intercellular gaps 
(Korthuis et al., 1991; Schnittler et al., 1990; Shasby et al., 1982). However, 
those effects can totally be abolished by actin stabilization agents in vitro and ex 
vivo, such as phalloidin, antamanide, cytochalasin B, or cytochalasin D 
(Korthuis et al., 1991; Shasby et al., 1982). In a study using confocal 
microscopic analysis in rat mesenteric venules, the time course of development 
and recovery of histamine-induced venular leaks is coincident with the 
rearrangement of endothelial actin fibers (Baldwinand & Thurston, 1995). Local 
breaks in the peripheral actin rim of endothelial cells are accompanying 
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histamine-induced focal leaks and hyperpermeability, whereas the central actin 
fibers are involved in the structural and functional recovery phase rather than 
the hyperpermeability-inducing phase. (For review see Yuan, 2002; Schnittler et 
al., 1990). 
 
In addition to actin and myosin, microtubules, another important cytoskeletal 
component in endothelial cells, are also implicated in response to inflammatory 
stimuli (Mehta & Malik, 2006). Microtubule assembly is necessary for 
maintenance of actin-dependent barrier integrity (Vadenbroucke et al., 2008). In 
human pulmonary artery endothelial cells, TNFα- induced barrier disruption was 
shown to be independent of MLC phosphorylation and involved the 
destabilization of the microtubule network (Petrache et al., 2003). TNFα can 
induce a decrease in stable tubulin content and partial dissolution of peripheral 
microtubule network as detected by immunofluorescent analysis of acetylated 
tubulin and beta-tubulin (Petrache et al., 2003). Inhibitors of microtubule 
polymerization (e.g. nocodazole or vinblastine), disrupt endothelial barrier 
function associated with increased stress fiber content and MLC 
phosphorylation, whereas a microtubule stabilizer (paclitaxel) attenuates this 
effect (Verin et al., 2001). The increase of MLC phosphorylation and endothelial 
cell contractility are attributed to a RhoA/ROCK-dependent and MLCK-
independent mechanism (Verin et al., 2001).  More in-depth, the downstream 
effector of ROCK, LimK domain containing kinase 1 (LIMK1), is considered be 
of importance in regulating actin and microtubule assembly in a MLCK-
independent manner (Gorovoy et al., 2005; Verin et al., 2001). Taken together, 
microtubule destabilization may serve to amplify endothelial cell contractility 
(beyond that induced by myosin-actin cross-bridging), thereby inducing a 
profound endothelial hyperpermeability (reviewed by Vadenbroucke et al., 
2008).  
3.2.3. Role of cAMP in regulating vascular permeability 
The intracellular second messenger cAMP is involved in a multitude of 
biological functions, ranging from metabolism, gene expression, cell division 
and growth, cell differentiation and apoptosis, as well as secretion and 
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neurotransmission. So diverse essential physiological processes, such as 
learning and memory, contractility and relaxation of the heart, and fluid 
homeostasis in the gut and kidney are regulated by cAMP. Cyclic AMP 
mediated signaling is also involved in pathological conditions, such as diabetes 
mellitus, heart failure, and cancer (reviewed by Cheng et al., 2008).  
 
Binding of a ligand to a GPCR at the cell surface transduces the extracellular 
signal across the cell membrane via stimulatory or inhibitory heterotrimeric G-
proteins, interacting with the membrane-bound adenylate cyclase (AC), and 
regulates intracellular cAMP production. In eukaryotic cells, cAMP mediates its 
biological function via two ubiquitously expressed intracellular cAMP receptors, 
the classic protein kinase A (PKA) as well as the recently discovered exchange 
protein directly activated by cAMP (Epac). However, it is believed that cAMP 
mediates its biological function in mammalian cells predominantly via PKA. In 
addition cyclic nucleotide-gated ion channels (CNGs) are directly regulated by 
cAMP in photoreceptor cells, olfactory sensory neurons, and cardiac sinoatrial 
node cells (Zufall et al., 1997; Cheng et al., 2008).   
 
A large number of studies extensively document that stimulation of cAMP 
signaling stabilizes endothelial barrier function (Stelzner et al., 1989). By using 
tool compounds, such as forskolin (FSK), an activator of membrane associated 
adenylat cyclases, or 8-Br-cAMP, a cAMP analogous, the effects of cAMP on 
vascular contact integrity are demonstrated (reviewed by Mehta & Malik, 2006; 
Aslam et al., 2010; Yuan, 2002). Other cAMP increasing receptor agonists, 
such as prostacyclins or prostaglandins, also attenuate inflammatory stimuli-
induced endothelial hyperpermeability (Farmer et al., 2001). Interestingly, also 
the glycocalyx of endothelial cells contributes to cAMP-mediated stabilization of 
endothelial barrier function in intact microvessels (Huxley et al., 1997; Huxley & 
Williams, 2000).  
 
The signaling of cAMP/PKA is assumed to stabilize endothelial barriers due to 
an inactivation of the contractile machinery and a decrease of phosphorylation 
of MLC. Besides the initial identified action to directly inactivate MLCK, 
cAMP/PKA is also shown to induce site-specific MLC phosphatase activation 
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(Bindewald et al., 2004). Moreover, PKA is shown to inhibit RhoA activation via 
phosphorylation of Rho-GDP dissociation inhibitor, a negative regulator of Rho, 
and thus protects the endothelial barrier against Rho-dependent 
hyperpermeability (Qiao et al., 2003). In addition, PKA can also directly inhibit 
RhoA activity through direct phosphorylation of RhoA (Dong et al., 1998; Lang 
et al., 1996). Beside its effect on the contractile apparatus, cAMP dependent 
PKA activity is also involved in cytoskeleton rearrangement and microtubule 
assembly in endothelial cells (Liu et al., 2001; Birukova et al., 2004a).  
 
Upon binding to cAMP, Epac, activates the small GTPases Rap1 and Rap2, 
which are involved in diverse cAMP-mediated biological functions and 
pathologies, ranging from integrin-mediated cell adhesion, cadherin-mediated 
cell junction formation, exocytosis and secretion, cell differentiation and 
proliferation, phagocytosis, gene expression, apoptosis, as well as cardiac 
hypertrophy (reviewed by Cheng et al., 2008). Studies using human umbilical 
vein endothelial cells (HUVECs) show that Epac can induce redistribution of 
junctional molecules to cell-cell contacts and increase cortical actin, contributing 
to stabilization of endothelial barrier function. This effect of Epac is mediated by 
activation of Rap1, which is enriched at endothelial cell-cell contacts (Cullere et 
al., 2005; Kooistra et al., 2005; Fukuhara et al., 2005). Activation of Epac can 
suppress Rho GTPase activation and thus antagonize thrombin-induced 
hyperpermeability (Cullere et al., 2005). Cyclic AMP strengthens VE-cadherin 
mediated cell-cell junction in an Epac-Rap1 dependent manner thus supporting 
endothelial barrier function (Kooistra et al., 2005; Fukuhara et al., 2005). In rat 
mesentery, Epac/Rap1 pathway attenuates the platelet-activating factor (PAF)-
induced microvascular hyperpermeability as measured by hydraulic 
conductivity, and prevents the PAF-induced rearrangement of VE-cadherin 
(Adamson et al., 2008). These results suggest an important role of Epac/Rap1 
signaling in maintaining endothelial barrier function. Moreover, Mei et al. 
showed that Epac promotes microtubule growth in a Rap1-independent manner 
(Mei & Cheng, 2005). Epac activation is observed to reverse microtubule-
dependent vascular leakage induced by tumor necrosis factor-α (TNFα) and 
transforming growth factor-β (TGFβ) (Mei & Cheng, 2005). These studies 
suggest a two-leg strategy of Epac1 to regulate endothelial barrier function: a 
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Rap1-depedent regulation of cortical actin and VE-cadherin mediated cell-cell 
contacts, as well as a Rap-independent regulation of microtubules (Sehrawat et 
al., 2008). 
3.3. Transendothelial migration of leukocytes 
An important aspect of the inflammatory process is the translocation of 
leukocytes from blood stream to tissue. Transendothelial migration (TEM) of 
leukocytes is elemental in both adaptive and innate immune reaction and is of 
importance in routine immune surveillance and homing (Ley et al., 2007; 
Vestweber et al., 2008). Following stimulation in response to inflammation, 
immune cells, such as neutrophils, monocytes, and antigen-experienced 
lymphocytes, migrate across the vascular wall into lymphoid organs and 
infected tissues. However, excessive translocation of leukocytes can aggravate 
or even initiate a pathological process, such as atherosclerosis, multiple 
sclerosis, rheumatoid arthritis and acute lung injury (Hansson et al., 2006; 
Mattay & Zemans, 2011; Frohman et al., 2006).  
 
Transmigration of leukocytes occurs in a sequential set of four phases which 
are illustrated below in Figure 5. Each single step is required to initiate 
signaling that facilitates progression to the next stage. The key element of this 
process is the interaction between leukocytes and endothelium which is 
facilitated by adhesion proteins from both endothelial cells and leukocytes as 
well as by direct signal exchange via adhesion proteins and cytokines (Panés & 
Granger, 1998).  
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Figure 5 Schematic diagram of leukocyte adhesion and transendothelial migration (Yuan et al., 
2012) 
In response to inflammatory stimuli, leukocytes initially weekly adhere on the endothelial cells, 
rolling along the vascular endothelial wall through transient selectin-mediated interactions. The 
activation stage allows the up-regulation of adhesion receptors expressed on the cell surfaces 
of both endothelial cells and leukocytes. This is required to initiate the firm adhesion of 
leukocytes to endothelium through binding intergrins on leukocytes to ICAM-1 and VCAM-1 on 
endothelial cells. Subsequently, leukocytes cross the endothelium and exit the bloodstream 
(transmigration or diapedesis). 
 
 
Rolling adhesion step 
Rolling adhesion occurs when leukocytes are first captured from the 
bloodstream, and loosely tethered to the endothelial cells lining blood vessel 
wall. This first transient adhesion of rolling leukocytes is mediated by E-, L-, and 
P-selectins, which bind to sialyzed glykoligand of glykoproteins (Barreiro et al., 
2004). While L-selectin is expressed on leukocytes, E- and P-selectin are 
expressed on the apical sites of activated endothelial cells (Vestweber & 
Blanks, 1999). Upon binding to selectins, leukocytes slow down and roll on the 
surface of the endothelium, allowing exposure to a local environment and 
initiating the activation step.  
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Activation step 
In this stage, β1- and β2-integrins take over the function from selectins. While 
leukocytes initiate to up-regulate the expression of integrins upon activation of 
G-protein coupled chemokine receptors, endothelial cells increase expression 
of immunoglobulin family proteins, such as intercellular adhesion molecule 
(ICAM-1, ICAM-2, ICAM-3), vascular adhesion molecule (VCAM)-1 and 
MAdCAM-1  (Ebnet & Vestweber, 1999). All these processes result in 
deformation of leukocytes morphology and facilitating transmigration.  
 
Firm adhesion step 
In the next step, strong adhesion of leukocytes to the surface of endothelial 
cells is mediated through the interaction of Ig-family adhesion molecules on 
endothelial cells and integrins on leukocytes, including ICAM-1 binding to LFA-1 
(CD11a/CD18; αLβ2), MAC-1 (CD11b/CD18; αMβ2), and p150,95 (αXβ2), as well 
as VCAM-1 binding to αDβ2 (reviewed by Yuan et al., 2012). In vitro-studies 
using HUVECs show that the firm adhesion of leukocytes on endothelial cells 
forms transmigratory cups or docking structures, containing microvilli around the 
attached leukocytes which are composed of high levels of ICAM-1, VCAM-1 
and LFA-1 (Carman & Springer, 2004). ICAM-1 is considered to be predominant 
in this interaction. Furthermore, cross-linking of ICAM-1 causes the activation of 
Rho, PLCγ, PKC and Src, as well as the phosphorylation of cortactin 
(Vestweber, 2007). 
 
Diapedesis step 
The final step is the diapedesis, in which leukocytes transmigrate through 
endothelial barrier, basal membrane, and the pericyte layer, and thus enter into 
inflammatory sides of infected tissue along a cytokine gradient (Springer, 1994). 
The mechanisms in this process are largely unknown, and have been intensely 
investigated in the recent years (Vestweber, 2007). The route by which 
leukocytes transmigrate through the endothelium can be broken down into two 
distinct modes: transcellular and paracellular. The transcellular route occurs 
when a leukocyte transmigrates directly through the body of a single endothelial 
cell, probably via the transient formation of a pore. The factors for the 
preference of paracellular or transcellular route are still largely unknown. For 
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leukocytes, both paracellular and transcellular routes are observed, although 
the paracellular route is considered as the most prevalent mechanism in vitro 
(Carman & Springer, 2004). Moreover, in regions where specific matrix proteins 
are less expressed, neutrophils prefer the transcellular route to penetrate the 
vascular basement membrane in vivo (Wang et al., 2006).  
 
Linking transmembrane junctional proteins to the actin cytoskeleton dynamically 
regulates endothelial junctions during transendothelial migration of leukocytes. 
The actin-myosin based generation of contractile force promotes the cell shape 
changes and junctional breakdown necessary for transendothelial migration of 
leukocytes. While pre-treating endothelial cells with specific MLCK inhibitors 
significantly reduces neutrophil transmigration, the adhesion of neutrophils to 
endothelial monolayer directly increases MLC phosphorylation (Garcia et al., 
1998; Saito et al., 1998; Hixenbaugh et al., 1997). It is believed that acto-
myosin based endothelial contractility facilitates the actual migration of 
leukocytes across the endothelium (Wittchen, 2009). 
 
3.4. Aims of the study 
In summary the extensive body of evidence from literature supports the concept 
that ADM has a strong protective potency during inflammatory processes which 
might be mediated by modulation of the endothelial barrier function with respect 
to transition of fluid and cells of the immune defense. Notably, the potential 
translation of this concept into clinical trials is supported by the recent positive 
opinion of the Committee for Orphan Medicinal Products of the European 
Medicines Agency. On the 9th June 2010, the development of ADM as an 
orphan medicinal product (EU/3/10/744) was granted by the European 
Commission to Prof Dr. Stefan Hippenstiel (Charité, Berlin, Germany) for the 
treatment of acute lung injury (EMA/COMP/169921/2010). 
 
In endothelial cells, binding of ADM to its receptor was shown to induce 
measurable accumulation of intracellular second messenger cAMP.  The effects 
of cAMP on vascular contact integrity have been extensively demonstrated by 
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using tool compounds (reviewed by Mehta & Malik, 2006; Aslam et al., 2010; 
Yuan, 2002). However, as previous studies have shown, cAMP levels that were 
measurable at comparable efficacy were notably lower with ADM than with FSK 
(Hippenstiel et al., 2002). Therefore, it was hypothesized that beside cAMP-
dependent pathways, also cAMP-independent pathways might be involved in 
ADM mediated regulation of vascular permeability (e.g. direct effects on cell-
cell-junctions, on cytoskeleton, on ion channels, or on endothelial glycocalyx) 
(Hippenstiel et al., 2002; Szokodi et al., 1998).  
 
The main goal of the present studies was to investigate and determine the 
signal transduction mechanisms which are responsible for ADM-mediated 
improvement of endothelial barrier function with respect to transition of fluid, 
macromolecules and polymorphonuclear garnulocytes. The following main 
topics have been worked out:  
 
• Analysis of ADM-mediated effects on endothelial barrier function in response 
to inflammatory stimuli.  
• Search for evidence of cAMP-independent effects of ADM in modulation of 
endothelial barrier function - including ADM-mediated effects on endothelial 
gene expression. 
• Dissection of the cAMP signaling pathways: impacts of PKA and Epac/Rap1 
in ADM signaling on endothelial cell-cell junctions and cytoskeleton 
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4. MATERIAL AND METHODS 
4.1. Material 
4.1.1. Chemical reagents and assay kits 
Table 1 List of chemical reagents, assay kits and their providers 
Chemical/Reagent/Kit Provider 
Adrenomedullin human Bachem (Weil am Rhein) 
Alexa Fluor® 555 phalloidin Invitrogen (Darmstadt) 
Aprotinin from bovine lung Merck (Darmstadt) 
Gibco® Cell Culture β-mercaptoethanol  Invitrogen (Darmstadt) 
BAPTA/AM Merck (Darmstadt) 
BCECF/AM   Invitrogen (Darmstadt) 
Benz-cAMP  Biolog (Bremen) 
Β-Mercaptoethanol Sigma Aldrich (Steinheim) 
Bond-Breaker TCEP Solution, Neutral pH  Thermo Scientific (Bonn) 
Bovine serum albumin (BSA) Sigma Aldrich (Steinheim) 
Rp- isomer (Rp-8-Br-cAMP) Biolog (Bremen) 
Casy™ blue Roche (Basel) 
Casy™ clean Roche (Basel) 
Casyton isoton solution Roche (Basel) 
Cell Freezing Medium-DMSO Serum free 1x Sigma Aldrich (Steinheim) 
C5a R&D (Wiesbaden) 
8-pCPT-2'-O-Me-cAMP or “007”) Biolog (Bremen) 
Complete EDTA-free protease inhibitor cocktail Roche (Basel) 
Cytochalasin B Sigma Aldrich (Steinheim) 
Cytochalasin D Sigma Aldrich (Steinheim) 
DAKO fluorescent mounting medium Dako Inc. (Glostrup) 
Deoxyribonuclease I, Amplification Grade Invitrogen (Darmstadt) 
Dextran fluorescein 40,000MW  Invitrogen (Darmstadt) 
Dimethyl sulfoxide (DMSO) Sigma Aldrich (Steinheim) 
Dulbecco’s Phosphate Buffered Saline Sigma Aldrich (Steinheim) 
Dulbecco`s PBS with Ca/Mg PAA laboratories (Cölbe) 
ECL™ Western Blotting Detection Reagents GE healthcare (Munich) 
EBM-2 Basal Medium 500 ml Lonza (Cologne) 
EGM-2 MV SingleQuot Kit Suppl. & Growth Factors Lonza (Cologne) 
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EGM-2 SingleQuots Lonza (Cologne) 
Ethanol Merck (Darmstadt) 
Ethylendiamintetra essig acid (EDTA) Serva (Heidelberg) 
Evans Blue E2129 - Dye content ≥75 % Sigma Aldrich (Steinheim) 
Fetal bovine serum (FBS) mycoplex PAA laboratories (Cölbe) 
Fibronctin from bovine plasma Sigma Aldrich (Steinheim) 
fMLP  Sigma Aldrich (Steinheim) 
Formamid zur Analyse EMSURE®  Merck (Darmstadt) 
Forskolin Sigma Aldrich (Steinheim) 
Gelatin solution 2% Sigma Aldrich (Steinheim) 
Glycerin Merck (Darmstadt) 
HBSS without Ca/Mg with Phenolred PAA laboratories (Cölbe) 
HBSS without Phenolred PAA laboratories (Cölbe) 
Hanks’-based cell dissociation buffer Gibco®  Invitrogen (Darmstadt) 
HEPES solution (1M, pH 6,5-7,5) Sigma Aldrich (Steinheim) 
Histamine Sigma Aldrich (Steinheim) 
Histopaque 1077 Sigma Aldrich (Steinheim) 
Histopaque 1119 Sigma Aldrich (Steinheim) 
Hoechst dye  33342 (10mg/ml) Invitrogen (Darmstadt) 
Hydrogen peroxide Serva (Heidelberg) 
IBMX  Sigma Aldrich (Steinheim) 
IL-1ß/IL-1F2 (recombinant Human) R&D (Wiesbaden) 
IL-8 (recombinant Human) Peprotech (Hamburg) 
Isofluran (Foren) Baxter (Unterschleißheim) 
Isopropanol Merck (Darmstadt) 
Leupeptin, Hemisulfate, Microbial  Merck (Darmstadt) 
L-Glutamin Gibco® Cell Culture (100x) Invitrogen (Darmstadt) 
Lipopolysaccharides from Escherichia coli  Sigma Aldrich (Steinheim) 
Magnesium chlorid Sigma Aldrich (Steinheim) 
MCDB 131 medium Invitrogen (Darmstadt) 
Medium 199 (10x) Invitrogen (Darmstadt) 
Methanol EMPLURA® Merck (Darmstadt)  
ML-9  Merck (Darmstadt) 
N6-Benzoyl-cAMP Biolog life science (Bremen) 
Nonessential amino acids (NEAA) (100x) Invitrogen (Darmstadt) 
Novex® Sharp Pre-stained Protein Standard Invitrogen (Darmstadt) 
NuPAGE® LDS Sample Buffer (4X)  Invitrogen (Darmstadt) 
NuPAGE® MES SDS Running Buffer  Invitrogen (Darmstadt) 
NuPAGE® MOPS SDS Running Buffer  Invitrogen (Darmstadt) 
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Paraformaldehyde (PFA) Sigma Aldrich (Steinheim) 
8-pCPT-2´-O-Me-cAMP / ``007`` Biolog life science (Bremen) 
Penicillin / Streptomycin Gibco® Cell Culture  Invitrogen (Darmstadt) 
2-Propanol Merck (Darmstadt) 
Protein A Sepharose Sigma Aldrich (Steinheim) 
Sodium Bicarbonate Gibco® Cell Culture 7.5%,  Invitrogen (Darmstadt) 
Sodium fluoride for analysis EMSURE®  Merck (Darmstadt) 
Sodium Orthovanadate  Merck (Darmstadt) 
Sodium pyruvat Gibco® Cell Culture (100x) Invitrogen (Darmstadt) 
Stop Reagent for TMB Substrate Sigma Aldrich (Steinheim) 
Thrombin from human plasma Sigma Aldrich (Steinheim) 
TMB Liquid Substrate System Sigma Aldrich (Steinheim) 
TNFα (recombinant human) Peprotech (Hamburg) 
Triza base Sigma Aldrich (Steinheim) 
Trypsin-EDTA- solution Lonza (Cologne) 
Trypanblue solotion Sigma Aldrich (Steinheim) 
Tyrode puffer (calcium free, pH7.4) (CAFTY) PAA laboratories (Cölbe) 
Tween-20 Merck (Darmstadt) 
VEGF 165 (recombinant human) R&D (Wiesbaden) 
Triton buffer PAA laboratories (Cölbe) 
TRIzol® RNA extraction reagent Invitrogen (Darmstadt) 
Water, sterile-filtered (cell culture) Sigma Aldrich (Steinheim) 
W54011  Sigma Aldrich (Steinheim) 
Assay/Kits Provider 
cAMP Biotrak Enzymeimmunoassay System GE healthcare (Munich) 
 BCA Protein Assay (bicinchoninic acid) Thermo Scientific (Bonn) 
ImProm-IITM Reverse Transcription System Promega (Mannheim) 
Nucleofector® kit-OLD Lonza (Cologne) 
qPCR MasterMix Plus 7.5 ml Eurogentec (Belgium) 
Rap1 activation assay kit Upstate technology (Billercia) 
RNase mini kit Qiagen (Hilden) 
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4.1.2. Antibodies 
Table 2 List of primary antibodies and their providers 
Antigen (reactivity) Clone Source Company  
β-actin (monoclonal) Mouse  Sigma Aldrich (Steinheim) 
β-tubulin SAP.4G5 
(monoclonal) 
Mouse  Sigma Aldrich (Steinheim) 
CD11b/Mac-1 ICRF44 Mouse BD Bioscience 
(Heidelberg) 
Cortactin (p80/85) 4F11 
(monoclonal) 
Mouse  Upstate technology (Billercia) 
E-selectin (CD62E) 1.2B6 
(monoclonal) 
Mouse  Abcam (Cambridge, UK) 
ICAM-1 (CD54) MEM-111 
(monoclonal) 
Mouse  Abcam (Cambridge, UK) 
ICAM-1 (CD54) BBIG-l1 (11C81) 
(monoclonal) 
Mouse  
 
R&D systems (Wiesbaden) 
 
Phospho-MLC 2 
(Thr18/Ser19) 
Polyclonal Rabbit  Cell Signaling 
(Frankfurt) 
VCAM-1 6G9 
(monoclonal) 
Mouse  Abcam (Cambridge, UK) 
VASP (phospho Ser157) (polyclonal) Rabbit  Abcam (Cambridge, UK) 
VASP (monoclonal) Mouse  Abcam (Cambridge, UK) 
VE-cadherin (C-19)  (polyclonal) Goat  Santa Cruz (Santa Cruz) 
VE-cadherin (11D4.1) 11D4.1 
(monoclonal) 
Rat  BD Bioscience 
(Heidelberg) 
Vinculin hVIN-1 
(monoclonal) 
Mouse  Sigma Aldrich (Steinheim) 
 
Table 3 List of secondary antibodies and their providers 
Antibody Company 
ECL rabbit IgG, HRP Linked Secondary Ab GE healthcare (Munich) 
Peroxidase AffiniPure Donkey Anti- Rat IgG (H+L) Jackson (West Grove, PA)   
ECL Mouse IgG, HRP-Linked Whole Ab (from sheep)  GE healthcare (Munich) 
Alexa Fluor® 488 donkey anti-goat IgG (H+L) 2 mg/mL Invitrogen (Darmstadt) 
Alexa Fluor® 488 donkey anti-mouse IgG (H+L) 2 mg/mL Invitrogen (Darmstadt) 
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4.1.3. Buffers 
Table 4 Composition of buffers 
Buffer Composition 
ACK lysis buffer 4.145 g NH4Cl 
0.5 g NaHCO3 
18.6 mg EDTA 
Add H2O 500 ml 
pH 7.3 
Lysis buffer for Co-immunoprecipitation 
(CoIP) 
20 mM Imidazol (pH=6.8) 
100 mM NaCl 
2 mM CaCl2 
1% (v/v) Triton-X-100 
0.04% (w/v) NaN3 
Lysis buffer to detect phosphorylation of MLC 20 mM Imidazol (pH=7.4) 
150 mM NaCl 
2 mM CaCl2 
1 mM Na3VO4 
1% (v/v) Triton-X-100 
0.04% (w/v) NaN3 
Migration assay medium (MAM) M199 
20% (v/v) FBS 
25 mM HEPES 
PBST PBS 
0.1% (v/v) Tween®-20 
PMN wash buffer HBSS 
10% (v/v) FBS 
25 mM HEPES 
Phosphate Buffer (pH 6.8) 46.3 ml Na2HPO4 (1M) 
53.7 ml NaH2PO4 (1M) 
Add H2O 1,000 ml 
Rap1 lysis buffer 100 mM Tris-HCl, pH 7.4 
10% (v/v) glycerol 
5 mM MgCl2 
1 M NaCl 
2% (v/v) NP40 
10 ug/ml aprotinin 
10 ug/ml leupeptin 
25 mM NaF 
1 mM sodium orthovanadate 
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TBST (10x) 80 g NaCl 
2 g KCl 
30 g Tris 
5 ml Tween 20 
Add H2O 1,000 ml 
PH 7.5 
Transfer buffer 2.42 g Tris 
11.25 g glycin 
5 ml 10% (m/v) SDS 
100 ml MeOH 
Add H2O 1,000 ml 
PH 8.3-8.5 
 
4.1.4. Materials 
Table 5 List of materials and their providers 
Mterials Company 
Amersham Hybond-P (30 cm × 3 m) GE healthcare (Munich) 
Falcon Conical Tubes (polystyrene) (15 ml, 50 ml, 200 ml) BD (Heidelberg) 
Falcon Cell Culture Flasks (75 cm2, 175 cm2) BD (Heidelberg) 
Biohit proline (25-250 µl, 5-100 µl, 50-1200 µl) Biohit (Rosbach) 
CASY cups Roche (Basel) 
Falcon Multiwell(6-well, 12-well, 24-well) BD (Heidelberg) 
Cannula (27G.3/4”) (26G.1/2”) (23G.1 1/4”) BD (Heidelberg) 
Cell cultrue dishes CELLBIND 100 mm Corning (Kaiserslautern) 
Costar Stripette Serological Pipets, (polystyrene)(5 - 50 ml) Corning (Kaiserslautern) 
Corning Cell Lifter Corning (Kaiserslautern) 
Corning Vacuum Filter/Storage Bottle System, 0.22 µm Pore  Corning (Kaiserslautern) 
Corning Tubes (polypropylene)(15 ml, 50 ml) Corning (Kaiserslautern) 
Cryo 1oC freezing container Nalgene  Nalgene (Tuntenhausen) 
CryoTube Vials 1.8 ml NUNC Thermo Scientific (Bonn) 
ECIS arrays-10 electrode array (96 well) Ibidi (Munich) 
Eppendorf- reaction tubes (0.5 ml, 1.5 ml, 2.0 ml) Eppendorf (Hamburg) 
EpT.I.P.S.  Pipettenspitzen (10 µl - 1000 µl) Eppendorf (Hamburg) 
Eppendorf Pipetten (2.5 µl - 1000 µl) Eppendorf (Hamburg) 
Glas coverslides (12 mm, round) Menzel (Braunschweig) 
Kodak BioMax XAR Film  Sigma (Steinheim) 
Membrane Nitrocellulose GE healthcare (Munich) 
Membrane PVDF GE healthcare (Munich) 
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Microscope slides 76-26 mm Menzel (Braunschweig) 
Microplates 96-well (UB, VB, FB) Greiner (Frickenhausen) 
Microtiter plates Cellstar 384-well Greiner (Frickenhausen) 
Millex GP 0.22 µm Filter Millipore (Bedford, MA) 
Neolus 20G x2 ¾’’0.9x70 mm steril Terumo (Eschborn) 
NuPAGE Novex 4-12% Bis-Tris Gel 1.0 mm, 10 well Invitrogen (Darmstadt) 
NuPAGE Novex 12% Bis-Tris Gel 1.0 mm, 10 well Invitrogen (Darmstadt) 
NuPAGE Novex 10% Bis-Tris Gel 1.0 mm, 10 well Invitrogen (Darmstadt) 
NuPAGE Novex 8% Bis-Tris Gel 1.0 mm, 10 well Invitrogen (Darmstadt) 
NuPAGE Novex 6% Bis-Tris Gel 1.0 mm, 10 well Invitrogen (Darmstadt) 
PC transwell inserts 6.5-mm-diameter, 5.0-µm pore size Corning (Kaiserslautern) 
PC transwell inserts 6.5-mm-diameter, 0.4-µm pore size Corning (Kaiserslautern) 
QIAshredder (250) Qiagen (Hilden) 
STIEFEL Biopsy punch 8 mm GSK (Bühl) 
Thick Blot paper BioRad (Munich) 
 
4.1.5. Equipments 
Table 6 List of equipments and their providers 
Equipments Company 
PRISM 7900HT sequence detection system  Applied Biosystems (Darmstadt) 
BBD 6220 Incubator Heraeus (Hanau) 
GFL water quench GFL (Burgwedel) 
CASY cell counter Roche (Basel) 
Cell QuestTM Pro (Version 5.2.1) Becton Dickinson (Heidelberg) 
Centrifuge Varifuge 3.0R Heraeus (Hanau) 
Centrifuge 5415R Eppendorf (Hamburg) 
ECIS Model 9600 Applied Biosystems (Darmstadt) 
Developer Curix 60 Agfa (Mortel-Belgien) 
FACS Calibur Becton Dickinson (Heidelberg) 
Fluorescence microscope Axioskop Carl Zeiss AG (Jena) 
GeneChip® Human Gene 1.0 ST Affymetrix (Santa Clara, CA, USA) 
Genedata Expressionist®  Genedata (Martinsried, Germany) 
iBlot Gel Transfer Device Invitrogen (Darmstadt) 
KS250 basic IKA (Staufen) 
LSM 510 meta Carl Zeiss AG (Jena) 
LSM 710 Carl Zeiss AG (Jena) 
Lumino box Hamamatsu (Japan) 
Microscope Axiovert 135 Carl Zeiss AG (Jena) 
Amaxa Nucleofector® I Device Lonza (Cologne) 
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pH meter WTW (Weilheim) 
Steril bank HeraSafe Heraeus (Hanau) 
Tecan Safire miccroplate reader  Tecan (Crailsheim) 
Thermomixer comfort (1.5 ml and 2.0 ml) Eppendorf (Hamburg) 
Trans-Blot SD Semi-Dry Transfer Cell BioRad (Munich) 
XCell SureLock™ Mini-Cell Electrophoresis System Invitrogen (Darmstadt) 
MATERIAL AND METHODS   35 
4.2. Methods 
4.2.1. Molecular biological methods 
4.2.1.1. Microarray analysis 
After 12 h of serum starvation in basal medium, HUVECs were further cultured 
in EBM-2 supplemented with 100 nM ADM, 10 µM FSK or without compounds 
for 4 h and 16 h. The entire process was performed according to the Affymetrix 
instructions. Total RNA was isolated from the cells using TRIzol® RNA 
extraction reagent. Double-stranded cDNA was synthesized from total RNA, 
and in vitro-transcription was performed to produce biotinlabeled cRNA. After 
fragmentation, the cRNA was hybridized onto a GeneChip® Human Gene 1.0 
ST Array at 45 °C with 60 rpm for 17 hours in a Hyb ridization oven. 
Normalization, filtering, and gene ontology analyses of the data were performed 
with Genedata Expressionist® software. GeneChip® Human Gene 1.0 ST Array 
consists of approximately 764,885 probe sets with a resolution number of 26 
probes per gene, covering over 28,869 genes, whereas only genes with at least 
two fold changes were considered as significant. (Microarray and computational 
analysis were performed by Dr. Stefan Golz, Bayer HealthCareAG) 
4.2.1.2. Quantitative Real-Time RT-PCR analysis 
Endothelial cells cultured in 6 well plates or fresh isolated human PMNs were 
lysed with RLT buffer. Total RNA was isolated from the cell lysate using 
RNeasy mini kit, and converted to cDNA by reverse transcription using ImProm-
IITM Reverse Transcription System. The PCR was carried out under the 
following conditions: an initial denaturation step at 95 °C for 10 min, followed by 
40 cycles at 95 °C for 15 s and 60 °C for 60 s. Qua ntitative Taq-Man analysis 
was performed using the PRISM 7900 sequence detection system. 
Normalization was performed using β-actin as internal control, and relative 
expression was calculated using the following formula: relative expression=2(15 - 
(CTprobe - CTactin))
. The parameter CT is defined as the threshold cycle number at 
which the amplification plot passed a fixed threshold above baseline. The 
resulting expression is given in arbitrary units.  
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Table 7 List of primers and fluorescent probes 
CRLR (mouse) 
Primer 1 5’- GGCTTTTCCCACTCTGATGCT -3’ 
Primer 2 5’- GGCTGTACCCTTGCATGTCA -3’ 
Probe 5’- TCCGCAGTGCATCCTACACAGTG -3’ 
RAMP2 (mouse) 
Primer 1 5’- GCAGCCCACCTTCTCTGATC -3’ 
Primer 2 5’- GGAACGGGATGAGGCAGAT -3’ 
Probe 5’- AGAGGATGTGCTCCTGGCCATG -3’ 
RAMP3 (mouse) 
Primer 1 5’- ACCCCCCGGATGAAGTACTC -3’ 
Primer 2 5’- ACCACCAGGCCAGCCATAG -3’ 
Probe 5’- ATCGCGGTTCCTGTCGTGCTGACT -3’ 
β-actin (mouse) 
Primer 1 5’- ACGGCCAGGTCATCACTATTG -3’ 
Primer 2 5’- AGGAAGGCTGGAAAAGAGCC -3’ 
Probe 5’- CAACGAGCGGTTCCGATGCCC -3’ 
CRLR (human) 
Primer 1 5’- CTGATTCCATGGCGACCTG -3’ 
Primer 2 5’- CCCTGGAAGTGCATAAGGATG -3’ 
Probe 5’- AGGAAAGATTGCAGAGGAGGTATATGACTACATCATG -3’ 
RAMP2 (human) 
Primer 1 5’- GATCCACTTTGCCAACTGCTC -3’ 
Primer 2 5’- TGGCCAGGAGTACATCCTCTG -3’ 
Probe 5’- TGGTGCAGCCCACCTTCTCTGACC -3’ 
RAMP3 (human) 
Primer 1 5’- TTCTCATCCCGCTGATCGTT -3’ 
Primer 2 5’- ACACCACCAGGCCAGCC -3’ 
Probe 5’- ACCCGTCGTTCTGACTGTCGCCA -3’ 
ICAM-1 (human) 
Primer 1 5’- CCCCCCGGTATGAGATTGT -3’ 
Primer 2 5’- GCCTGCAGTGCCCATTATG -3’ 
Probe 5’- CATCACTGTGGTAGCAGCCGCA -3’ 
VCAM-1 (human) 
Primer 1 5’- AAGAGGCTGTAGCTCCCCG -3’ 
Primer 2 5’- TGACATGCTTGAGCCAGGG -3’ 
Probe 5’- ATCCTGTGGAGCAGGCAGCTCCCTA -3’ 
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E-Selectin (human) 
Primer 1 5’- TGCCTACTATGCCAGATGCCT -3’ 
Primer 2 5’- CGTCCTTGCCTGCTGGACT -3’ 
Probe 5’- ACCGCAACACCCATCACCACTTCAAT -3’ 
PECAM (human) 
Primer 1 5’- TCTCCCAGCCCAGGATTTC -3’  
Primer 2 5’- GATTCGCAACGGACTTCGAT -3’ 
Probe 5’- ATGCCCAGTTTGAGGTCATAAAAGGA -3’ 
β-actin (human) 
Forward 5’- TCCACCTTCCAGCAGATGTG -3’ 
Reverse 5’- CTAGAAGCATTTGCGGTGGAC -3’ 
Probe 5’- ATCAGCAAGCAGGAGTATGACGAGTCCG -3’ 
 
4.2.1.3. RNA interference 
SiRNAs directed against the mRNAs of cortactin (QIAGEN) were transfected 
into HUVECs by Nucleofector® I device according to manufacturer’s 
instructions. 1~1.5x106 HUVECs (Passage 2) were transfected with 3 µg siRNA 
using Nucleofector® Kit-OLD. Hs_CTTN_5 (target sequence: 5’- 
CACCAGGAGCATATCAACATA -3’) and Hs_CTTN_6 (target sequence: 5’- 
ATGCAACTTATTGTATCTGAA -3’) were used to down-regulate gene 
expression of human cortactin. The Lamin A/C siRNA (target sequence: 5’-
AACTGGACTTCCAGAAGAACA-3’) served as negative control. Efficiency of 
gene silencing was evaluated by Western blot of cortactin (1 µg/ml mouse-anti-
cortactin antibody). All experiments to detect endothelial permeability and 
leukocyte extravasation were performed 48 h after transfection. 
4.2.2. Biochemical methods 
4.2.2.1. Measurement of cyclic AMP 
Measurements of intracellular cAMP levels were performed using Amersham 
cAMP biotrack enzymeimmunoassay system according to the manufacturer`s 
instructions with minor modifications. Briefly, endothelial cells cultured in 24-well 
cell culture plate or freshly isolated PMNs were washed and stimulated at 37 ºC 
as indicated. After being stimulated, endothelial cells were washed with ice-cold 
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PBS containing Ca2+/Mg2+ and extracted in 70% (v/v) ethanol overnight at -20 
ºC. The extracts were collected in 1.5 ml Eppendorf tubes and ethanol was 
removed using vacuum centrifugation. Aliquots of the extracts and standards 
were processed for ELISA according to the manufactures instructions. 
4.2.2.2. Detection of VASP activation 
After treatment, HUVECs grown in 6-well cell culture plate were rinsed with ice-
cold PBS containing Ca2+/Mg2+, lysed with 300 µl of SDS sample buffer with 
freshly added Bond breaker TCEP solution, scraped into 1.5 ml Eppendorf 
tubes, and boiled immediately for 5 min. Extracts (20 µl) were separated on 4-
12% gradient SDS-PAGE and transferred to polyvinylidenefluoride (PVDF) 
membrane using a Trans-Blot SD Semi-Dry Transfer Cell. PVDF blots were 
then incubated in TBST for 1 h and were blocked with 5% (w/v) nonfat milk in 
TBST for further 1 h. VASP phosphorylation was detected with 1 µg/ml of rabbit 
anti-phospho Ser157-VASP antibody and total VASP was detected with 1 µg/ml 
mouse monoclonal anti-VASP antibody. After incubation with primary antibodies 
diluted in TBST at 4 ºC overnight, PVDF blots were washed with TBST (3 x 5 
min), incubated with peroxidase-conjugated secondary antibodies (goat anti-
rabbit IgG, 1:10,000 dilution; or goat anti-mouse IgG, 1:10,000 dilution) diluted 
in TBST for 1 h, and completely washed with TBST (4 x 15 min). Finally, binding 
of antibodies was visualized on Hyperfilm x-ray films using ECL detection 
system. Tubulin blots were performed as loading control. 
4.2.2.3. Detection of MLC phosphorylation 
After treatment, endothelial cells cultured in 6-well plate were washed with ice-
cold PBS containing Ca2+/Mg2+, lysed with 200 µl of lysis buffer for detection of 
tyrosine-phosphorylation, and scraped into 1.5 ml Eppendorf tubes. Lysates 
were centrifuged at 4 °C for 10 min at 13,000 rpm. Supernatants were then 
adjusted with SDS sample buffer (4x) and bond-breaker solution (20x), and 
boiled immediately for 5 min. 20 µl of Extracts were separated on 12% SDS-
PAGE and transferred to PVDF membrane. Blots were analyzed as previously 
described (4.2.2.2). However, blocking buffer was replaced by 2% (w/v) BSA 
and 200 µM Na3VO4 was added overall to TBST, to preserve tyrosine 
phosphorylation during Western blot process by inhibition of any phosphatase 
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activity. MLC phosphorylation was detected with 1 µg/ml of rabbit anti- phospho-
MLC 2 (Thr18/Ser19) antibody and vinculins were detected with mouse 
monoclonal anti-VASP antibody (1:1,000) as loading control. 
4.2.2.4. Rap1 Pull-down assay 
To test for the activation levels of the small GTPase Rap1 the Rap1 pull down 
assay (Millipore) was employed according to the manufacturer’s 
recommendations. In brief: a GST-tagged fusion protein, corresponding to 
residues 788-884 of human Ral GDS-Rap Binding Domain (RBD), expressed in 
E. Coli. and bound to glutathione-agarose (Millipore) is provided with the 
detection kit as probe for coimmunoprecipitation of GTP bound (active) Rap1.. 
RBD is a specific interaction partner of GTP-RAP1.Endothelial cells grown in 
90-mm dishes were cultured to 85-90% confluence and treated with either 
agonists or vehicle control in medium. The cells were lysed on ice in lysis buffer, 
scraped into 1.5 ml Eppendorf tubes and debris was removed by a 10 min 
centrifugation at 13,000 rpm (4 ºC). 50 µl of the supernatants were transferred 
into new 1.5 ml Eppendorf tubes and kept on ice during the assays as control of 
total Rap-1 expression in total lysates. The rest of supernatants were 
incubatede with 30 µg of Ral GDS-RBD glutathione-agarose for 1 h at 4 ºC with 
gentle agitation. Agarose beads with precipitated GTP-Rap-1 were washed 
three times with lysis buffer, lysed with 25 µl of 2x SDS sample buffer with Bond 
breaker TCEP solution and boiled immediately for 5 min. 
 
20 µl Extracts were separated on 12% gradient SDS-PAGE and transferred 
electrophoretically to PVDF membranes. Blots were analyzed as previously 
described (4.2.2.2). PVDF blots were probed in primary anti-Rap1 antibodies 
(1:500 dilution in TBST) at 4 ºC overnight, and incubated with peroxidase-
conjugated secondary antibodies (goat anti-rabbit IgG, 1:10,000 dilution in 
TBST) for 1 h at room temperature, followed by ECL detection system. Total 
Rap1 iwas determined in cell lysates without previous precipitation.  
4.2.2.5. Co-immunoprecipitation of VE-PTP/VE-cadherin 
bEnd.5 cells were washed and starved with MCDB 131 medium containing 1% 
(w/v) BSA for 2 h, followed by incubation with ADM (100 nM, 15 min) and 
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subsequently stimulation with VEGF (100 ng/ml, 30 min) in MCDB 131 medium 
with 1% (w/v) BSA. After stimulation, bEnd.5 cells were washed twice with ice-
cold PBS to remove the stimulation medium. For docking of lymphocytes, 
bEnd.5s cells were pre-stimulated with TNFα (5 nM) overnight. On the day of 
assay, 3x107 ovalbumin-specific antigen-stimulated T cells were allowed to bind 
to the bEnd.5 cells in a 90 mm-falcon cell culture dish for 10 min. Then, T-cells 
were carefully and completely removed by washing the cells with warm PBS, to 
avoid the degradation of VE-cadherin by lymphocyte proteases.  
 
After stimulation with VEGF or docking of T-lymphocytes, bEnd.5 cells were 
lysed on ice in 500 µl lysis buffer for co-immunoprecipitations (CoIP) and 
scraped into 1.5 ml Eppendorf tubes. Lysates were centrifuged at 4 °C for 30 
min at 13,000 rpm. 50 µl Aliquots were set aside on ice for direct blot 
analysis.Supernatants for CoIP were incubated for 2 h at 4 °C with 30 µl protein 
A-sepharose loaded with the 3 µg VE-PTPc antibodies (provided by Prof. 
Dietmar Vestweber). Immunocomplexes were washed five times with lysis 
buffer, subsequently dissolved in 25 µl SDS sample buffer (2x), and boiled 
immediately for 5 min. Total cell lysates were separated by electrophoresis on 
8% SDS-PAGE, whereas immunocomplexes were separated on 6% SDS-
PAGE. After being transferred to nitrocellulose membranes, blots were 
analyzed as previously described (4.2.2.2). Nitrocellulose blots were probed in 1 
µg/ml primary anti-VE-cadherin (11D4) antibody at 4 °C overnight and 
incubated with peroxidase-conjugated secondary [donkey anti-rat antibodies 
(1:10,000)] for 1 h at room temperature. After washing with TBST, 
chemiluminescence signals were detected by use of ECL-detection system. 
After detection of VE-cadherin, blots were further used to detect VE-PTP. The 
same blots were washed with TBST for 1 h, blocked with 5% (w/v) nonfat milk 
for additional 1 h, and probed with anti-VE-PTPc antibody (0.5 µg/ml) for 1 h at 
room temperature, followed by incubation in peroxidase conjugated anti-rabbit 
antibody (1:10,000) for further 1 h. Chemiluminescence signals for VE-PTP 
were recorded on Hyperfilm x-ray films using ECL detection system.  
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4.2.2.6. Immnuofluorescence staining 
HUVECs were cultured on fibronectin-coated, 12-mm-diameter glass cover 
slides bathed in full medium. After the HUVECs reached confluence, endothelial 
monolayers were treated with the agonist or vehicle, fixed and permeabilized 
with ice-cold 100% (v/v) ethanol for 10 minutes at -20 ºC and were then 
incubated for 60 min in PBS containing 5% (w/v) BSA. Thereafter, the cover 
slides were immunolabeled for 60 min at room temperature with 5 µg/ml goat 
anti-VE-cadherin (C19) antibody or 10 µg/ml monoclonal anti-cortactin antibody. 
After rinsing twice with PBST and three times with PBS, binding of primary 
antibodies was visualized by incubation with Alexa-488-conjugated donkey anti-
goat antibody (for VE-cadherin; 1:1,000) or Alexa-488-conjugated donkey anti-
mouse antibody (for cortactin; 1:1,000) for 60 min at room temperature. The F-
actin cytoskeleton was visualized by incubating cover slides with Alexa-555-
conjugated phalloidin. The cover slides were then washed again twice with 
PBST and three times with PBS and covered with DAKO mounting medium. 
Prepared cover slides were analyzed using a confocal laser-scanning 
microscope LSM 710. 
4.2.3. Cell culture methods 
4.2.3.1. Cell culture condition 
bEnd.5 
The mouse endothelioma cell lines bEnd.5 cells were kindly provided by Prof. 
Dietmar Vestweber (MPI Münster, Germany). The bEnd.5 cells were cultivated 
at 37 °C and 10% CO 2 in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% (v/v) inactivated fetal calf serum (FCS), 2 mM L-
glutamine, 1% (v/v) sodium pyruvate, 1% (v/v) penicillin/streptomycin, 1% (v/v) 
NEAA and 0.1% (v/v) β-mercaptoethanol. Cells were passaged 1:4 every 14 
days in 90 mm falcon cell culture dishes. 
CHO-ADM1-reporter cells 
CHO-ADM1-reporter cells were generated and kindly provided by Dr. Frank 
Wunder (Bayer Healthcare, Wuppertal, Germany). Cells were cultured as 
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previously descript (Wunder et al., 2008) at 37 °C and 5% CO 2 in DMEM/NUT 
mix F-12 with L-glutamine, supplemented with 10% (v/v) inactivated FCS, 1 mM 
sodium pyruvate, 0.9 mM sodium bicarbonate, 50 U/ml penicillin, 50 µg/ml 
streptomycin, 2.5 µg/ml amphotericin B, 0.6 mg/ml hygromycin B, and 0.25 
mg/ml zeocin. In addition, 1 mg/ml G-418 was added to the cell culture medium 
used for the ADM1 receptor cell lines. Cells were passaged using enzyme-
free/Hanks’-based cell dissociation buffer.  
CREB-reporter cells 
Cells were generated and kindly provided by Dr. Frank Wunder (Bayer 
Healthcare, Wuppertal, Germany). Transfected CHO cells were cultured at 37 
°C and 5% CO 2 in DMEM/NUT mix F-12, supplemented with 10% (v/v) 
inactivated FCS, 2% (v/v) sodium pyruvate, 2% (v/v) sodium bicarbonate, 1% 
(v/v) penicillin/streptomycin, 1% (v/v) HEPES, and 2% (v/v) Glutamin. Cells 
were passaged using 0.05% trypsin-EDTA.  
Human umbilical vein endothelial cells (HUVECs) 
HUVES were purchased from Lonza Inc. and propagated in EBM-2 basal 
medium supplemented with EGM-2 Single Kit containing 2% fetal bovine serum 
(FBS), hFGF-B, VEGF, R3-IGF, ascorbic acid, hEGF, GA-1000, heparin, and 
hydrocortisone at 37 ºC in a humidified atmosphere of 5% CO2. Confluent 
cultures of primary endothelial cells were detached with 0.05% trypsin-EDTA 
and seeded on 90-mm cell-culture CELLBIND dishes at 1:4 to confluence. 
Experiments were performed using confluent endothelial cell monolayer at 
passage 1-4. 
Human lung microvessel endothelial cells (HLMECs) 
HLMECs were obtained from Lonza Inc., cultured according to the 
manufacturer`s recommendations and used for experiments at passage 1-4. 
Cells were cultured in EBM-2 basal medium supplemented with EGM-2 MV 
SingleQuot Kit containing 5% FBS, hFGF-B, VEGF, R3-IGF, ascorbic acid, 
hEGF, GA-1000, heparin, and hydrocortisone at 37 ºC in a humidified 
atmosphere of 5% CO2. Cells were passaged with 0.05% trypsin-EDTA 1:4 in 
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90 mm Cellbind corning cell culture dishes. Confluent endothelial cell monolayer 
at passage 1-4 was used for our experiments. 
OTII-Ova1-T-cells 
OTII-Ova 1 T-cells with ovalbumin specific T-cell receptors were isolated from 
6-8 week old OTII mice and were kindly provided by Prof. Dietmar Vestweber 
(MPI Münster, Germany).  T-cells were restimulated at 37 °C and 10% CO 2 in 
RPMI medium supplemented with 10% (v/v) T-cell FCS, 4 mM L-glutamine, 1% 
(v/v) sodium pyruvate, 1% (v/v) penicillin/streptomycin, 1% (v/v) NEAA, 0.1% 
(v/v) β-mercaptoethanol, and 1% (v/v) IL-2 supernatant. 1~1.5x106 T-cells were 
cultured for 2 days in a 90 mm-falcon cell culture dishes. 
4.2.3.2. Aequorin luminescence measurements 
Luminescence measurements were performed on opaque 384-well microtiter 
plates as previously describt with minor modification (Wunder et al., 2008). For 
the assays, 2,500 cells/well cultured for 24 h and were then loaded for 3 h with 
0.6 µg/ml coelenterazine in Ca2+-free Tyrode solution (CAFTY) at 37 °C and 5% 
CO2. To prevent cAMP degradation by endogenous phosphodiesterases 
(PDEs), cells were pre-incubated with 3-Isobutyl-1-methylxanthine (IBMX) (200 
µM) for 30 min. Afterwards, compounds were added for 6 min in CAFTY 
containing 0.1% bovine serum albumin. Immediately before adding Ca2+ ions 
(final concentration 3 mM), measurement of the aequorin luminescence was 
started using a luminometer. Luminescence was monitored continuously for 60 
s. 
4.2.3.3. CREB phosphorylation in luciferase-transfected CHO cells 
Detection of CREB phosphorylation was performed on opaque 384-well 
microtiter plates using Luceferase-transfected CHO cells. 10,000 CHO-cells 
were cultured for 24 h in 25 µl medium on 384-well microtiter plates at 37 °C 
and 5% CO2. For the assays, cells were incubated with 10 µl compounds for 4 h 
at 37 °C and 5% CO 2, followed by the addition of 35 µl luciferase buffer 
containing triton. Measurement of the luminescence was immediately started by 
using a luminometer. Luminescence was monitored continuously for 60 s.  
MATERIAL AND METHODS   44 
4.2.3.4. Cell surface expression of adhesion molecules 
Cell surface expression of adhesion proteins (ICAM-1, VCAM-1, and E-selectin) 
by HUVECs was quantified by use of cell surface ELISA. HUVECs were grown 
to subconfluence (~80%) in 96-well plates coated with 0.01% (v/v) fibronectin. 
After overnight pre-incubation with TNFα (5 nM), indicated concentrations of 
compounds were added to HUVECs for 30 min. Subsequently, the cells were 
washed with PBS (Ca2+/Mg2+) and fixed with 4% paraformaldehyde (PFA) for 30 
min at 4 ºC, followed by the addition of 3% (v/v) nonfat milk in PBS for 1 h at 
room temperature to reduce nonspecific binding. Following washes with PBS, 
HUVECs were incubated with primary monoclonal antibody overnight at 4 ºC 
[ICAM-1 antibody (clone: MEM 111) 1:500; VCAM-1 antibody (clone: 6G9) 
1:1,000; and E-selectin antibody (clone: 1.2B6) 1:3,000]. On the next day, the 
cells were washed with PBS and incubated with peroxidase-conjugated goat 
anti-mouse secondary antibody (1:500) for 1 h. After being completely washed 
with PBS, the cells were exposed to the TMB substrate solution, followed by 
addition of TMB stop solution. The absorbance at 490 nm was measured by use 
of a Tecan microplate reader.  
4.2.3.5. Measurement of transendothelial electrical resistance (TEER) 
Measurement of transendothelial electrical resistance (TEER) across confluent 
endothelial cells was performed using the electrical cell-substrate impedance 
sensing system (ECIS). Confluent cultures of primary endothelial cells were 
detached with 0.05% trypsin-EDTA, resuspended in fresh medium and 3x104 
cells in 300 µl medium were seeded per ECIS well coated with 0.25% (v/v) 
gelatine. Cells were cultured for 24 h or 48 h to reach the confluence before the 
assay. For each assay, one group of wells without seeded endothelial cells was 
used to control the function of electrical arrays during the experimentation, while 
one group with seeded endothelial cells without any treatment was considered 
as control for the monolayer. Relative TEER in % was presented as the ratio of 
TEER measured at a given time point set to the middle value of TEER in the 
same group at the beginning time point of the experiment. Area under the curve 
(AUC) was calculated to quantify this assay by using a baseline at 100%. AUC 
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above the baseline was considered as positive value, whereas AUC under the 
baseline was considered as negative value. 
4.2.3.6. Detection of paracellular macromolecular permeability 
To determine paracellular permeability, 4x104 HUVECs were seeded per 
Transwell® filter (6.5-mm-diameter, 0.4-µm pore size), coated with 0.01% (v/v) 
bovine fibronectin. After 48 h incubation HUVECs reached confluence and were 
used for permeability assay on the third day after plating. Macromolecular 
permeability was analyzed with 0.25 mg/ml FITC-dextran (40 kDa). 50 µl FITC-
dextran was added to the upper compartment of Transwell® filter. 30 min later, 
100 µl aliquot was taken from the lower compartment for fluorescence 
measurement as the baseline value of the assay and 100 µl fresh medium was 
added immediately. 50 µl Vehicle or compounds as indicated were dissolved in 
FITC-dextran and added to the upper compartment. Every 30 min, fluorescence 
of a 100 µl aliquot from the lower compartment was measured and 100 µl fresh 
medium was refilled immediately during the whole assay. For the quantitative 
analysis of ADM and FSK, AUC was calculated. Area above X-axis and under 
the curve with relative FITC-intensity, as referred to to the mean value of the 
same group at the beginning time point of the experiment, was calculated as 
AUC. 
4.2.3.7. Isolation of human neutrophils 
Human polymorphonuclear neutrophils (PMNs) were isolated by Histopaque 
density gradients using the manufacturer’s protocols with slight modification. 
First, 4 ml Histopaque-1077 was added to a 15 ml polypropylene centrifuge 
tube, after which 4 ml Histopaque-1119 was carefully added under the 
Histopaque-1077. 5 ml venous EDTA-coated blood samples were then carefully 
added to the upper gradient and centrifuged at 700x g for 30 min without brake 
at room temperature. After centrifugation, the neutrophils were located at the 
interface of the Histopaque-1077 and Histopaque-1119. The neutrophils were 
then transferred to a tube containing 30 ml PMN wash buffer and were washed 
twice by centrifugation at 400 x g for 10 min. Contaminating red blood cells 
were lysed by adding 5 ml ACK buffer for 4 min. Finally, neutrophils were 
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resuspended in migration assay medium (MAM) at a concentration of 1x107 
PMN/ml and were kept at room temperature until used in the experiments. 
4.2.3.8. In vitro-transendothelial migration assay (TEM) 
Quantitative leukocyte transmigration assay was performed using HUVECs 
plated at confluent density (2x104 cell/well) on Transwell® filter inserts (6.5-mm-
diameter, 5.0 µm pore size), coated with 0.01% (v/v) bovine fibronectin. After 2 
days, HUVECs reached confluence and were activated with 5nM TNFα 
overnight. As indicated, HUVECs or human PMNs were pre-treated with 
vehicle, compounds or antibodies for 30 min, then medium was removed and 
cells were washed three times to ensure that test compounds were largely 
absent during the incubation with leukocytes. 500,000 Human PMNs were 
added to the top Transwell® filter and were bathed in 600 µl MAM. 
Transmigration of PMNs across HUVEC monolayers was allowed for 60 min in 
MAM or 30 min in IL-8 stimulated MAM in a humidified incubator (37 ºC, 5% 
CO2). After the transmigration, 500 µl cell-suspension from the bottom well was 
collected and transmigrated PMNs were counted using a CASY cell counter 
system. 
4.2.3.9. Adhesion assay 
HUVECs were cultured on 96-well plates to confluence and pre-stimulated with 
5 nM TNFα overnight. On the day of assay, HUVECs were washed twice with 
warm medium and treated with compounds for 30 min. Human PMNs were 
freshly isolated as previously described (4.2.3.7) and incubated in BCECF 
solution for 10 min at room temperature. After being labeled with BCECF, 
neutrophils were added to HUVEC monolayers and coincubated for 30 min at 
37 °C. Fluoresce intensity of the total applied cel ls was read using a Tecan 
plate reader. After being washed with medium (once, twice, and three times), 
the fluorescence intensity was measured after each wash. Relative 
fluorescence intensity was set to the fluorescence of total applied cells.  
4.2.3.10. Myeloperoxidase (MPO) activation assay 
Human PMNs were freshly isolated from healthy volunteers as previously in 
4.2.3.7 described. 2.5x104 PMNs in HBSS without Phenolred and 0.1% (v/v) 
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gelatine were pre-incubated with cytochalsin B (10 µg/ml) for 10 min at 37 ºC. 
The cells were then incubated with 10 µl PBS or increasing doses of 
compounds (ADM or FSK) for 10 min at 37 ºC, followed by further incubation 
with 10 µl C5a (10 nM) or fMLP (3 nM) for 10 min at 37 ºC. For the experiments 
to detect dose-response curves of C5a or fMLP, the cells were incubated with 
increasing doses of C5a (30 pM-30 nM) or fMLP (10 pM-30 µM) for further 10 
min at 37 ºC. Finally, 30 µl of phosphate buffer (0.1 M, pH 6.8) were added to 
each well, followed by 60 µl of TMB substrate reagent for 20 min at room 
temperature. The reaction was stopped using 60 µl TMB stop solution. 
Absorbance was measured at 450 nm in a Tecan plate reader. Absorbance is 
an indicator for the level of released MPO. 
4.2.3.11. Fluorescence activated cell sorting (FACS) analysis 
PMNs (2x106) were incubated with vehicle and increasing doses of ADM (1 nM-
1 µM) for 30 min at 37 °C in MAM buffer, followed b y stimulation with 100 nM 
fMLP for further 30 min. Cells were then washed and incubated with 
phycoerythrin (PE)-labeled anti-CD11b monoclonal antibody or isotype control 
for 45 min on ice. Subsequently the neutrophils were washed three times with 
PBS and fixed with 1% PFA at room temperature. The expression level of 
CD11b was detected using FACSCalibur and data were analyzed with the 
software CellQuestTM Pro 5.2.1. 
4.2.4. In vivo-experiments 
4.2.4.1. Animals 
All of the experiments conformed to the German federal animal protection law 
and were approved by the legal district authority. We used 5-6 weeks old adult 
male BALB/c mice (Harlan Nederland) and adult male 200 g -250 g Wistar rats 
(Harlan Nederland) for our study. All of the animals were housed in a standard 
room with a 12/12-hour light/dark cycle: white lights were on from 06:00 to 
18:00 hours and the night phase was from 18:00 to 06:00 hours. The laboratory 
temperature was 23 ˚C and humidity 51.5% controlled. Food and water were 
available ad libitum, except during testing. The animals were randomly assigned 
to their respective treatment groups. 
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4.2.4.2. Miles assay to determine vascular permeability 
Modified Miles assays were performed as described previously (Schnoor et al., 
2011). For mice, 100 µl Evans blue dye [1% (w/v)] and 100 µl vehicle or 
compounds (ADM, Benz-cAMP, and “007”) were intravenously administered 
through retro-orbital injection under deep anesthesia with isoflurane. 10 min 
later, 50 µl PBS and 4.5 µg/ml histamine in PBS were injected intradermally into 
the back skin that was shaved 24 h before the assay. For rats, intravenous 
injection of 1 mg/kg body weight (BW) Evans blue dye [2% (w/v)] through a 
catheter into the femoral vein was performed. Afterwards, 100 µl PBS and 2.5 
µg/ml, 5 µg/ml, 10 µg/ml, 20 µg/ml, and 40 µg/ml histamine were intradermally 
injected into the abdominal skin. 30 min later, mice and rats were sacrificed by 
an overdose of isoflurane and subsequent neck dislocation, and skin areas 
surrounding the sites of injections were excised using biopsy punch. Evans blue 
dye was extracted from the skin by incubation in formamide for 5 days at room 
temperature. Subsequently, the optic density of extracted dye was measured at 
620 nm using a spectrophotometer. The concentration of extracted dye was 
calculated via a standard curve using 0, 1.25 mg/ml, 2.5 mg/ml, 5 mg/ml, 10 
mg/ml, 20 mg/ml, 40 mg/ml, and 80 mg/ml Evans blue dyes. The ratio of 
extracted Evans blue dyes to skin sample weight was taken as a measure of 
vascular permeability. 
4.2.4.3. LPS-induced acute lung injury model 
Neutrophil recruitment into the lung was analyzed in a murine model of LPS-
induced pulmonary inflammation as previously described (Kang et al., 2001; 
Arsalane et al., 2000). Briefly, 1 mg/kg body weight (BW) of LPS in 100 µl saline 
was injected intratracheally under deep anesthesia with isoflurane and lungs 
were analyzed 48 h later. Sham animals received saline instead of LPS in the 
same manner. ADM or saline was injected subcutaneously immediately before 
and 24 h after LPS application. Mice were sacrificed with an overdose of 
isoflurane and the trachea of each mouse was intubated with a tube (PE 90) 
and bronchoalveolar lavage (BAL) fluid was collected (3x0.5 ml saline). BAL 
fluid was homogenated and the number of white blood cells (WBC) was 
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determined using Celldyn. Protein concentration was measured in the BAL fluid 
after the experiment using BCA Protein Assay Reagent. 
4.2.5. Statistical analysis 
Data are expressed as the means ± standard error of mean (SEM) or standard 
deviation (SD). The significance of differences between groups was assessed 
by the unpaired Student’s t-test if allowed or otherwise by Mann-Whitney Rank 
Sum Test. Analysis, curve-fitting and calculation of the half-maximal effective 
concentrations (EC50) were performed using GraphPad Prim software (version 
5.0; GraphPad Software Inc., San Diego, CA). Values of probability (P) < 0.05 
were considered statistically significant.  
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5. RESULTS 
5.1. Analysis of ADM receptor expression and signalling 
ADM exerts its biological actions through binding to a heterodimeric GPCR 
complex composed of the CRLR associated with RAMP-2 or RAMP-3, which 
are essential to the receptor specificity, ligand affinity, and receptor 
desensitization. The first aim of the present studies was to characterize receptor 
expression and evaluate functional cAMP signaling of ADM in different 
endothelial cells.  
 
First of all, the expression patterns of CRLR, RAMP-2, and -3 were analyzed by 
quantitative RT-PCR in three types of endothelial cells from mouse and man 
which are widely used in endothelial cell biology research:  the murine brain 
endothelial cell line (bEnd.5), human primary umbilical vein endothelial cells 
(HUVECs) and human lung microvascular endothelial cells (HLMECs). 
Normalization was performed using β-actin as internal control, and relative 
expression was calculated as 2(15 - (CTprobe - CTactin)). The parameter CT is defined 
as the threshold cycle number at which the amplification plot passed a fixed 
threshold above baseline. The resulting expression is given in arbitrary units.  
 
As shown in Figure 6A, in bEnd.5, relative expression levels of CRLR, RAMP-
2, and -3 mRNA normalized to β-actin were equally high with approximately 
10.000 arbitrary units. The absolute CT values of CRLR, RAMP-2, and -3 in 
bEnd.5 cells were 22.3 ± 0.4, 19.8 ± 0.3, 22.0 ± 0.1, respectively (mean ± SD). 
In primary human endothelial cells, the relative expressions of CRLR and 
RAMP 2 were lower than those in bEnd.5 cells. The CT values of CRLR and 
RAMP 2 in HLMECs were 33.2 ± 1.3 and 23.8 ± 0.2; while in HUVECs 31.7 ± 
0.3 and 22.4 ± 0.1 (mean ± SD). The normalized expression levels of CRLR 
and RAMP-2 were comparable in HLMECs and HUVECs with 10 and 1,000 
arbitrary units, respectively. RAMP-3 mRNA was hardly detectable (CT=40.0). 
In HUVECs, stimulation with ADM lead to an increase of intracellular cAMP in a 
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dose-dependent manner (Figure 6B). The saturation dose was achieved at 3 
nM ADM inducing a maximal three-fold increase of cAMP levels. Because of 
their easy accessibility and their representative expression pattern of ADM 
receptor constituents for human endothelial cells and functional cAMP signaling 
after ADM stimulation, primary human umbilical endothelial cells were chosen to 
evaluate effects and signaling events of ADM in vitro.  
 
Figure 6 Analysis of ADM receptor expression and signaling in endothelial cells 
(A): Expression of CRLR, RAMP-2 and -3 in different endothelial cells. Quantitative real-time 
RT-PCR analysis was performed on mouse bEnd.5 cells (white bar), human lung microvascular 
endothelial cells (HLMVECs) (black bars) and human umbilical vein endothelial cells (HUVECs) 
(striped bars) using specific oligonucleotide primers and probes.  Expression levels were 
normalized to β-actin as a house–keeping gene. (n=2, mean ± SD) (B): Evaluation of cAMP 
signaling in human endothelial cells. Intracellular cAMP accumulation was measured by use of 
a commercial ELISA. HUVECs were stimulated with different doses of ADM for 15 min and 
subjected to extraction in 70% (v/v) Ethanol overnight at -20 ºC. (n=2, mean ± SEM) 
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5.2. Effects of ADM on endothelial barrier integrity 
Disruption of endothelial barrier contributes to tissue edema and facilitates 
leukocyte transmigration, which are hallmarks of inflammation. To evaluate the 
effects of ADM on endothelium under inflammatory conditions, two separate 
directions were explored: the regulation of endothelial permeability and the 
interference with granulocyte extravasation.  
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5.2.1. Anti-edematous effects of ADM in vitro 
Cytokines such as TNFα, as well as components of the activated coagulation 
cascade such as thrombin are important mediators of acute inflammation. 
Thrombin impairs endothelial permeability via activation of protease activated 
receptors (PAR1-3) and in concert with TNFα, leads subsequently to vascular 
leakage thereby contributing to severe organ dysfunction (Seybold et al., 2005). 
Different stimuli, such as thrombin, TNFα, histamine, VEGF, IL-1β, and LPS, 
were used to mimic inflammation in vitro. Whether ADM could antagonize 
stimuli-induced hyperpermeability was first analyzed using different in vitro-
models. 
5.2.1.1. Effects of ADM on thrombin-induced endothelial 
hyperpermeability 
Binding of thrombin to its PAR receptor activates heterotrimeric G-proteins, 
resulting in decrease of intracellular cAMP level, increase of calcium influx and 
activation of Rho-kinase, initially leading to phosphorylation of MLC and 
disrupted endothelial integrity (Garcia et al., 1995; Birukova et al., 2004b). On 
primary cultured HUVECs, two of the thrombin-responsive PARs, PAR-1 and -3, 
are expressed, of which only PAR-1 appears to be responsible for thrombin to 
affect cytoskeletal reorganization (Vouret-Craviari et al., 2002). Previous studies 
have demonstrated that pretreatment of ADM could reduce thrombin-induced 
hyperpermeability within 50 minutes using measurement of hydraulic 
conductivity (Hippenstiel et al. 2002). However, whether ADM could 
therapeutically attenuate thrombin-induced barrier dysfunction was still not 
investigated. 
 
The ECIS model and the FITC-dextran model were applied to characterize 
permeability of endothelial monolayer in vitro. Using ECIS, the transendothelial 
electrical resistance (TEER) was determined as a surrogate for the permeability 
of the endothelial cell monolayer for water and ions. Untreated HUVECs 
displayed a stable monolayer over the entire experiment (Figure 7A and B). 
Thrombin induced a rapid decrease in TEER, which reached the peak of 36 ± 
4.5% (mean ± SD) 45 min after stimulation. But this decrease was transient, 
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and TEER returned to its original level within 3 h after thrombin addition. The 
initial peak decrease is due to the release of calcium from intracellular stores, 
whereas the plateau phase accounts for extracellular calcium influx (Sandoval 
et al., 2001). The addition of ADM as a bolus rapidly enhanced the TEER of 
resting cells to 171 ± 5.7% (mean ± SD). TEER remained stable within the time 
frame tested. Addition of thrombin after ADM pre-incubation caused a similar 
netto decrease of TEER  as without ADM pretreatment, however, the TEER 
was above the baseline value during the entire period and returned to 136 ± 
15.9%  (mean ± SD) similar to the ADM group without thrombin stimulation. 
Moreover, the decrease of TEER induced by thrombin was reverted 
immediately after ADM post-treatment and returned to 150 ± 7.4% (mean ± SD) 
which was in the same range as after ADM treatment without thrombin 
stimulation. Taken together, addition of ADM 30 min before or after thrombin 
administration antagonized and reversed thrombin-induced decrease of TEER, 
respectively.  
  
In addition to TEER measurements, paracellular permeability for 
macromolecular 40 kDa FITC-dextran through an endothelial cell monolayer 
was analyzed (Figure 7C-D). Thrombin administration induced an increase of 
macromolecular permeability to 153 ± 27.2% (mean ± SD) after 60 min, which 
was consistent with the observations in the ECIS model. ADM pretreatment 
totally antagonized thrombin-induced hyperpermeability and even resulted in a 
less permeable monolayer as compared to the control cell monolayer during the 
entire experiment. Moreover, ADM post-treatment reversed thrombin-induced 
hyperpermeability to the levels of control monolayer. 
 
Both methods consistently revealed that thrombin rapidly caused 
hyperpermeability of EC monolayers, whereas ADM attenuated this barrier 
disruption in both a prophylactic and therapeutic manner. 
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Figure 7 Effects of ADM on thrombin-induced hyperpermeability using different in vitro-
models.  
(A-B): HUVECs were seeded on 96-well ECIS microelectrode plates and TEER was 
continuously recorded. At the time points indicated by arrows, cells were treated with vehicle or 
100 nM ADM or 0.5 U/ml thrombin and TEER was measured over 6 hours. Relative TEER was 
normalized to the TEER measured at the beginning of the experiment. (C-D): Endothelial cells 
were cultured on transwell filters and paracellular permeability for 40kDa FITC-dextran was 
determined at different time points. (A and C): Endothelial monolayer was pre-incubated with 
ADM 30 min prior to thrombin stimulation. (B and D): ADM administration was followed 30 min 
after thrombin incubation. (n=8 for ECIS and n=4 for FITC-dextran-permeability, mean ± SEM) 
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In the next step, fluorescence microscopy was applied to investigate whether 
the observed ADM effect on barrier integrity was paralleled by an effect on 
junctional proteins and the contractile apparatus. Cellular actin was visualized 
with Alexa-555 phalloidin and no changes in regular stress fiber and cortical 
actin architecture were observed after addition of ADM to quiescent cells 
(Figure 8A and B). Thrombin induced pronounced stress fiber formation 
followed by reduced cortical actin staining and retraction of cell mass toward the 
center (Figure 8C). In quiescent cells, the staining for VE-cadherin around cell 
border represents a continuous straight line (Figure 8A). This pattern was not 
changed by addition of ADM to normal cells (Figure 8B). Thrombin stimulation 
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led to visible cellular retraction and distorted VE-cadherin linear structure with 
visibly deficient VE-cadherin staining, forming a zigzagged line with gaps 
(Figure 8C). ADM incubation prevented the VE-cadherin distortion and gap 
formation, as well as stress fibers formation and retraction of the cell mass 
toward the center (Figure 8D). These findings suggested that ADM enhanced 
the association of VE-cadherin with membrane structures, particularly 
peripheral cortical actin, thus stabilizing barrier integrity. 
 
Figure 8 Effect of ADM on thrombin-induced F-actin and VE-cadherin distribution.  
HUVECs were grown to confluence on fibronectin-coated glass cover slides, stained for F-actin 
(red) and VE-cadherin (green), nucleus (blue), and visualized with 100-fold magnification. Cells 
treated with vehicle (A) or 100 nM ADM (B) displayed a well-arranged cortical actin with few 
stress fibers and continuous cell-cell junctions. Stimulation with 0.5 U/ml thrombin (C) caused a 
massive increase of stress fibers, distortion of VE-cadherin and formation of intercellular gaps. 
Pretreatment of ADM prior to thrombin stimulation (D) prevented VE-cadherin distortion and gap 
formation, and reduced stress fibers. Bars = 20 µm.. 
 
 
 
 
 
 
A B C D
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5.2.1.2. Effects of ADM on TNFα-induced endothelial hyperpermeability 
TNFα is reported to induce vascular hyperpermeability in vivo and in vitro via 
direct activation of endothelial actomyosin-based cytoskeleton and formation of 
paracellular gaps via phosphorylation of MLCK. In addition, TNFα upregulates 
cyclic guanosine monophosphate (cGMP) -stimulated PDE2 thus decreasing 
intracellular cAMP levels thus facilitating barrier disruption (Seybold et al., 
2005). 
  
Unlike thrombin, TNFα provoked a slow and long lasting diminishing in TEER 
levels (Figure 9A and B). TEER gradually reached its trough at 63 ± 11.1% 
(mean ± SD) 5 h after stimulation with TNFα, and remained stable throughout 
the rest of the experiment. TEER did not recover as after thrombin stimulation. 
Addition of ADM as a bolus rapidly enhanced the TEER of resting cells to 159 ± 
50.0% (mean ± SD) and stayed stable within the time frame tested. Similar to 
the group without ADM treatment, TNFα stimulation decreased TEER by ~50% 
after ADM pre-incubation, however, the TEER decreased only to its initial 
baseline level. Moreover, the TNFα induced decrease of TEER was reverted 
immediately after ADM posttreatment and returned to its initial baseline level 
with reaching the same level as the control group without stimulation. Addition 
of ADM 30 min prior to or 5 h following TNFα administration could both 
antagonize and reverse the decrease of TEER towards the baseline level of the 
control monolayer. This effect of ADM was also observed in the FITC-dextran 
model (Figure 9C). Addition of ADM reduced the endothelial permeability for 
FITC-dextran to 68 ± 7.2% (mean ± SD).  7 h TNFα stimulation induced a 
hyperpermeability of the endothelial monolayer to 164 ± 4.7%, whereas only to 
143 ± 9.7% (mean ± SD) after ADM pretreatment. Like under thrombin 
stimulation, ADM attenuated TNFα induced endothelial hyperpermeability in 
both, a prophylactic and therapeutic manner. 
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Figure 9 Prophylactic and therapeutic potency of ADM on TNFα stimulation in vitro.  
(A-B): HUVECs were grown on ECIS microelectrode plates to confluence. Monolayers were 
treated with vehicle or 100 nM ADM prior to or following 1 nM TNFα stimulation. (C): HUVECs 
were seeded onto transwell filters and paracellular permeability for 40 kDa FITC-dextran was 
determined. (A and C): Endothelial monolayer was pre-incubated with ADM 30 min prior to 
TNFα stimulation. (B): ADM was added 7 h after TNFα incubation. (n=8 for ECIS and n=4 for 
FITC-dextran-permeability, mean ± SEM) (*p<0.05; ***p<0.0005 vs. control group; ###p<0.0005 
vs. TNFα group) 
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5.2.1.3. Effects of ADM on endothelial hyperpermeability induced by 
different stimuli (LPS, Histamine, IL-1β, and VEGF) 
Since ADM showed significant effects on stabilization of endothelial 
permeability against thrombin and TNFα stimulation, the question was raised 
whether these effects could also be transferred to other inflammatory stimuli, 
such as histamine, vascular endothelial growth factor (VEGF), 
lipopolysaccharide (LPS), and Interleukin 1β (IL-1β). 
 
Histamine, an edematogenic factor mainly released by basophilic granulocytes, 
contributes to microvascular leakage in response to the acute inflammation 
associated with trauma, burns, and allergy. Upon binding of histamine to Gq-
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coupled H1 receptor, intracellular calcium concentration is elevated, 
subsequently activating MLCK and triggering actin-myosin contraction. 
Histamine was also reported to activate MAP kinase downstream and to have 
direct effects on junctional proteins, phosphorylating and disrupting components 
of the adherence junction and tight junctions (reviewed by Kumar et al., 2009). 
In ECIS the barrier disrupting effects of histamine were less pronounced than 
after administration of thrombin. After application of saturating dose (data from 
pre-experiment not shown), the electrical resistance of a HUVEC monolayer 
rapidly dropped within 1 hour by 35 ± 9.7% (mean ± SD) and recovered 
completely to the level of control monolayer after 1 hour (Figure 10A). 
Pretreatment with 100 nM ADM (30 min) induced an increase of TEER to 134 ± 
11.7% (mean ± SD) and attenuated the histamine evoked decrease of electrical 
resistance. However, the histamine induced drop-down by 16 ± 10.0% (mean ± 
SD) was not totally antagonized by treatment with ADM.   
 
Beside its important role as angiogenesis factor, VEGF was originally identified 
as a vascular permeability factor, causing interstitial accumulation of 
intravenously injected dyes and ascites in vivo. There is evidence from ultra-
structural studies that VEGF increases transcellular permeability, but also 
increase of paracellular permeability by promoting cellular contraction, 
influencing focal adhesion dynamics, as well as opening of cell-cell junctions 
(reviewed by Kumar et al., 2009). Similar to histamine, administration of 
saturating concentration of VEGF (100 ng/ml) induced a rapid decrease of 
electrical resistance by 23 ± 11.1% (mean ± SD) (as compared to control 
monolayer) within 1 hour (Figure 10B). However, the effect of VEGF was not 
reversible and remained at the same level during 20 h experiment. Pretreatment 
with ADM prevented the initial VEGF-induced drop in TEER by ~10%. This 
protective effect was gradually lost over the observation interval.   
 
LPS has been identified as an important pathogenetic factor derived from the 
outer membrane of gram-negative bacteria which induces systemic 
inflammation and sepsis in mammals. Binding of LPS to Toll-like receptor 4 
(TLR4) activates the MAP kinase cascade, contributing to gene expression of 
pro-inflammatory cytokines, remodeling of endothelial cytoskeleton, as well as 
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permeability changes (reviewed by Xing & Birukova, 2010). LPS in the 
saturating dose of 300 ng/ml provoked a slow and long lasting dwindling in 
TEER levels with the trough at 85 ± 4.0% (mean ± SD) after 5 h stimulation, 
which remained stable throughout the rest of the experiment (Figure 10C). 
Following treatment with ADM TEER was rapidly enhanced to 131 ± 8.7% and 
LPS stimulation decreased this TEER to 102 ± 5.5% (mean ± SD). Addition of 
ADM 30 min prior to LPS administration could antagonize the decrease of 
TEER towards the baseline level of the control monolayer. However, the 
amplitude of decrease in TEER was not influenced. 
 
In the similar manner to LPS, the pro-inflammatory cytokine IL-1β in saturating 
dose of 10 pM slowly and irreversibly induced a decline of TEER levels with 
maximal drop-down to 59 ± 14.3% (mean ± SD) after approximately 5 h 
stimulation (Figure 10D). ADM pretreatment rapidly increased the TEER to 137 
± 5.6%, which was reduced to 87 ± 2.4% with the extent of 50 ± 6.9% (mean ± 
SD).  Despite stimulation with IL-1β, ADM stabilized TEER. However, the 
absolute changes of TEER following IL-1β addition were not affected by ADM.   
 
In summary the net gain in TEER which was inducible by treatment with ADM 
was not dependent on the cellular condition (i.e. resting or inflammatory 
stimulated).  Therefore it might be speculated that ADM exerts its barrier 
stabilizing effects via a signaling pathway that is independent of the pathway(s) 
addressed by the stimuli tested. 
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Figure 10 Effects of ADM on endothelial barrier dysfunction induced by different stimuli 
HUVECs were seeded on 96-well ECIS microelectrode plates and TEER was continuously 
recorded. At the time points indicated by the arrows, cells were pretreated with vehicle or 100 
nM ADM for 30 min, followed by different stimuli, including 4.5 µg/ml histamine (A), 100 ng/ml 
VEGF (B), 300 ng/ml LPS (C), and 10 pM IL-1β (D). Relative TEER was normalized to the 
TEER measured at the beginning of the experiment. (n=8, mean ± SEM) 
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5.2.2. Effects of ADM on leukocyte transmigration in vitro 
Transmigration of leukocytes from the bloodstream into the tissue is essential to 
the immune response that enables leukocytes to reach the site of infection and 
injury. This situation can be mimicked in vitro in a transmigration assay in which 
leukocytes are allowed to migrate through an endothelial monolayer grown on a 
filter membrane. While endothelial cells are stimulated by overnight 
pretreatment with TNFα, PMNs migrate towards the chemokine gradient of IL-8 
(Downey et al., 1995). In pre-experiments, buffy coat which contained all kinds 
of leukocytes (~40% neutrophilic granulocytes, 40% lymphocytes, 10% 
monocytes, 4% eosinophilic-, and 1% basophilic-granulocytes; data from pre-
experiment) was added to HUVEC monolayer. With >95% neutrophilic 
granulocytes (PMNs) were the predominant cell type having transmigrated the 
membraneBased on this observation, isolated PMNs were further used and 
discussed in the in vitro-leukocyte transmigration assays. 
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Because of the vital importance of leukocyte extravasation and an anti-
inflammatory role of ADM described in the literature, it was questioned whether 
ADM could affect this process. ICAM-1 is the major endothelial adhesion 
receptor relevant to firm adhesion of neutrophils to endothelial cell surfaces; 
therefore ICAM-1 antibody was used as a positive control in the assays. After 
the incubation with ICAM-1 antibody, only ~10% of PMNs transmigrated 
through TNFα- stimulated HUVEC monolayers (Figure 11A). Also ADM 
significantly reduced PMN transmigration to 61 ± 14.1% (mean ± SD). In order 
to distinguish whether the effect of ADM was due to an effect on the endothelial 
cells or the leukocytes, in a parallel experiment PMNs were incubated with ADM 
and washed prior to transmigrating through the HUVEC monolayer. In contrast 
to its significant effect on endothelial cells, treatment of PMN with ADM or 
ICAM-1 antibody had no effect on the transmigration of leukocytes (Figure 
11B).  
 
Figure 11 Effects of ADM on TNFα-induced leukocyte transmigration  
PMNs were allowed to transmigrate toward the chemokine IL-8 through a HUVEC monolayer on 
transwell filter which was stimulated overnight by TNFα (5 nM). Either the HUVECs (A) or the 
human neutrophils (B) were treated for 30 min with vehicle, ICAM-1 antibody (60 µg/ml), or 
ADM (100 nM). In each case, the number of neutrophils migrating under control condition was 
set to 100%. (n=3, mean ± SEM) (***p<0.0005 vs. control group) 
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To more accurately comprehend any possible anti-inflammatory action of ADM 
on PMN, the expression of ADM receptors CRLR, RAMP-2, and -3 in PMNs 
were analyzed (Figure 12A). The absolute CT value of CRLR, RAMP-2 and -3 
were 32.0 ± 0.1, 25.9 ± 0.7, 28.6 ± 0.3, respectively (mean ± SD). The relative 
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expression levels of CRLR and RAMP-2 normalized to β-actin were roughly at 
the same levels as in HUVECs, with 10 and 1000 arbitrary units, respectively. 
While RAMP-3 was hardly detectable in HUVECs, it was expressed in PMNs 
with relative expression of 100 arbitrary units. In PMNs, increasing 
concentrations of ADM (1 pM-1µM) had no effects on accumulation of 
intracellular cAMP (Figure 12B). In this assay, FSK, known as a strong cAMP 
elevator via direct activation of adenylate cyclase (AC), was used as positive 
control. Stimulation with FSK (100 µM) significantly increased intracellular 
cAMP in PMNs. Taken the data together, despite the expression of ADM 
receptor mRNA (CRLR, RAMP-2, and -3), no functional cAMP signaling of ADM 
was detectable in PMNs. Wheter ADM receptor protein is expressed by PMNs 
could not be decided due to the unavailability of a specific and sufficiently 
sensitive antibody.  
 
Stimulated PMNs release a couple of hydrolytic and proteolytic enzymes as well 
as myeloperoxidase (MPO) from their cytoplasmic granules. MPO has a dual 
activity as peroxidase and chlorinating enzyme, generating other oxidant 
species and more particularly hypochlorous acid (HOCl), one of the most 
powerful oxidant molecules in vivo. Thus, MPO is an important component of 
the defense machinery (Franck et al., 2009). MPO release is a measure of MPO 
activation. A wide variety of stimuli (e.g. fMLP and the anaphylatoxin C5a) 
initiate the degranulation process of PMNs via specific receptor signaling 
(Patrick et al., 1996). In a modified MPO release assay (described by 
Paczkowski et al., 1999). it was examined whether ADM could affect MPO 
release from PMNs after stimulation with C5a or fMLP.  
 
C5a is a component of the complement system that causes chemotaxis and 
degranulation of PMNsAs shown in Figure 12C, human C5a dose-dependently 
increased activation of human PMNs, with the minimal dose of 3 nM. In the next 
step PMNs, stimulated with 10 nM C5a, were pre-incubated with increasing 
doses of ADM (1 nM to 1 µM) and forskolin (FSK) (100 nM to 100 µM) (Figure 
12D). W54011, a potent and highly selective C5a antagonist, was used in doses 
of 30 nM to 10 µM as positive control. While 1 µM W54011 totally antagonized 
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C5a-induced MPO release, neither ADM nor FSK showed any effects on PMN 
stimulation. 
 
The synthetic tripeptide, N-Formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP), 
mimics the effect of various bacterial cell wall-derived peptides activating PMN 
via binding to a specific GPCR and thus is widely used as a GPCR-dependent 
stimulus of the PMNs and as a chemo attractant molecule (Brazil et al., 1998; 
Sheppard et al., 2005). As shown in Figure 12E, fMLP dose-dependently 
increased activation of human PMNs, with the minimal dose of 100 pM and the 
saturation dose of 1 µM. Increasing doses of ADM (1 nM to 1 µM) and FSK 
(100 nM to 100 µM) were applied to - PMNs stimulated with 3 nM fMLP (Figure 
12F). Similarly to C5a-induced PMN activation, neither ADM nor FSK affected 
fMLP-induced activation of PMNs. A positive control was not available. 
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Figure 12 ADM Receptor expression and its effects on MPO release from human 
neutrophils  
(A): Quantitative real-time RT-PCR analysis was performed on freshly isolated human 
neutrophils using specific oligonucleotide primers and probes.  Expression levels of CRLR, 
RAMP-2, and -3 were normalized to β-actin. (n=2, mean ± SD) (B): Intracellular cAMP 
accumulation was measured by use of a commercial ELISA. 5x106 Human PMNs were 
stimulated with different doses of ADM (1 pM-1 µM) and FSK (10 µM) for 15 min. Then the cells 
were subjected to extraction in 70% (v/v) ethanol overnight at -20 °C. (n=2, mean ± SD)  (C) - 
(F): To investigate the activation of human neutrophils, levels of released MPO were 
determined. (C) and (E): 2.5×104 PMNs  were incubated with increasing concentrations of C5a 
(C) or fMLP (E). (D) and (F): PMNs were incubated with increasing concentrations of test 
compounds (W-54011, ADM or FSK) for 10 min at 37 °C,  following by incubating the cells for a 
further 10 min at 37 °C with 10 nM C5a (D) or 3 nM fMLP (F). The level of released MPO was 
determined by measuring absorbance at 450 nm. (n=2, mean ± SEM)  
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In response to inflammtion, cytokines up-regulate expression of CD11b/18 on 
neutrophils and ICAM-1 on endothelial cells, promotiong adhesion and 
interaction of neutrophils with endothelium (Smith, 1993; Saito et al., 2001). In a 
static adhesion assay, different doses of ADM were tested whether they wre 
able to affect the adhesion of PMNs to HUVECs (Figure 13A-C). None of the 
ADM doses were able to influence the adhesion of PMNs upon short term 
exposure for 30 min. In consistency with this observation, the cell surface 
expression level of CD11b on neutrophils was also not affected by ADM (Figure 
13D).  
 
Taken all these data together, prevention of TNFα-induced leukocytes 
transmigration was rather mediated by direct action of ADM on endothelial cells 
than on leukocytes. Despite the receptor mRNA expression, a significant effect 
of ADM on PMN activation and adhesion could not be established, which was 
consistent with lack of functional cAMP signaling.  
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Figure 13 Effect of ADM on cell adhesion of neutrophils to endothelial cells  
(A): Static cell adhesion assay was performed for human neutrophils to HUVECs. HUVECs 
were pretreated with 5 nM TNFα and incubated with increasing doses of ADM (10 pM-100 nM) 
for 30 min. BCECF-labeled human neutrophils were added to HUVEC monolayer and allowed 
for 30 min co-incubation. Fluorescence intensity was measured for the total applied PMNs and 
for each wash.  The relative fluorescence was set to the value of total applied PMNs. (n=4, 
mean ± SD) (B): The protein expression of CD11b was measured by use of FACS. Human 
PMNs were incubated with different doses of ADM (1 pM-1 µM) for 30 min, followed by 
stimulation with fMLP (100 nM). Then the cells were subjected to PE-labeled anti-CD11b 
antibody and isotype control, and then performed for FACS analysis. Only the data with 100 nM 
ADM was shown below. 
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5.2.3. Anti-edematous effects of ADM in vivo 
The in vitro-data provided evidence that ADM stabilized the endothelial barrier 
for water, ions and macromolecules and attenuated endothelial barrier 
disruption provoked by thrombin and TNFα. Next, it was addressed whether this 
in vitro-finding could be translated to in vivo-models. A modified Miles assay 
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was performed to detect vascular permeability in the skin of rats (Figure 14A) 
and mice (Figure 14B) using intravenously administered Evans blue dye as 
indicator for vascular hyperpermeability. Evans blue is a highly plasma protein 
bound dye and therefore used as an indicator for protein-rich fluid extravasation 
and vascular leakage. 
 
In the rat vehicle group, intradermal administration of histamine dose-
dependently increased permeability of Evans blue dye in the skin about two-fold 
(194 ± 37.0%; mean ± SD) at 40 µg/ml, as compared to basal permeability with 
intradermal PBS application. Intravenous application of 10 µg/kg BW ADM 
reduced basal permeability by ~33% and decreased histamine-induced 
hyperpermeability by ~35%. 30 µg/kg BW and 100 µg/kg BW ADM reduced 
basal permeability by ~80% to 19 ± 6.2% and 22 ± 11.1% (mean ± SD), 
respectively, and the histamine-induced hyperpermeability was both decreased 
by ~75%. 30 µg/kg BW ADM reached the maximal effect on regulation of 
permeability and thus represented the saturation dose. Albeit on a four-fold 
lower level, histamine still caused a two-fold increase of permeability in rats, 
which was not diminished by the saturating dose of ADM.  
 
In the mouse vehicle group, intradermal administration of 4.5 µg/ml histamine 
induced a three-fold increase of permeability of Evans blue dye in the skin. 
Unlike Miles assay in rats, intravenous administration of 10 µg/kg BW ADM had 
no significant effect on vascular permeability in mice. Both 30 µg/kg BW and 
100 µg/kg BW ADM decreased basal permeability by ~50% and histamine-
induced hyperpermeablility by ~80%, which were consistent with the saturating 
doses in rats. These data were in support of the in vitro-finding that ADM 
stabilized endothelial barrier function and underscored its strong anti-
edematous potency.  
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Figure 14 Effects of ADM on histamine-induced vascular hyperpermeability in the skin of 
rats and mice  
Anesthetized rats (A) and mice (B) were i.v. injected with vehicle or ADM, then with Evans blue 
dye, and finally underwent intradermal injection of PBS or histamine and were sacrificed 30 min 
thereafter. The dye was extracted from skin samples and quantified. (A): Evans blue dye was 
normalized to the sample weight. Rats were divided into four groups: control (black), ADM 10 
µg/kg BW (green), ADM 30 µg/kg BW (blue), and ADM 100 µg/kg BW (red). (Data are 
expressed as mean ± SEM, n=4~7.) (B): Mice were divided into five groups: vehicle, 3 µg/kg 
BW, 10 µg/kg BW, 30 µg/kg BW and 100 µg/kg BW ADM followed by intradermal injections of 
PBS (black bars) and histamine (white bars). (Data were expressed as mean ± SEM, n=5~8.) 
(#p<0.05 vs. control group with PBS injection; ***p<0.0005 vs. control group with histamine 
injection) 
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5.2.4. Anti-inflammatory effects of ADM in vivo 
As the previous in vitro-data indicated the protective effects of ADM on 
endothelial permeability and granulocyte extravasation, anti-inflammatory 
effects of ADM in vivo were investigated. Intratracheal administration of LPS 
was performed in anesthetized mice as a model for acute lung injury which is 
characterized by increased permeability and granulocytes extravasation. As 
shown in Figure 15, after 48 h, challenge with LPS dose-dependently induced 
significant lung injury as indicated by increased lung weight (A), WBC-counts 
(B), and protein content (C) in bronchoalveolar lavage (BAL) fluid as compared 
to the sham group. 0.5 mg/kg BW LPS represented the saturating dose, which 
induced ~1.5 fold increase of lung weight, ~3.5 fold increase of protein content 
and ~20 fold increase of WBC in BAL fluid. Increased protein content in BAL 
fluid and increased lung weight are regarded as markers for increased 
endothelial permeability of macromolecules and water, while increased WBC 
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counts are resulting from the interaction of endothelium with leukocytes. The 
LPS induced acute lung injury model allowed the in vivo-detection of those two 
inflammatory parameters, permeability and leukocytes extravasation. 
 
As shown in Figure 16A, 48 h after LPS challenge (1 mg/kg BW) a lung edema  
was present with increased lung weight to 170 ± 17.1% (mean ± SD), as 
compared to sham group. Treatment with ADM ameliorated the formation of 
lung edema, reducing the lung weight to 147 ± 17.8% (mean ± SD). 
Accompanied with lung edema formation, LPS challenge induced a 16 ± 5.4 
(mean ± SD) -fold increase of WBC counts in BAL fluid, which was reduced to 
12 ± 3.8 (mean ± SD) folds after ADM administration (Figure 16B). This in vivo-
observation was consistent with the previous in vitro-finding, that ADM 
significantly prevented TNFα-induced PMN transmigration through HUVEC 
monolayers.  
 
Figure 15 Challenge of LPS induced lung edema and accumulation of leukocytes and 
proteins in BAL fluid 
Mice were intratracheally administrated with vehicle, 0.1 mg/kg BW, 0.5 mg/kg BW, 1 mg/kg BW 
and 3 mg/kg BW LPS. 48 hours later BAL was performed and lung injury was evaluated by 
measurement of wet lung weight (A), WBC (B) and protein (C) counts in the BAL fluid. The 
values are shown as mean ± SEM, n=4. (*p<0.05, **p<0.005, and ***p<0.0005 vs. sham group) 
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Figure 16 Anti-inflammatory effects of ADM in acute lung injury induced by LPS 
challenge  
Mice were divided into three groups: 1) the sham group with intratracheal administration of 
saline (n=9); 2) the LPS group with intratracheal challenge of 1 mg/kg BW LPS (n=18); and 3) 
the LPS-ADM group pre-treated with ADM (100 µg/kg BW) and underwent intratracheal 
challenge with 1 mg/kg BW LPS (n=18). The severity of lung injury was evaluated regarding wet 
lung weight (A) and WBC (B) counts in the BAL fluid after 48 hours LPS administration. Data 
are shown as mean ± SEM. (***p<0.0005 vs. sham group; #p<0.05 and ###p<0.0005 vs. LPS 
group) 
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5.3. Analysis of cAMP-dependent pathway in ADM signalling 
As shown in Figure 6 ADM caused intracellular cAMP accumulation in primary 
endothelial cells. The intracellular second messenger cAMP is known to 
stabilize endothelial barrier function via two distinct downstream mechanisms 
(Bindewald et al., 2004), on one hand via PKA activation reducing 
phosphorylation of MLC and thereby relaxing the contractile machinery (Essler 
et al., 2000), and on the other hand increasing VE-cadherin mediated cell 
adhesion via Epac/Rap1 activation (Fukuhara et al., 2005). It seems reasonable 
to hypothesize that ADM exerts its regulatory function on the endothelial barrier 
mainly through cAMP signaling. However, ADM-cAMP-independent signaling 
has also been discussed with the consideration that ADM fully exerts its barrier 
protective function at much lower cAMP levels as compared to forskolin (FSK), 
a direct activator of adenylate cyclase (AC) (Hippenstiel et al., 2002). Therefore 
additional signaling pathways were postulated. However, the precise correlation 
of induced cAMP levels and their protective effects have not been elaborated by 
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these authors. It was the aim of the following studies to precisely determine the 
lowest effective doses and pEC50 values of ADM and FSK under exactly the 
same experimental conditions with respect to reduction of endothelial 
permeability and leukocyte transmigration. Accumulation of cAMP and further 
activation of cAMP signaling pathways (activation of PKA and Epac/Rap1) were 
analyzed and correlated with their effects. 
5.3.1. Comparison of ADM and FSK effects on generation cAMP 
For the initial characterization of ADM and FSK-induced cAMP response, a 
CHO cell line stably expressing cAMP-gated cation channel, the ADM receptor 
(CRLR and RAMP-2), and cytosolic apoaequorin was employed. In this CHO-
ADM1-reporter system, ligand-mediated activation of Gs-coupled GPCRs 
increase cAMP levels by activation of adenylate cyclase and subsequent 
opening of the cAMP-gated cation channel, resulting in calcium influx from 
extracellular stores, which can be detected as aequorin luminescence signal. In 
addition, activation of Gq-coupled GPCR stimulates phospholipase C/IP3 
pathway which can also be detected via aequorin luminescence stimulated by 
calcium release from intracellular stores, the endoplasmic reticulum (Wunder et 
al., 2008). As shown in Figure 17A and B, stimulation of CHO-ADM1-reporter 
cell line with ADM and FSK resulted in concentration-dependent luminescence 
signals with pEC50 value of -8.1 ± 0.1 [M] and -5.6 ± 0.1 [M] (mean ± SD), 
respectively. Furthermore, 1 nM ADM and 1 µM FSK were the lowest effective 
doses able to increase luminescence signals significantly. ADM was about 4-
fold less efficacious than FSK. 
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Figure 17 Characterization of ADM and FSK in CHO-ADM1-reporter cells  
Concentration-dependent luminescence signals generated after stimulation with ADM (A) and 
FSK (B) were detected in CHO-ADM1-reporter system. Agonists were added for 6 min in 
CAFTY solution and measurements were started immediately prior to adding the final 
concentration of Ca2+ at 3 mM. (n=4, mean ± SEM) 
 
 
5.3.2. Comparision of ADM and FSK effects on cAMP accumulation 
In the next step, the intracellular cAMP levels which were induced by ADM and 
FSK in primary human endothelial cells, were compared (Figure 18A and B). 
The lowest effective doses of ADM and FSK able to induce significant increase 
of cAMP were 100 pM and 100 nM, respectively. In addition, stimulation of ADM 
and FSK resulted in concentration-dependent increase of cAMP with pEC50 
value of -9.9 ± 0.3 [M] and -5.5 ± 0.6 [M] (mean ± SD), respectively. Moreover, 
FSK could induce ~40-fold increase of cAMP levels, whereas ADM induced 
only ~4-fold increase at its saturation dose. 
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Figure 18 ADM and FSK increased accumulation of intracellular cAMP  
Intracellular cAMP accumulation in HUVEC was measured using a commercial cAMP ELISA. 
The primary endothelial cells were stimulated with different doses of ADM (A) and FSK (B) for 
30 min and were subjected to incubation in 70% (v/v) ethanol overnight at -20ºC to extract 
intracellular cAMP. ∆cAMP was set as the difference to the values measured in control wells in 
each group. (n=4, mean ± SEM) (* and # vs. control group; * parametric t-test, # non-parametric 
Mann-Whitney test)(*p<0.05, **p<0.005, ***p<0.0005, #p<0.05, and ##p<0.005) 
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5.3.3. Comparision of ADM and FSK effects on permeability 
The goal of the following studies was to correlate ADM and FSK-induced 
intracellular cAMP accumulation with their effects on permeability of HUVEC 
monolayer. In direct comparison using the ECIS methodel, ADM and FSK 
prevented thrombin induced hyperpermeability (as quantified by reduction of 
TEER) with pEC50 value of -9.6 ± 0.2 [M] and -5.6 ± 0.4 [M] (mean ± SD), 
respectively (Figure 19). 30 pM ADM and 30 nM FSK were the minimum doses 
to significantly reduce thrombin-induced hyperpermeability, respectively. In 
addition, FSK stimulation could induce much higher TEER after further dose 
escalation, as compared to ADM stimulation, which was consistent with the 
difference in accumulation of cAMP levels. 
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Figure 19 Comparison of ADM and FSK effects on electrical resistance by using ECIS  
HUVECs were incubated with ADM (A) or FSK (B), and were stimulated with 0.5 U/ml thrombin. 
Measurement of TEER was performed over 4 hours. Relative TEER values were normalized to 
the time point prior to adding thrombin and the TEER-AUC was calculated to quantify the effects 
of ADM and FSK. AUC was normalized to control group. (n=8, mean ± SEM) (*p<0.05, 
**p<0.005, ***p<0.0005 vs. thrombin group) 
    
 
By using the FITC-dextran model for a further side by side comparison, both 
ADM and FSK dose-dependently reduced macromolecular permeability through 
a HUVEC monolayer with the lowest effective doses of 1 nM and 1 µM, 
respectively (Figure 20A and B). Similar to the observation in ECIS, FSK 
stimulation could induce stronger effects on macromolecular permeability after 
further dose escalation, as compared to ADM stimulation, which might be 
explained by the accumulation of much higher cAMP levels. 
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Figure 20 Comparison of ADM and FSK effects on macromolecular permeability  
HUVECs were stimulated with ADM (A) and FSK (B) followed by stimulation with 0.5 U/ml 
thrombin. Macromolecular permeability was measured over 4 hours. The AUC was calculated to 
quantify the effects of ADM and FSK. (n=4, mean ± SEM) (###p<0.0005 vs. control group; 
*p<0.05, **p<0.005, ***p<0.0005 vs. thrombin group) 
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5.3.4. Comparision of ADM and FSK effects on PMN extravasation 
As shown in Figure 11, ADM reduced granulocyte extravasation in vitro and 
protected the lungs against LPS-induced injury in terms of reduced lung edema 
and leukocytes in BAL fluid. The question is whether this anti-inflammatory 
effect results from cAMP signaling or whether additional signaling pathways are 
involved. Therefore, it was further investigated whether FSK could also affect 
granulocyte extravasation in a similar manner as ADM. Both ADM and FSK 
dose-dependently reduced transendothelial migration of leukocytes with 
effective doses of 1 nM and 1 µM, respectively (Figure 21). However, as 
compared to ADM, FSK caused stronger reduction of PMN transmigration after 
further dose escalation, which could be explained by a still increasing cAMP 
accumulation over this dose range, while cAMP accumulation was already 
saturated after exposure to 1 nM ADM (Figure 18). This data indicated the key 
role of cAMP signaling in ADM-mediated modulation of leukocyte 
transmigration. It can be speculated that the limited number of ADM receptors 
on endothelial cells is responsible for saturation of its effects at doses ≥10 nM. 
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Figure 21 Comparison of ADM and FSK effects on granulocyte extravasation  
HUVEC monolayers on transwell filters were stimulated overnight with TNFα (5 nM) and treated 
with different doses of ADM (A) and FSK (B) prior to adding human PMNs. PMNs were allowed 
to transmigrate toward the chemokine IL-8 through EC monolayer for 30 min. The number of 
neutrophils migrating under control condition was set to 100%. (n=6, mean ± SEM) (**p<0.005, 
and ***p<0.0005 vs. control group) 
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5.3.5. Comparision of ADM and FSK effects on PKA and Epac/Rap1 
activation 
The aforementioned data have shown that cAMP signaling is strongly involved 
in the regulation of endothelial permeability and granulocyte extravasation and a 
sufficient explanation for the effects of ADM on endothelial permeability. 
Because of the importance of cAMP pathway in ADM signaling, the downstream 
events of cAMP signaling were further investigated, namely the activation status 
of PKA and Epac/Rap1. Activation of PKA was assessed by the 
phosphorylation status of its direct substrate vasodilator-stimulated 
phosphoprotein (VASP), which is specifically phosphorylated by PKA at Ser157 
(Butt et al., 1994). The specific PKA activator, N(6)-benzoyl-adenosine-3',5'-
cyclic monophosphate (Benz-cAMP) and the Epac/Rap1 activator, 8- (4- 
Chlorophenylthio)- 2'- O- methyladenosine- 3', 5'- cyclic monophosphate (8-
pCPT-2'-O-Me-cAMP or “007”), were employed as positive and negative 
controls in the experiment. As shown in Figure 22, Benz-cAMP increased the 
phosphorylation of VASP, indicating the activation of PKA; in contrast, “007” 
had no influence on the phosphorylation of VASP. Both ADM and FSK dose-
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dependently increased the phosphorylation status of VASP with the lowest 
equally effective doses tested at 10 pM ADM and 10 nM FSK, respectively.  
 
Figure 22 Effects of ADM and FSK on PKA activation  
HUVECs were stimulated with ADM (A) and FSK (B) for 30 min. Upper panel: represented 
western blots of three separate experiments with independent cell preparation. Lower panel: 
densitometric analysis of western blots, in which VASP phosphorylation was normalized to total 
VASP. Relative VASP phosphorylation in control group was set to 100%. Β-tubulin was used as 
loading control. (n=3, mean ± SEM) (*p<0.05 and **p<0.005 vs. control group) 
 
   
To analyze Epac/Rap1 signaling, the activation status of Rap1-GTPase, the 
direct target of Epac (de Rooij et al., 1998), was analyzed by using Rap1-pull-
down assay. Both ADM and FSK increased the level of Rap1-GTP in a time-
dependent manner, with the maximal activation at 15 min (Figure 23). 
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Figure 23 Effects of ADM and FSK on activation of Rap1 signaling  
HUVECs were stimulated with 100 nM ADM (A) and 10 µM FSK (B) for 5 min, 15 min, and 30 
min. Rap1-pull-down assay was performed to detect the activation status of Epac/Rap1 
signaling.  
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5.3.6. Comparision of ADM and FSK effects on gene expression 
In the next study, the effects of ADM and FSK on gene expression in HUVECs 
were investigated through genome-wide microarray analysis. Gene expression 
after ADM and FSK stimulation with minimal two-fold changes was considered 
significant. Both stimulations were performed at two different time intervals: 3 
hours and 16 hours. After 3 h ADM stimulation, 36 genes were found to be 
regulated (24 up- and 12 down-regulated), while 16 h ADM stimulation caused 
only 13 gene regulations (8 up- and 5 down-regulated). The ADM effect seemed 
to be weakened after 16 hours. Similarly, 3 h FSK incubation modified 
expression of 57 genes (43 up- and 14 down-regulated), while 16 h FSK 
incubation caused changes in expression of 43 genes (26 up- and 17 down-
regulated).  
 
After 3 h stimulation, there was an overlap in the exepression of 20 genes which 
were stimulated by ADM and FSK, including PDE3A, RND1 (Rho family 
GTPase 1), MMP16 (Matrix metallopeptidase 16), CCRL1 (Chemokine C-C 
motified receptor like 1), as well as cell adherent receptors VCAM-1 and E-
selectin. After 16 h stimulation only 5 genes were induced by both agents. Also 
ICAM-1 which was reported to be down-regulated in lymphatic endothelium by 
ADM (Jin et al., 2011), was also down-regulated by FSK with a factor of 1.9-
fold, just below the limit of the exclusion criterion. Overall, both ADM and FSK 
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were shown to have similar effects and a tendency on gene regulation through 
the use of microarray analysis. An overview of regulated genes is given in 
Table 8 for 3 h incubation and in Table 9 for 16 h incubation. 
 
Table 8 Microarray analysis in HUVECs after 3 h incubation with ADM and FSK  
“Fold of changes” set to control group was listed. Only the gene expression after ADM and FSK 
stimulation with minimal two-fold changes was considered significant. (n.s.: not significant for 
<2.0 or >0.5 fold of changes) 
Gene Symbol Gene description 
Fold of 
changes 
ADM 
Fold of 
changes 
FSK 
Gene regulated by ADM 
Septin14 septin 14 0.4 n.s. 
CEP170 centrosomal protein 170kDa 0.5 n.s. 
GRK5 G protein-coupled receptor kinase 5 0.5 n.s. 
GNA14 guanine nucleotide binding protein  alpha 14 0.5 n.s. 
SFRS2IP splicing factor. arginine/serine-rich 2. interacting protein 0.5 n.s. 
ITPR1 inositol 1.4.5-triphosphate receptor. type 1 0.5 n.s. 
TMF1 TATA element modulatory factor 1 0.5 n.s. 
RELB v-rel reticuloendotheliosis viral oncogene homolog B 2.0 n.s. 
TNFAIP3 tumor necrosis factor. alpha-induced protein 3 2.0 n.s. 
FLJ42220 FLJ42220 protein 2.1 n.s. 
ICAM1 intercellular adhesion molecule 1 2.1 n.s. 
CSF1 colony stimulating factor 1 (macrophage) 2.1 n.s. 
CYP1A1 cytochrome P450. family 1. subfamily A. polypeptide 1 2.2 n.s. 
TIFA TRAF-interacting protein (forkhead-associated domain) 2.2 n.s. 
CX3CL1 chemokine (C-X3-C motif) ligand 1 2.3 n.s. 
SPRY4 sprouty homolog 4 (Drosophila) 2.4 n.s. 
Gene regualted by FSK 
LOC388692 hypothetical LOC388692 n.s. 0.3 
SIK1 salt-inducible kinase 1 n.s. 0.4 
SOCS3 suppressor of cytokine signaling 3 n.s. 0.4 
DUSP10 dual specificity phosphatase 10 n.s. 0.4 
RNU4-2 RNA. U4 small nuclear 2 n.s. 0.4 
PCMTD2 protein-L-isoaspartate O-methyltransferase domain cont.2 n.s. 0.4 
RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5 n.s. 0.4 
HLA-DPB1 major histocompatibility complex. class II. DP beta 1 n.s. 0.4 
CREM cAMP responsive element modulator n.s. 0.4 
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DUSP1 dual specificity phosphatase 1 n.s. 0.5 
ZNF518A zinc finger protein 518A n.s. 0.5 
NIPBL Nipped-B homolog (Drosophila) n.s. 0.5 
MGC24103 hypothetical MGC24103 n.s. 0.5 
NBEAL1 neurobeachin-like 1 n.s. 0.5 
PRKAA2 protein kinase. AMP-activated. alpha 2 catalytic subunit n.s. 0.5 
LOC100128868 testin-related protein TRG n.s. 0.5 
CP110 CP110 protein n.s. 0.5 
SAMD9L sterile alpha motif domain containing 9-like n.s. 0.5 
PGAP1 post-GPI attachment to proteins 1 n.s. 0.5 
ITPRIP inositol 1.4.5-triphosphate receptor interacting protein n.s. 0.5 
PPAP2B phosphatidic acid phosphatase type 2B n.s. 0.5 
PDE4D phosphodiesterase 4D. cAMP-specific  n.s. 0.5 
TTC30B tetratricopeptide repeat domain 30B n.s. 0.5 
TAF4B TAF4b RNA polymerase II.  n.s. 0.5 
PSD3 pleckstrin and Sec7 domain containing 3 n.s. 0.5 
ZNF81 zinc finger protein 81 n.s. 0.5 
TBXA2R thromboxane A2 receptor n.s. 2.0 
C10orf41 chromosome 10 open reading frame 41 n.s. 2.0 
CELF5 CUGBP. Elav-like family member 5 n.s. 2.0 
NCAN neurocan n.s. 2.0 
CEACAM16 carcinoembryonic antigen-related cell adhesion molecule  n.s. 2.0 
VSIG7 V-set and immunoglobulin domain containing 7 n.s. 2.0 
KIR3DL1 killer cell immunoglobulin-like receptor.  n.s. 2.1 
MYCN v-myc myelocytomatosis viral related oncogene.  n.s. 2.3 
FLJ31958 hypothetical LOC143153 n.s. 2.4 
FLJ14100 hypothetical protein FLJ14100 n.s. 2.4 
RUNDC2C RUN domain containing 2C n.s. 3.5 
Gene regulated by both ADM and FSK 
CCRL1 chemokine (C-C motif) receptor-like 1 0.3 0.4 
SESN3 sestrin 3 0.3 0.3 
RIMKLB ribosomal modification protein rimK-like family member B 0.3 0.4 
PITPNC1 phosphatidylinositol transfer protein. cytoplasmic 1 0.4 0.4 
PDE3A phosphodiesterase 3A. cGMP-inhibited 0.4 0.4 
SEMA3A sema domain, secreted. (semaphorin) 3A 0.4 0.4 
RNF152 ring finger protein 152 0.4 0.4 
MMP16 matrix metallopeptidase 16 (membrane-inserted) 0.4 0.4 
NOX4 NADPH oxidase 4 0.4 0.5 
MOBKL1A MOB1. Mps One Binder kinase activator-like 1A (yeast) 0.4 0.4 
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C12orf63 chromosome 12 open reading frame 63 0.4 0.5 
N4BP2 NEDD4 binding protein 2 0.5 0.4 
C10orf118 chromosome 10 open reading frame 118 0.5 0.5 
ADAMTS18 ADAM metallopeptidase type 1, modif. 18 0.5 0.4 
ADAMTS1 ADAM metallopeptidase with type 1, modif.1  0.5 0.4 
CYorf15B chromosome Y open reading frame 15B 0.5 0.5 
ZNF654 zinc finger protein 654 0.5 0.4 
RND1 Rho family GTPase 1 2.2 2.2 
VCAM1 vascular cell adhesion molecule 1 6.6 3.3 
SELE selectin E 12.4 5.5 
 
Table 9: Microarray analysis in HUVECs after 16 h incubation with ADM and FSK 
“Fold of changes” set to control group was listed. Only the gene expression after ADM and FSK 
stimulation with minimal two-fold changes was considered significant. (n.s.: not significant for 
<2.0 or >0.5 fold of changes) 
Gene Symbol Gene description
 
Fold of 
changes 
ADM 
Fold of 
changes 
FSK 
Gene regulated by ADM 
CDRT1 CMT1A duplicated region transcript 1 0.3 n.s. 
ZNF737 zinc finger protein 737 0.4 n.s. 
LOC646508 hypothetical LOC646508 0.4 n.s. 
RFC1 replication factor C (activator 1) 1. 145kDa 0.5 n.s. 
ZNF680 zinc finger protein 680 0.5 n.s. 
ZNF814 zinc finger protein 814 0.5 n.s. 
EFCAB4B EF-hand calcium binding domain 4B 2.1 n.s. 
CSRP2 cysteine and glycine-rich protein 2 2.3 n.s. 
Gene regulated by FSK 
PDE3A phosphodiesterase 3A. cGMP-inhibited n.s. 0.4 
SELE selectin E n.s. 0.4 
ANKRD11 ankyrin repeat domain 11 n.s. 0.4 
GNA14 guanine nucleotide binding protein (G protein). alpha 14 n.s. 0.4 
LOC100131826 TSSP3028 n.s. 0.4 
BDNF brain-derived neurotrophic factor n.s. 0.4 
FILIP1 filamin A interacting protein 1 n.s. 0.4 
MME membrane metallo-endopeptidase n.s. 0.5 
FAT1 FAT tumor suppressor homolog 1 (Drosophila) n.s. 0.5 
C12orf63 chromosome 12 open reading frame 63 n.s. 0.5 
C5orf53 chromosome 5 open reading frame 53 n.s. 0.5 
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MMP16 matrix metallopeptidase 16 (membrane-inserted) n.s. 0.5 
DGKH diacylglycerol kinase. eta n.s. 0.5 
TMEM229A transmembrane protein 229A n.s. 0.5 
VSIG6 V-set and immunoglobulin domain containing 6 n.s. 0.5 
DNAJC8 DnaJ (Hsp40) homolog. subfamily C. member 8 n.s. 2.0 
RFT1 RFT1 homolog (S. cerevisiae) n.s. 2.1 
DHODH dihydroorotate dehydrogenase n.s. 2.1 
FLJ43860 FLJ43860 protein n.s. 2.2 
SNORD25 small nucleolar RNA. C/D box 25 n.s. 2.5 
Gene regulated by both ADM and FSK 
ADAMTS18 ADAM metallopeptidase with type 1 motif. 18 0.5 0.4 
ANGPT2 angiopoietin 2 0.5 0.5 
NCRNA00116 non-protein coding RNA 116 2.0 2.2 
PRAMEF15 PRAME family member 15 2.3 2.4 
GJA5 gap junction protein. alpha 5. 40kDa 2.6 2.9 
 
5.3.7. Qualitative and quantitative comparision of ADM- and FSK-
induced effects in different models 
From a qualitative perspective, ADM and FSK showed identical effects 
throughout all the different models, which are summarized in Table 10. In the 
CHO-ADM1-reporter system, ADM and FSK resulted in concentration-
dependent luminescence signals in correspondence with increased cAMP 
levels. In primary human endothelial cells, ADM and FSK induced significant 
accumulation of cAMP and activated cAMP signaling pathways, demonstrated 
by the activation of PKA and Epac/Rap1. Activation of PKA was demonstrated 
by downstream VASP phosphorylation, while activation of Epac was 
demonstrated by the levels of directly activated Rap1-GTPase (de Rooij et al., 
1998). In primary human endothelial cells, both ADM and FSK are capable of 
increasing electrical resistance, decreasing macromolecular permeability, and 
inhibiting transendothelial migration of leukocytes. 
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Table 10 Effects of ADM and FSK in different models 
Models Effects 
CHO-ADM1 reporter cell Increase of luminescence signals  (cAMP  increase) 
cAMP ELISA Increase of intracellular cAMP levels 
ECIS Increase of transendothelial electrical resistance (TEER) 
FITC-dextran permeability assay Decrease of macromolecular permeability 
TEM assay Inhibition of leukocytes transmigration 
VASP phosphorylation Increased phosphorylation of VASP (PKA activation) 
Rap1 activation Activation of Epac/Rap1 pathway 
Microarray analysis Down regulation of ICAM-1, VCAM-1, and E-selectin 
 
For a quantitative comparison, the ratio between the lowest effective doses of 
FSK and ADM was calculated (Table 11). On a molar basis equally effective 
concentrations of FSK and ADM differ from each other in all models tested by a 
factor of about 1,000. A factor of 103 to 104 is obtained by using pEC50 as the 
parameter for ratio calculation, although it must be mentioned that pEC50 could 
be analyzed in only three assays due to a limited number of the tested doses in 
the other assays or due to assay formats not suited for calculation of EC50 
values. The relevant question was which increase in cAMP was required to 
achieve equivalent effects by FSK and ADM, respectively. As shown in Table 
12, the effects at the lowest effective doses of ADM and FSK were comparable 
in all assays. However, the increase in cAMP (∆cAMP) needed to achieve this 
effect was by a factor ~ 3-5 higher for FSK as compared with ADM. 
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Table 11 Quantitative comparison of ADM and FSK in different assays  
Models  
 
pEC50 
Lowest 
effective 
doses 
Factors 
of lowest 
effective 
doses 
CHO-ADM reporter cell 
ADM -8.1 ± 0.1 1 nM 
1,000 
FSK -5.6 ± 0.1 1 µM 
∆cAMP 
ADM -9.9 ± 0.3 100 pM 
1,000 
FSK -5.5 ± 0.6 100 nM 
ECIS 
ADM -9.6 ± 0.2 30 pM 
1,000 
FSK -5.6 ± 0.4 30 nM 
FITC-dextran permeability assay 
ADM not determined 1 nM  
1,000 FSK not determined 1 µM 
TEM assay 
ADM not determined 1 nM  
1,000 FSK not determined 1 µM 
VASP phosphorylation 
ADM not determined 10 pM 
1,000 
FSK not determined 10 nM 
 
 
Table 12 Quantitative comparison of ∆cAMP induced by ADM and FSK in different assays  
Models  
Lowest 
effective 
doses Effects 
∆cAMP 
(fmol/well) 
(n=8) 
Factors 
of 
∆cAMP 
ECIS 
ADM 30 pM -56 ± 21.5% 94 ± 162.4  
4.7 FSK 30 nM -42 ± 17.8% 439 ± 990.8 
FITC-dextran 
permeability assay 
ADM 1 nM 94.7 ± 18.2%  270 ± 169.3  
4.7 FSK 1 uM 101.2 ± 7.3% 1245 ± 1396.7 
VASP-
Phosphorylation 
ADM 10 pM 332.2 ± 29.4% 112 ± 212.5  
3.3 FSK 10 nM 335.0 ± 14.2% 375 ± 603.9 
TEM assay 
ADM 1 nM 68.9 ± 8.5% 270 ± 169.3  
4.7 FSK 1 µM 59.7 ± 18.3% 1245 ± 1396.7 
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5.4. Effects of ADM on gene expression 
Data from the genome-wide microarray-analysis suggested that ADM down-
regulated the expression of cell adhesion molecules (CAMs), such as ICAM-1, 
VCAM-1, and E-selectin which all exert distinct functions in the recruitment, 
adhesion and transmigration of leukocytes. Cytokines and growth factors which 
down-regulate the expression of cell adhesion molecules, are thought to have 
an anti-inflammatory effect. As data from Microarray analysis are not 
quantitative, the effects of ADM on the expression of those genes were 
analyzed in more details by use of quantitative RT-PCR (TaqMan® technique). 
5.4.1. Analysis of time-dependent effects of ADM on CAMs 
First of all, actions of ADM on gene expression were analyzed in quiescent 
HUVEC cells without any stimulation. ADM was used at a concentration of 100 
nM which was previously shown to have satuated effects on endothelial barrier 
function. ADM reduced the mRNA levels of ICAM-1 by maximal 30%, as 
compared to control group (Figure 24A) in a time frame of 2 to 8 h. Similarly, 
mRNA levels of E-selectin were reduced maximally by 30% after 2h stimulation 
with ADM (Figure 24C). 16 h ADM stimulation had no impacts on regulation of 
E-selectin anymore. Expression of VCAM-1 and PECAM-1 were not influenced 
by ADM (Figure 24B and D). Taken together, under basal conditions, ADM 
showed no effects on gene regulation of VCAM-1 and PECAM-1 and only slight 
effects on ICAM-1 and E-selectin mRNA expression.  
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Figure 24 Effects of ADM on gene expression of adhesionce molecules  
HUVECs were incubated with 100 nM ADM as indicated and mRNA levels were measured by 
QRT-PCR. mRNA expression levels were normalized to that of β-actin. Relative gene 
expression levels of ICAM-1 (A), VCAM-1 (B), E-selectin (C), and PECAM-1 (D) are shown. 
Data are plotted as mean ± SEM, n=4. 
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5.4.2. Effects of ADM on TNFα-induced expression of CAMs 
Effects of ADM on gene expression were further analyzed in TNFα-stimulated 
HUVEC cells. As previously shown 5 nM TNFα induced endothelial barrier 
dysfunction, particularly endothelial hyperpermeability and granulocyte 
extravasation. Effects of increasing doses of TNFα (1 pM to 10 nM) were 
analyzed by using quantitative RT-PCR analysis. TNFα dose-dependently 
increased mRNA levels of ICAM-1, VCAM-1 and most prominently of E-selectin 
while mRNAs of PECAM-1 was slightly decreased. Induction factors as fold of 
changes refered to control group are given in Table 13. Interestingly, the mRNA 
levels of ADM receptors (CLRLR and RAMP-2) in HUVECs were down-
regulated in a dose-dependent manner.  
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Table 13 Effects of TNFα on gene expression of adhesion molecules and ADM receptors 
HUVECs were overnight incubated with increasing concentrations of TNFα (1 pM to 10 nM), 
and mRNA levels were measured by QRT-PCR. Relative gene expression levels were 
normalized to that of β-actin and fold of changes set to control group were listed. Cell adhesion 
molecules such as ICAM-1, VCAM-1, E-selectin, and PECAM-1, as well as ADM receptors 
CRLR and RAMP-2 were analyzed. Data are expressed as mean ± SD with n=4 
 
In the next step, HUVECs were treated with 100 nM ADM for 3 h and 16 h, and 
effects of ADM on basal as well as TNFα- induced mRNA levels of cell 
adhesion molecules were analyzed (Figure 25).  None of the changes induced 
by 10 pM TNFα were affected by exposure to 100 nM ADM for 3 h or 16 h. 
Taken these data together, ADM showed no effects on mRNA expression of cell 
adhesion molecules, such as ICAM-1, VCAM-1, E-selectin and PECAM-1 in 
TNFα-stimulated endothelial cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fold of 
changes  
(mRNA)                       
TNFα 
1 pM 
TNFα 
10 pM 
TNFα 
100 pM 
TNFα 
1 nM 
TNFα 
10 nM 
ICAM-1 1.0 ± 0.1 3.5 ± 0.6 21.7 ± 1.0 31.4 ± 2.2 37.6 ± 4.1 
VCAM-1 0.9 ± 0.1 4.7 ± 0.6 50.8 ± 8.6 87.5 ± 12.5 87.6 ± 7.2 
E-selectin 2.9 ± 0.7 6.3 ± 0.8 351.2 ± 44.9 721.2 ± 98.3 825.9 ± 77.0 
PECAM 0.4 ± 0.3 0.7 ± 0.1 0.5 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 
CRLR 0.5 ± 0.1 0.8 ± 0.3 0.5 ± 0.2 0.4 ± 0.1 0.3 ± 0.1 
RAMP2 1.1 ± 0.3 0.7 ± 0.3 0.3 ± 0.1 0.1 ± 0.0 0.2 ± 0.0 
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Figure 25 Effects of ADM on TNFα-induced gene expression of cell adhesion molecules  
HUVECs were overnight treated with 10 pM TNFα and 100 nM ADM for 16 h, or HUVECs were 
treated with ADM (100 nM) for 3 hours followed by overnight incubation with 10 pM TNFα. After 
stimulation, mRNA levels were measured by QRT-PCR. The mRNA expression levels were 
normalized to that of β-actin. Relative gene expression levels of cell adhesion molecules such 
as ICAM-1 (A), VCAM-1 (B), E-selectin (C), and PECAM-1 (D) are shown. Data are plotted as 
mean ± SD, n=4. 
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5.4.3. Effects of ADM on surface expression of CAMs 
In addition to gene regulation of mRNAs, the protein expression of adhesion 
molecules on cell surface was further investigated by use of ELISA with specific 
antibodies against adhesion molecules. Similar to gene expression study, 100 
pM TNFα caused a 7.3 ± 1.8 fold, 5.6 ± 0.8 fold, and 3.7 ± 0.4 fold increases in 
cell surface expressions of ICAM-1, VCAM-1, and E-selectin, respectively. 
However, pretreatment or post-treatment with ADM could not affect those 
increases of cell adhesion molecules on cell surface. Therefore, changes in 
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gene expression or surface expression of endothelial adhesion molecules 
cannot be used as explanation for the inhibition of PMN transmigration by ADM. 
 
Figure 26 Effects of ADM on cell surface expressions of adhesions molecules after TNFα-
stimulation  
HUVECs were treated with 100 nM ADM 30 min prior to or following overnight incubation with 
100 pM TNFα. After stimulation, primary antibodies against ICAM-1 (A), VCAM-1 (B), and E-
selectin (C) were incubated for 60 min followed by incubation with peroxidase-conjugated 
secondary anti-mouse antibody for further 60 min. After adding TMB substrate solution, the 
absorbance signal on cell surface was measured. Cell surface expressions of adhesion proteins 
were quantified as the absorbance signals on cell surface. Data were expressed as mean ± 
SEM with n=4. 
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5.5. Role of PKA and Epac/Rap1 in ADM signalling 
The previous data showed, that the effects of ADM on endothelial barrier 
function can entirely be explained as cAMP-mediated. Therefore the two 
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downstream branches of cAMP signaling relevant for endothelial barrier 
function, the PKA and Epac/Rap1 pathways, were further investigated for their 
relative contribution to effects of ADM signaling. 
5.5.1. Dissection of PKA and Epac/Rap1 signaling 
The specific PKA activator Benz-cAMP and the specific Epac/Rap1 activator 
“007” were chosen to further dissect cAMP downstream events. However, it 
was reported that the cAMP analogous “007”, might have the potential to 
activate PKA at high concentrations (Holz et al., 2006). To verify or exclude the 
potential effect of “007” on PKA activation, the following experiments were 
performed: detection of CREB phosphorylation in Luceferase-transfected CHO 
cells as well as detection of VASP phosphorylation in primary human cells.  
 
The cyclic AMP response element (CRE)-binding protein (CREB) is one of the 
best understood phosphorylation dependent transcription factors. Increased 
cAMP activates PKA by dissociating the regulatory from the catalytic subunits, 
which in turn is translocated into the nucleus and phosphorylates CREB, 
promoting CREB to recruit transcriptional co-activators that induce transcription 
of a variety of immediate early response genes. The CREB reporter cell line is 
derived from CHO cells with chromosomal integration of a luciferase reporter 
construct regulated by a cAMP response element (CHO-CRE-luciferase). As 
shown in Figure 27C, increasing doses of Benz-cAMP and “007” (10 µM-10 
mM) were tested in the CREB reporter cell line. Beginning at 30 µM Benz-cAMP 
started to activate CREB-dependent luciferase transcription, serving as an 
indirect indicator of PKA activation.  The maximum effect was at 3 mM. In 
contrast, “007” up to doses of 10 mM showed no effect on CREB dependent 
transcription. 
 
PKA activation was indirectly monitored in HUVECs by detection of substrate 
phosphorylation by means of immnoblotting with an antibody against phospho-
VASP. Different doses of Benz-cAMP and “007” (100 nM-1 mM) were analyzed 
(Figure 27A and B). At a concentration of 100 µM Benz-cAMP and higher 
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phosphorylation of VASP could be detected, whereas “007” had no effect on the 
VASP activation up to a concentration of 1mM.  
 
In addition, to exclude potential effects of Benz-cAMP on Epac/Rap1 signaling, 
a Rap1 Pull-down assay was performed in which activated GTP-bound Rap1 is 
detected (Figure 27D). While 100 µM “007” activated Epac/Rap1 signaling, 500 
µM Benz-cAMP - a dose which significantly activated PKA signaling - had no 
effects. Based on this observation, 500 µM Benz-cAMP and 100 µM “007” were 
chosen for further experimental settings to dissect both pathways specifically. 
 
Figure 27 Dissection of Benz-cAMP and “007” in different assays.  
(A) and (B): HUVECs were treated with vehicle, Benz-cAMP (100 nM-1 mM) (A) or “007” (100 
nM-1 mM) (B) or for 15 min followed by sample collection and western blot analysis of signaling 
pathway activation. Representative results from three independent experiments. (C): CHO-
CREB-luciferase reporter cells were treated with Benz-cAMP (10 µM-10 mM) and “007” (10 µM-
10 mM) for 15 min. The cAMP dependent increase of CREB phosphorylation is read out by 
luminescence signals. (n=4, mean ± SEM, *p<0.05, **p<0.005, ***p<0.0005 vs. vehicle group) 
(D): HUVECs were treated with vehicle, “007” (100 µM) or Benz-cAMP (500 µM) for 15 min 
followed by sample collection and western blot analysis of signaling pathway activation. The 
small GTPase Rap1 activity was measured using Rap1-pull down assay. Representative results 
from a series of three independent experiments.  
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5.5.2. Impact of Epac/Rap1- and PKA-signaling on regulation of 
vascular permeability 
Since the cAMP analogues Benz-cAMP and “007” were confirmed to 
specifically address the PKA and Epac/Rap1 pathways, the relative impact of 
the distinct cAMP-dependent signaling in the regulation of vascular permeability 
was further investigated by using these two tool compounds.  
 
In ECIS, the addition of both cAMP analogues rapidly enhanced the 
transendothelial resistance of resting cell monolayer up to 175% within 30 min 
and remained constantly elevated over the entire experiment. This was the 
maximum achievable effect during dose escalation of the individual compounds 
(Figure 28A). However, combination of Benz-cAMP and “007” further enhanced 
TEER to 200% of control monolayer. The TEER reducing effect of thrombin was 
partially prevented by the individual compounds, more strongly by Benz-cAMP 
than by “007”. Again the combination of both compounds showed enhanced 
effects also on thrombin induced hyperpermeability (Figure 28B). Like after 
ADM and FSK the level of TEER modulation by thrombin was shifted to more 
positive values rather than showing a true antagonism.  
 
In parallel to TEER measurements, paracellular permeability for FITC-dextran 
was analyzed (Figure 28C). Both Benz-cAMP and “007” antagonized thrombin-
induced hyperpermeability. However, both treatments reversed the permeability 
to that of resting cells, which was in contrast to ADM which reduced 
permeability below that of resting cell monolayers (Figure 7C and D).   
 
In the next step, the effects of Benz-cAMP and “007” on vascular permeability in 
the skin of mice were examined by use of the modified Miles assay (Figure 
28D). Intradermal application of histamine increased skin permeability to three-
fold above base line. This effect was partially prevented by pretreatment with 
Benz-cAMP and “007”. While Benz-cAMP reduced Histamine-induced 
hyperpermeability by about one third, “007” reduced permeability to almost 
normal values. In contrast to the in vitro-findings, combination of Benz-cAMP 
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and “007” showed no further enhancement of effects. In addition, Benz-cAMP 
and “007” also reduced basal vascular permeability significantly.  
 
Throughout all these three models, both Benz-cAMP and “007” were equally 
effective with respect to resulting stabilization of endothelial barrier function in 
vitro and in vivo. However, combination of maximal active doses showed further 
enhancement of resulting effects. These observations suggest that both PKA- 
and Epac/Rap1-dependent cAMP signaling activate at least partially 
independent anti-edematous mechanisms. 
 
Figure 28 Both PKA and Epac/Rap1 signaling are involved in regulating endothelial 
permeability in vitro and in vivo.  
Transendothelial electrical resistance (A and B) and paracellular permeability for FITC-dextran 
(C) were measured over the time. HUVECs were pretreated with vehicle. “007” (100 µM) or 
Benz-cAMP (500 µM) followed by stimulation with thrombin (0.5 U/ml). Both cAMP analogues 
reduced thrombin-induced endothelial hyperpermeability in vitro. (D) Miles Assay: “007” (3 
µM/mouse) as well as Benz-cAMP (3 µM/mouse) attenuated histamine-induced vascular 
hyperpermeability in the skin of mice. (N=6-10, mean ± SEM; #p<0.05 and ##p<0.005 vs. vehicle 
group with PBS injection; *p<0.05 and ***p<0.0005 vs. vehicle group with histamine injection) 
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5.5.3. Role of PKA and Epac/Rap1 in regulation of granulocyte 
extravasation 
5.5.3.1. Effects of PKA- and Epac/Rap1-signaling in PMN transmigration 
As shown above ADM and FSK inhibited granulocyte extravasation in a dose-
dependent manner, which was correlated with the induced intracellular cAMP 
levels. The question was raised whether both PKA and Epac/Rap1 signaling 
were involved in controlling granulocyte extravasation. As shown in Figure 29A, 
PKA activator, Benz-cAMP, inhibited granulocyte transmigration to 71.4 ± 5.0% 
(mean ± SD), which was comparable with the effect of ADM. In contrast, “007” 
showed no effect on granulocyte extravasation. Even the combination of Benz-
cAMP and “007” had no additional inhibitory effects on granulocyte 
extravasation (56.3 ± 6.3%, mean ± SD), as compared to single treatment with 
Benz-cAMP. This result gave the first suggestion that only PKA-dependent 
cAMP-signaling might be involved in the regulation of granulocyte 
transmigration.  
 
To further verify the effect of PKA on granulocyte transmigration, another cAMP 
analogous, 8- Bromoadenosine- 3', 5'- cyclic monophosphorothioate, Rp- 
isomer (Rp-8-Br-cAMP) was used to block the PKA dependent pathway 
(Aandahl et al., 1998). As shown in Figure 29C, 200 µM and 400 µM Rp-8-Br-
cAMP, reduced ADM-induced phosphorylation of VASP in HUVECs, indicative 
of its inhibitory effect on PKA activation in endothelial cells. Thus, the dose of 
400 µM was further used to fully block the PKA dependent pathway in ADM 
signaling in order to investigate its effect in the granulocyte transmigration 
assay (Figure 29B). While the PKA inhibitor alone had no effects on 
granulocyte transmigration, the initial inhibitory effect of ADM (56.7 ± 2.9%) was 
significantly weakened to 80.1 ± 2.6% of control group, further substantiating 
the PKA-dependency of the ADM effect (mean ± SD). Using both the activator 
and inhibitor of PKA signaling, evidence was provided for an involvement of 
PKA in the ADM-cAMP signaling in the regulation of granulocyte transmigration, 
while the Epac/Rap-1 pathway seems not to be involved. 
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Figure 29 PKA but not Epac/Rap1 is involved in leukocyte transmigration  
(A): TNFα-stimulated HUVECs on Transwell filters were pretreated with vehicle, “007” (100 µM), 
Benz-cAMP (500 µM), or combination of “007” (100 µM) and Benz-cAMP (500 µM) for 30 min. 
(n=6; **p<0.005 vs. control group) (B): HUVEC on Transwell filters were stimulated overnight 
with TNFα (5 nM). On the day of experiment, HUVECs were pretreated with vehicle or Rp-8-Br-
cAMP (400 µM) for 40 min, and subsequently treated with vehicle or ADM (100 nM) for 20 min. 
(n=6; *p<0.05 and **p<0.005 vs. control group; ###p<0.0005 vs. ADM group without Rp-8-Br-
cAMP pretreatment) (C): Western blot was performed to detect phosphorylation status of VASP 
in HUVECs, indicative of PKA activation. HUVECs were pre-treated with vehicle or different 
doses of Rp-8-Br-cAMP (20 µM, 40 µM, 200 µM, and 400 µM) for 40 min and followed by 
subsequent stimulation with vehicle or ADM (100 nM) for 20 min. Anti-vinculin antibody was 
used as loading control. Representative data result from two independent experiments.  
 
 
5.5.3.2. Role of PKA- and Epac/Rap1-signaling in regulation of PMN-
induced hyperpermeability 
There is emerging evidence that adhesion of activated leukocytes to endothelial 
cells not only actively prepares opening of endothelial contacts for 
transmigration but also contributes to endothelial hyperpermeability (reviewed 
by He, 2010; Yuan et al., 2012). It is further discussed that leukocyte induced 
hyperpermeability might be a prerequisite for transmigaration. Therefore the 
question was raised whether leukocyte-induced hyperpermeability could be 
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verified in the assay systems used, and if so, to which extent cAMP dependent 
signaling via PKA and Epac/Rap1 can modulate this process. Therefore similar 
conditions as used in the leukocyte transmigration assay were employed in the 
ECIS model. As shown in Figure 30A, in addition to TNFα-induced slow and 
prolonged decrease of electrical resistance to 74.3 ± 4.1% (mean ± SD), 
contact to PMN irreversibly reduced TEER and reached its trough within 2 
hours. The extent of this effect of PMN was dependent on amounts of PMN 
added per well: the resistance was lowered to 70.2 ± 4.0% by 100,000 PMNs, 
to 54.0 ± 3.2% by 300,000 PMNs, to 47.4 ± 2.6% by 500,000 PMNs, and to 
46.5 ± 1.3% by 1000,000 PMNs (mean ± SD). In the further assay (Figure 30B), 
the drop-down of electrical resistance evoked by 500,000 PMNs to 59.7 ± 4.0% 
was attenuated by addition of Benz-cAMP and “007” to 81.7 ± 3.1% and to 81.7 
± 4.8% (mean ± SD), respectively, when both compounds were added at 
maximal effective concentrations (as determined in pilot experiments, data not 
shown). The combined treatment of cells with both Benz-cAMP and “007” 
showed enhanced efficacy. These data were comparable to those obtained in 
TNFα stimulated cells without additional stimulation by PMNs: electrical 
resistance was decreased to 87.3 ± 6.4%, which was reversed to 127.1 ± 3.5% 
by Benz-cAMP, to 122.0 ± 7.8% by “007”, and to 151.0 ± 6.4% (mean ± SD) by 
combination of Benz-cAMP and “007” (Figure 30C).  
 
These data from ECIS assays confirm an additional and dose-dependent 
permeability inducing effect of PMN contact to TNFα stimulated HUVECs. Like 
in TNFα and Thrombin induced hyperpermeability both, PKA and Epac/Rap-1 
pathway are involved in regulation of leukocyte induced hyperpermeability in 
endothelial cells. However, as hyperpermeability can effectively be prevted and 
reversed by “007” which has no impact on PMN transmigration, based on these 
data it can be excluded that PMN induced endothelial hyperpermeability is a 
prerequisite for their transmigration. 
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Figure 30 Effects of PKA- and Epac/Rap1 activator in regulating PMN-induced 
hyperpermeability  
(A): HUVECs were grown on ECIS microelectrode plates to confluence and overnight incubated 
with TNFα (5 nM). On the day of experiment, cells were additionally stimulated with different 
amounts of PMNs (1x105, 3x105, 5x105 and 1x106 / well) and measurement of TEER was 
performed over 16 hours. (B)-(C): HUVECs were overnight stimulated with TNFα (5 nM). At the 
time indicated by the arrows, cells were treated with vehicle, “007” (100 µM), Benz-cAMP (500 
µM), or combination of “007” (100 µM) and Benz-cAMP (500 µM) for 30 min, without any further 
treatment (C) or following by additional stimulation with 5x105 PMNs /well (B). TEER was 
normalized to the TEER measured at the beginning of the experiment. (n=8; mean ± SEM). 
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5.5.3.3. Impact of PKA- and Epac/Rap1-signaling on endothelial 
contractility 
Adherence of neutrophils induces increase of intracellular calcium concentration 
and activation of MLC kinase in endothelial cells with subsequent activation of 
the contractile apparatus and paracellular gap formation, being a key 
determinant of leukocyte transendothelial migration in response to inflammation 
(Garcia et al., 1998).  MLC kinase phosphorylates MLC at Ser-19 and Thr-18, 
which subsequently facilitates the interaction of myosin with actin, leading to the 
acto-myosin based contractile response.  
 
ML-9 (1-[(5-chloro-1-naphthalenyl) sulfonyl] hexahydro-1H-1,4-diazepine) is a 
selective inhibitor of MLCK, which binds at or near the ATP-binding site of the 
active center and inhibits directly the catalytic activity of MLCK (Saitoh et al. 
1987).  BAPTA/AM, [1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid 
tetrakis(acetoxymethyl ester)], is a membrane-permeable intracellular calcium 
chelator, which inhibits calcium/calmodulin dependent activation of MLCK. In 
the established in vitro-leukocyte transmigration assay, both ML-9 and 
BAPTA/AM were shown to inhibit PMN transmigration dose dependently 
(Figure 31A and B). Transmigration was reduced to 76.6 ± 3.2% and to 29.9 ± 
11.2% (mean ± SD) by 100 and 300 µM ML-9, respectively, and to 70.3 ± 9.6% 
and to 51.1 ± 3.1% (mean ± SD) by 100 and 300 µM BAPTA/AM, respectively. 
The observations of those experiments were in line with previous reports (Saito 
et al., 1998), indicating that activity of calcium/calmodulin-dependent MLCK is 
necessary for transendothelial migration of granulocytes.  
 
In addition to MLCK, also Rho kinase on one hand phosphorylates MLC on 
serine 19, and on the other hand phosphorylates the myosin–binding subunit 
(MBS) of MLCP thereby inactivating this enzyme, which is also crucial for 
regulating the phosphorylation status of MLC (Kawano et al., 1999; Amano et 
al., 1996). The azaindole derivative, 6-chloro-N4-{3,5-difluoro-4-[(3-methyl-1H-
pyrrolo[2,3-b]pyridin-4-yl)oxy]-phenyl}pyrimidine-2,4-diamine (BAY77-7549), is a 
potent and selective Rho kinase inhibitor (Kast et al., 2007). BAY77-7549 
inhibits granulocyte transmigration in a dose-dependent manner: to 47.7 ± 
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16.8% by 10 µM and to 18.6 ± 7.4% by 100 µM (mean ± SD) (Figure 31C).  
Taken together, these results with all three inhibitors of independent pathways 
leading to MLC phosphorylation and activation, ML-9, BAPTA/AM, and BAY77-
7549, provided evidence for the crucial role of the phosphorylation status of 
endothelial MLC in regulating transendothelial migration of granulocytes.  
  
So, the question was raised whether Benz-cAMP and “007” which differently 
affect granulocyte transmigration show different effects on the phosphorylation 
of MLC. Phosphorylation status of MLC was analyzed using specific anti-
phosphor-Ser19/Tyr18 antibody and thrombin was used to increase basal 
phosphorylation of MLC. As shown in Figure 31D and E, 100 nM ADM, 10 µM 
FSK, and 500 µM Benz-cAMP, which effectively inhibited leukocyte 
transmigration, also significantly reduced phosphorylation of MLC. In contrast, 
100 µM “007” which protected endothelial permeability had no effect on the 
phosphorylation status of MLC.  These data suggest that the fact that PMN 
transmigration is inhibited by activation of PKA but not of Epac/Rap1 is most 
probably due to PKA dependent inhibition of MLC phosphorylation thereby 
counteracting endothelial contractility. 
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Figure 31 Regulation of MLC is involved in cAMP-PKA pathway on granulocyte 
transmigration  
(A) (B) and (C): Human neutrophils were allowed to transmigrate toward the IL-8 gradient 
through a HUVEC monolayer on transwell filter which was stimulated overnight with TNFα (5 
nM). Endothelial monolayers were treated for 30 min with different doses of ML-9 (30 µM, 100 
µM, and 300 µM) (A), BAPTA (30 µM , 100 µM, and 300 µM) (B), or RhoK-inhibitor BAY77-
7549 (1 µM, 10 µM, and 100 µM) (C). For each experiment, the number of neutrophils migrating 
under control condition (without compound treatment) was set to 100%. (n=3, mean ± SEM) 
(*p<0.05, **p<0.005, and ***p<0.0005 vs. control group) (D-E): HUVECs were pretreated with 
vehicle, ADM (100 nM), FSK (10 µM), Benz-cAMP (500 µM), and “007” (100 µM) for 15 min 
followed by 15 min stimulation with thrombin (0.5 U/ml). Anti-vinculin was used as loading 
control. Representative results of three independent experiments. 
 
 
It was further investigated by means of immunohistochemistry whether both 
pathway activators had effects on junctional structures and contractile 
apparatus. Similarly to ADM (Figure 8), both cAMP analogous prevented 
thrombin-induced gap formation on cell-cell junctions, preserving a continuous 
straight line of VE-cadherin around the cell borders (Figure 32). Benz-cAMP 
seemed to reduce formation of stress fibers and retraction of the cell mass 
toward the center and to enhance peripheral cortical actin (Figure 32C). 
However, with “007” the formation of stress fibers seemed to be less affected 
(Figure 32D).  
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Taken together, the cAMP-PKA pathway most likely counteracts granulocyte 
transmigration by regulating the contractile apparatus via inhibition of MLC 
phosphorylation in contrast to the Epac/Rap1 pathway which does not inhibit 
MLC phosphorylation and fails to interfere with granulocyte transmigration.  
 
Figure 32 Effects of PKA and Epac/rap1 on thrombin-induced F-actin and VE-cadherin 
distribution. 
HUVECs were grown to confluence on fibronectin-coated glass cover slides and pretreated with 
vehicle, Benz-cAMP (500 µM) (C) or “007” (100 µM) (D) for 30 min, following thrombin (0.5 
U/ml) stimulation for 30 min. Cells were fixed and permelized with 100% (v/v) ethanol (-20oC, 10 
min) and stained for F-actin (red), VE-cadherin (green), and nucleus (blue). (A) quiescent cells 
and (B) thrombin-stimulated cells. Scale bars = 20 µm. 
 
 
 
 
 
RESULTS   102 
5.6. Direct effects of ADM on endothelial cytoskeleton and 
cell-cell junctions 
5.6.1. Role of cortactin in ADM-mediated endothelial barrier 
modulation 
Barrier protective effects of ADM could be related to a reduction of dynamic 
changes in myosin-actin based cellular contractility as refelected by the 
reduction of Myosin light chain phosphorylation and stress fiber formation. In the 
next step, it was addressed whether ADM could directly affect static 
cytoskeleton and cell-cell junctions. Beside a role of myosin-actin mediated 
cellular contraction, disruption and rearrangement of cytoskeleton are reported 
to be of equal importance in the development of endothelial gaps. One of the 
most important cytoskeletal components is the 80 to 85 kDa actin-binding 
protein, cortactin. Cortactin is involved in cortical actin assembly and dynamic 
actin rearrangement (Ammer & Weed, 2008). An important role of endothelial 
cortactin in leukocyte transmigration and barrier integrity is likely. Therefore the 
question was addressed whether this actin-binding protein is involved in ADM 
signaling with respect to the regulation of endothelial barrier function. 
 
First of all, an immunocytochemical approach was performed to investigate 
whether ADM has influence on the distribution of cortactin in endothelial cells 
(Figure 33). In quiescent cells, cortical actin was well organized along the cell 
borders, while cortactin was diffusely distributed over the entire cytosol. The 
structure of cortical actin and the distribution pattern of cortactin seemed not to 
be affected after incubation of ADM and FSK. 
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Figure 33 Effect of ADM on cellular distribution of cortactin by using 
immunofluorescence microscopy 
HUVECs were grown on fibronectin-coated glass cover slides and incubated with vehicle (A), 
ADM (100 nM) (B), or FSK (10 µM) (C) for 30 min. Cells were fixed and permelized with 100% 
(v/v) ethanol (-20oC, 10 min) and stained for F-actin (red), cortactin (green), and nucleus (blue). 
Scale bars = 10 µm. 
B CA
 
 
In the next step, RNA interference technique was applied to down-regulate the 
gene expression of cortactin. Silencing of cortactin by SiRNA transfection 
reached its maximal effect after 48 h in human endothelial cells (Schnoor et al., 
2011) (Figure 34 A). Based on this result, assays for paracellular permeability 
for FITC-dextran (Figure 34 B) and transendothelial migration of human PMN 
(Figure 34 C) were performed 48 h after SiRNA transfection. Silencing of 
cortactin expression increased basal macromolecular permeability to 118.5 ± 
5.7% (mean ± SD), which could be reversed to 83.7 ± 5.0% (mean ± SD) with 
ADM treatment. In the lamin-SiRNA transfected control group, treatment of 
ADM reduced basal permeability to 81.8 ± 3.2% (mean ± SD), which was 
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identical with the ADM-treated cortactin-SiRNA transfected group. This 
observation suggested that a cortactin-independent pathway was partly 
involved in ADM signaling regulating endothelial permeability.  
 
Differently to endothelial permeability, down-regulation of cortactin expression 
decreased transendothelial migration of human neutrophils to 66.2 ± 5.4% 
(mean ± SD) of control SiRNA group. Similarly, in control-SiRNA group, ADM 
reduced transmigrated PMN to 66.2 ± 5.7% (mean ± SD) of vehicle group. 
However, in the group with down-regulated cortactin, ADM had no additional 
effect to 60.9 ± 2.6% (mean ± SD), meaning that the inhibitory effect of ADM on 
leukocyte transmigration disappeared in the absence of cortactin. In summary 
the consequences of cortactin knock down in HUVECs were inconsistent: with 
respect to leucocyte transmigration the data suggest a potential role of cortactin 
in ADM signaling but not with respect to endothelial permeability. 
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Figure 34 Role of cortactin in ADM signaling regulating endothelial permeability and 
granulocyte transmigration  
(A): HUVEC were transfected with either lamin- or cortactin-specific SiRNAs and after 48 h 
were lysed for immunoblotting to detect expression levels of cortactin. Blotting for tubulin was 
used as loading control. Transfected HUVECs were seeded on transwell filter for 48 h and were 
used for paracellular permeability for FITC-Dextran (B) and leukocytes transmigration assay 
(C). For both assays, the cells were incubated with vehicle or ADM (100 nM) for 30 min. The 
relative FITC or relative transmigrated PMNs were set to the control group with lamin-SiRNA. 
(n=6, mean ± SEM) (*p<0.05 and **p<0.005 as compared to lamin SiRNA-transfected group 
treated with vehicle; ###p<0.0005 and n.s. not significant p>0.05 as compared to cortactin 
SiRNA-transfected group treated with vehicle) 
 
 
5.6.2. Analysis of ADM effects on the background of disrupted actin 
cytoskeleton 
With the following experiments the question was addressed whether effects of 
ADM on endothelial barrier function are only based on its impact on actomyosin 
cytoskeleton. For this purpose, a mycotoxin which inhibited the actin 
polymerization, cytochalasin D (CytoD), was chosen to disrupt the endothelial 
actin cytoskeleton. The effects of ADM on junctional proteins and the 
cytoskeleton were investigated by laser scanning microscopy (Figure 35). In 
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quiescent cells, the staining for VE-cadherin around cell border represents a 
continuous straight line and staining of F-actin with Alex-555 phalloidin revealed 
a well-arranged structure of cortical actin fibers along the cell periphery (Figure 
35A). Cytochalasin D induced distortion of the linear structure of VE-cadherin 
with visibly defects of VE-cadherin staining, indicating intercellular clefts (Figure 
35B). In parallel, well-arranged distribution of cortical actin fibers along cell 
borders disappeared after treatment with cytochalasin D: the actin staining was 
intensely concentrated as a continuous straight line around the cell body and 
diffuse actin staining was also observed in the cytosol, indicating a severely 
disrupted endothelial cytoskeleton. Incubation of ADM prior to cytochalasin D 
seemed not to prevent the disruption of actin cytoskeleton, whereas the VE-
cadherin linear structure was reestablished and gap formation was prevented 
(Figure 35C). 
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Figure 35 Effect of ADM on VE-cadherin and actin fibers in endothelial cells with intact 
cytoskeleton.  
HUVECs were grown to confluence on fibronectin-coated glass cover slides, stained for F-actin 
(red) and VE-cadherin (green), nucleus (blue). Cells treated with vehicle (A) displayed well-
arranged cortical actin fibers with few stress fibers and continuous cell-cell junctions. Treatment 
with 300 nM cytochalasin D (B) caused a massive decrease of actin fibers, distortion of VE-
cadherin pattern and formation of intercellular gaps. Pretreatment of ADM prior to cytochalasin 
D (C) prevented VE-cadherin disruption and gap formation without affecting actin fibers. Scale 
bars = 20 µm.. 
10
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The effects of cytochalasin D on endothelial barrier integrity were further 
investigated by means of ECIS technique. As shown in Figure 36A, disruption 
of the actin cytoskeleton with cytochalasin D dose-dependently induced a rapid 
decline of TEER within minutes, which returned to baseline level after 13 hours. 
30 nM Cytochalasin D was the lowest dose to slightly decrease TEER to 92.4%, 
whereas 300 nM reduced the TEER to 31.4% and was also the maximal dose 
from which the cells were still able to recover after 13 hours. If the cells were 
pretreated with ADM for 30 min prior to cytochalasin D treatment, the dropdown 
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of TEER to 31.4% was reduced to 66.0%, with the amplitude of 34.6% (Figure 
36C). This amplitude was identical with the increase of TEER induced by ADM 
on control cells, suggesting that the effect of ADM was not changed by the 
treatment with cytochalasin D. In parallel, ADM was also administered after 
cytochalasin D, (Figure 36D). The decline of TEER to 31.4% induced by 
cytochalasin D was reversed by ADM to baseline within 2 hours and cells 
reached the same level of TEER followed by ADM on control cells after 12 
hours.  
 
In addition, the effects of cytochalasin D on macromolecular permeability were 
analyzed (Figure 36B). Cytochalasin D induced hyperpermeability over the time 
and reached its maximal effect to 140.0% of control group after 2 hours, 
whereas ADM reduced macromolecular permeability to 48.8%. The 
Cytochalasin D induced hyperpermeability was antagonized to 81.3% by pre-
treatment with ADM. The amplitude of ADM on cytochalasin D-induced 
hyperpermeability was 51.2%, identical with the direct ADM effect on basal 
permeability (51.2%). Taken all these findings together, in the endothelial cells 
with disrupted actin cytoskeleton, ADM could still stabilize barrier integrity with 
increased TEER and reduced macromolecular permeability, as well as VE-
cadherin distribution on cell borders. These observations implicate that effects 
of ADM on endothelial barrier function are at least partly independent of the 
actin cytoskeleton and lead to direct stabilization of the VE-cadherin dependent 
barrier function. 
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Figure 36 Effect of ADM on barrier integrity in endothelial cells with disrupted actin 
cytoskeleton.  
(A, C and D): HUVECs were grown on 96-well ECIS microelectrode plates and measurement of 
TEER was performed over 16 hour. Relative TEER was normalized to the TEER measured at 
the beginning of the experiment. (A): At the time indicated by the arrows, HUVECs were treated 
with vehicle or increasing doses of cytochalasin D (CytoD) (10 nM, 30 nM, 100 nM, and 300 
nM). (C): Endothelial monolayer was pre-incubated with ADM (100 nM) 30min prior to 
cytochalasin D (300 nM) treatment. (D): ADM (100 nM) administration was performed after 
maximal effect of cytochalasin D reached in ECIS. (B): ECs were cultured on transwell filters 
and paracellular permeability for 40kDa FITC-dextran was determined at different time points. 
(For ECIS, n=8, mean ± SEM; for FITC-dextran assay: n=6, mean ± SEM) 
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5.6.3. Effects of ADM on VE-PTP/VE-Cadherin complex 
Stability of the VE-cadherin-catenin complex is important for endothelial 
permeability (Vestweber, 2008). Increased tyrosine phosphorylation of various 
components of the VE-cadherin-catenin complex is correlated with the decrease 
of VE-cadherin-mediated adhesion. Vasoactive stimuli, such as histamine, 
thrombin, VEGF and TNFα, have in common that they induce phosphorylation 
of the VE-cadherin-catenin components and thus lead to destabilization of the 
complex (Angelini et al., 2006; Vestweber, 2008). An important regulator of this 
phosphorylation is the vascular endothelial protein tyrosine phosphatase (VE-
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PTP), which is associated with the Angiopoietin-1 receptor (Tie 2) and VE-
cadherin. The work by Nottebaum et al. demonstrates the important role of VE-
PTP in endothelial cell contact integrity. Down-regulation of VE-PTP expression 
inhibits VE-cadherin-mediated adhesion and thereby increases endothelial cell 
permeability and enhances leukocyte transmigration (Nottebaum et al., 2008). 
The importance of VE-PTP on regulation of cell-cell junctions raises the idea 
whether ADM mediates its regulatory effects in endothelial barrier function via 
action on VE-PTP. 
 
As previously reported, docking of lymphocytes to TNFα-stimulated endothelial 
cells leads to dissociation of VE-PTP from VE-cadherin and is followed by 
destabilization of the endothelial barrier function (Nottebaum et al., 2008). A co-
immunoprecipitation (CoIP) approach was performed to detect association and 
dissociation of VE-PTP from VE-cadherin in endothelial cells. Mouse brain 
endothelial cells bEnd.5 which expressed high level of ADM receptor (CRLR, 
RAMP2, and RAMP3) (see Figure 6) were chosen for this assay due to the 
availability of antibodies for mouse VE-PTP. Ovalbumin-specific antigen-
stimulated T-lymphocytes were freshly prepared from mice and allowed to bind 
to the TNFα-stimulated endothelial cells for 10 min, and thereafter were 
completely removed before lysing endothelial cells for CoIP, in order to avoid 
degradation of VE-cadherin by neutrophil proteases during the experimentation 
(Moll et al., 1998). Endothelial cell lysates were immunoprecipited by VE-PTP 
antibody and the amount of coprecipitated VE-cadherin with VE-PTP was 
visualized in immunoblots by use of a specific anti VE-cadherin antibody. 
Aliquots of total cell lysates were subjected to immunoblots for VE-cadherin and 
were handled in the same way as the aliquots subjected to 
immunoprecipitations during the entire experiment, to exclude proteolysis as a 
potential reason for weakened VE-cadherin signaling. Immunoprecipitation of 
cell lysates with no antibody and isotype control antibody served as negative 
controls to exclude unspecific binding of antibodies. As shown in Figure 37A, 
the amount of immunoprecipitated VE-PTP (middle panel) and control VE-
cadherin in total cell lysates (bottom panel) was at the same level in all 
samples, allowing a quantitative analysis of coprecipitated VE-cadherin (top 
panel). Upon docking of T-cells to the endothelial cells, the amount of 
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coprecipitated VE-cadherin was reduced to approximately 50%. Incubation of 
endothelial cells with ADM increased the amount of coprecipitated VE-cadherin 
to levels above control which was reduced to control level upon docking of T-
cells to endothelial cells. In conclusion, treatment of endothelial cells with ADM 
prior to exposure to T-cells could strengthen the associated VE-cadherin to VE-
PTP but could not abolish the T-cell induced dissociation of VE-PTP from VE-
cadherin.  
 
As another stimulus that leads to dissociation of the VE-PTP/VE-cadherin 
complex, VEGF was added to the starved endothelial cells for 30 min, and 
washed away before lysing endothelial cells for CoIP. As described above, 
endothelial cell lysates were immunoprecipited by VE-PTP antibody and the 
amount of coprecipitated VE-cadherin with VE-PTP was analyzed in 
immunoblots (Figure 37B). The amount of immunoprecipitated VE-PTP (middle 
panel) and control VE-cadherin in total cell lysates (bottom panel) were at the 
same level in all samples, allowing a quantitative analysis of coprecipitated VE-
cadherin (top panel). Stimulation of endothelial cells with VEGF reduced the 
amount of coprecipitated VE-cadherin to more than 50%. Incubation of 
endothelial cells with ADM increased the amount of coprecipitated VE-cadherin 
above control level, which was reduced to control level after VEGF stimulation. 
Also treatment with FSK increased the amount of coprecipitated VE-cadherin to 
above control level. VEGF stimulation after pre-treatment with FSK resulted in a 
reduction close to control levels. In conclusion pre-treatment of endothelial cells 
with FSK like ADM led to an increase of the VE-PTP/VE-cadherin complex in 
endothelial cells which was still sensitive to T-cell and VEGF induced 
dissociation. However the level of VE-PTP/VE-cadherin complex could be kept 
at normal levels. That the effect of ADM can be mimicked by FSK demonstrates 
its dependeny on cAMP mediated downstream signaling.  
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Figure 37 Effects of ADM on complex of VE-PTP and VE-Cadherin  
(A): Mouse T-cells were added to overnight TNFα stimulated bEnd.5 cells. 10 min later, T-cells 
were removed by washing with PBS, and VE-PTP was immunoprecipitated (middle) and 
coprecipitated VE-cadherin (top) was analyzed in immunoblotting. Immunoprecipitation of cell 
lysates with no antibody (VE-PTP-/-) and isotype control antibody (IgG) served as negative 
controls to exclude unspecific binding of antibodies. The expression level of VE-cadherin in total 
cell lysates (bottom) was immunoblotted to exclude degradation of VE-cadherin during the 
experimentation. (B): 100 ng/ml VEGF was added to bEnd.5 cells for 30 min and cells were 
lysed for immunoprecipitation of VE-PTP (middle). Co-precipitated VE-cadherin (top) and 
expression levels of VE-cadherin in total cell lysates (bottom) were analyzed by immunoblotting. 
Molecular weight markers (kDa) are indicated on the left. 
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6. DISCUSSION 
Vascular endothelium forms a semi-permeable barrier regulating the trafficking 
of macromolecules and blood cells across the blood vessel wall. Disruption of 
the endothelial barrier contributes to tissue edema and leukocyte extravasation, 
which are hallmarks of inflammation. The data from the present studies confirm 
the potent anti-edematous and anti-inflammatory effects of ADM in vitro and in 
vivo, and are in support of ADM as an attractive therapeutic target for 
inflammatory diseases. These effects of ADM are based on direct regulation of 
dynamic and static functions of the cytoskeleton (actomyosin-based 
contractility, cortical actin stability), and integrity of cell-cell junctions (VE-
PTP/VE-cadherin interaction), rather than on interference with specific signaling 
mechanisms of different inflammatory stimuli. Increase of intracellular cAMP is 
the most important downstream signaling event of ADM receptor activation in 
endothelial cells. As all barrier-protective effects of ADM can be mimicked by 
FSK, no other pathway than the cAMP-dependent pathway is likely to contribute 
to these effects. Dissection of the downstream cascade by means of cAMP 
analogs, specific for PKA and Epac-Rap1 signaling, demonstrates that both 
pathways are equally effective with respect to permeability. In contrast, 
granulocyte transmigration is only reduced by PKA activation, which decreases 
myosin light chain phosphorylation linking effects of ADM on leukocyte 
extravasation to modulation of the contractile apparatus of the endothelial cell. 
6.1. Effects of ADM in response to inflammation 
6.1.1. Effects of ADM on endothelial permeability 
The in vitro-ECIS methodology enables to show changes of electric resistance 
in endothelial cells in real time. As transendothelial electric resistance (TEER) is 
a surrogate for endothelial permeability, in addition, macromolecular 
permeability was directly determined in a second model in which labeled 
dextran was used as a tracer for permeability. Results from both systems are in 
line with the previous observations that ADM protects barrier permeability 
DISCUSSION   114 
seemingly in a way that is independent of stimuli (thrombin, VEGF, histamine, 
LI-1β, LPS, and TNFα) (Hippenstiel et al., 2002; Dunworth et al., 2008). 
Interestingly, ADM is therapeutically active even after effects of stimuli on 
permeability are fully established. As evident from ECIS data, the effects of 
ADM mainly consist in shifting endothelial resistance to higher levels rather than 
interfering with the stimulus induced reduction of TEER itself. It may be 
concluded that ADM exerts its effects via modulation of the factors determining 
endothelial permeability rather than counteracting specific signaling 
mechanisms induced by the different stimuli. 
 
To investigate whether the in vitro-situation could be translated into the in vivo-
models a modified Miles assay was applied. The Miles assay is a commonly 
used method to give information about the direct actions on vascular 
permeability in the skin using histamine as a short-acting agent causing 
microvascular leakage. Histamine contributes to vascular leakage in the course 
of acute inflammation associated with trauma, burns, and allergy. In line with in 
vitro-data, ADM reduces basal permeability, as well as antagonizes 
hyperpermeability induced by histamine in the skin of both rats and mice. It is of 
note that our present finding is in contradiction with previous reports (Grant et 
al., 2004; Tam et al., 2004), in which increased vascular permeability in the skin 
of mice after ADM administration was described. However, differing from our 
assay, ADM was directly injected into the skin of mice instead of intravenous 
administration, which might have caused increased vessel recruitment which 
potentially was misinterpreted as direct hyperpermeability (Grant et al., 2004; 
Tam et al., 2004). ). The anti-edematous effect of ADM in the Miles assay is the 
first in vivo-finding that demonstrates its direct action on basal vascular 
permeability rather than that on inflammatory disturbed barrier function. 
Moreover, in the LPS-induced lung injury model, ADM treatment reduces lung 
weight and protein contents in BAL fluid, which displays the anti-edematous 
action of ADM under inflammatory conditions. These findings substantiate that 
ADM stabilizes endothelial barrier function also in vivo and represents a 
strongly anti-edematous principle. 
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6.1.2. Effects of ADM on granulocyte extravasation 
Migration of leukocytes from the blood stream into the tissue at sites of 
inflammation is a key process of the immune system important for the clearance 
of infections and apoptotic cells. However, excessive or inappropriate 
translocation of leukocytes can contribute to pathological processes, such as 
atherosclerosis, multiple sclerosis, and rheumatoid arthritis. Overshooting 
leukocyte transmigration, predominantly of neutrophil granulocytes (PMN), is a 
hallmark of acute lung injury and accompanies disrupted endothelial barrier 
function. In the pre-experiment, the transmigrated leukocytes through TNFα 
stimulated HUVEC monolayer or in LPS-injured lung are mostly PMN (>95%). 
Thus, in the further experiments only this cell population was considered and 
discussed. ADM significantly prevents the TNFα-induced PMN transmigration. 
Notably, this is the first report about the direct effect of ADM on granulocyte 
extravasation in an in vitro-study, which may explain the beneficial effects of 
ADM observed in numerous in vivo-inflammatory models, in addition to its 
action on permeability. This finding is consistent with reduced white blood cells 
in BAL fluid in LPS-induced mouse models of acute lung injury.  
6.1.2.1. Direct actions of ADM on human neutrophils 
Neutrophils play an important role in the inflammatory reaction, such as acute 
lung injury. In animal studies of acute lung injury, both the lung tissues and 
bronchoalveolar lavage fluid exhibit dramatic neutrophil infiltration. Bacterially 
derived chemoattractants, such as LPS and fMLP, are shown to be able to up-
regulate CD11b/18 expression on PMN and ICAM-1 expression on endothelial 
cells, thus facilitating adhesion of neutrophils to endothelium and migration into 
inflamed tissue (Smith 1993). By using cAMP analogous Bt2cAMP in mouse 
lymphoid cell line and human PMNs, elevation of cAMP inhibits chemoattractant 
stimulation of α4β1-integrin in lymphoid cells, as well as β2-integrin triggering in 
neutrophils (Laudanna et al., 1997). This anti-adhesive effect of cAMP is 
downstream of RhoA dependent integrin-mediated adhesion (Laudanna et al., 
1997). However, in the transmigration assay used in the present study, ADM 
had no effects on adhesion of human PMNs to TNFα-stimulated HUVECs. 
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Notably, this adhesion assay was performed under static conditions. In vitro-
assays under flow conditions may give rise to different results.  
 
In the present study, the primary endothelial cells, HUVEC and HLMEC, 
expressed high levels of CRLR and RAMP2 (ADMR-1), which was in line with 
previously published reports (Wunder et al., 2008; Aslam et al., 2010). In mouse 
brain endothelioma cells (bEnd.5), CRLR, RAMP-2, and RAMP-3 (ADMR-1 and 
-2) are highly expressed. Similarly, CRLR, RAMP-2, and -3 (ADMR-1 and -2) 
are present in human PMN. While the expression level of CRLR and RAMP-2 in 
human PMN is comparable to that in human endothelial cells, RAMP-3 mRNA 
which is not detectable in endothelial cells is also abundantly expressed in 
human PMN. Despite the abundant expression of ADM receptor mRNAs, no 
functional cAMP signaling could be demonstrated in human PMN. FSK, 
however, induced cAMP albeit at higher concentrations than in endothelial cells 
and with lower efficacy. Increased intracellular cAMP in PMN is reported to 
antagonize fMLP-stimulated up-regulation of CD11b/18 as well as decreased 
bronchial epithelial cells (Derian et al., 1995; Friedman et al., 1998). ADM is 
also reported to suppress fMLP-induced up-regulation of CD11b/18 of human 
neutrophils, in a cAMP/PKA dependent manner (Saito et al., 2001). However, in 
the MPO activation assay neither ADM nor FSK had any influence on either 
fMLP or C5a activated PMNs. There was also no effect on CD11b expression 
on PMN after treatment with ADM by use of FACS analysis.  
 
Consistently, while transmigration of PMN through the HUVEC monolayer was 
significantly inhibited by treatment of HUVECs with ADM, pretreatment of PMN 
with ADM had no effects on their transmigration. Altogether these observations 
provide evidence that prevention of TNFα-induced granulocyte transmigration 
was rather mediated by direct action of ADM on endothelial cells than on 
granulocytes. 
6.1.2.2. Effects of ADM on gene expression of endothelial adhesion 
receptors 
The primary element of leukocytes transmigration is the interaction between 
leukocytes and endothelium, which is facilitated by adhesion proteins from both 
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endothelial cells and leukocytes, as well as by direct signaling exchange via 
adhesion proteins and cytokines (Panes & Granger, 1998). Rolling adhesion 
occurs when leukocytes first capture from the bloodstream and loosely tether to 
the endothelial cells lining the blood vessel wall due to transient selectin 
mediated weak interactions between endothelial cells and leukocytes (Barreiro 
et al., 2004). Upon this rolling adhesion step, leukocytes slow down to pass 
through the blood vessel, which allows binding to endothelial cells and exposure 
to a local environment that initiates the activation step. This activation step is 
triggered by chemokine signals, such as TNFα. In the next step, firm adhesion 
of leukocytes to the surface of endothelial cells is mediated through the 
interaction of Ig-family adhesion molecules, such as ICAM and VCAM on 
endothelial cells, and activated integrins on leukocytes. Activation and gathering 
of endothelial cell adhesion molecules trigger a variety of signals within the 
endothelial cells and facilitate progression to the final diapedesis step, in which 
immune cells enter to inflammatory sites in infected tissue along a cytokine 
gradient.  
 
In lymphatic endothelial cells, a genome-wide Microarray-analysis demonstrates 
that ADM profoundly suppresses gene expression of cell adhesion receptors 
and inflammatory factors, such as ICAM-1, VCAM-1, E-selectin, IL-8, and 
chemokines (Jin et al., 2011). Additionally, by using QRT-PCR and flow 
cytometry analysis, ADM dose-dependently suppresses the TNFα -induced 
mRNA and protein expression of ICAM-1 and VCAM-l in lymphatic endothelial 
cells (Jin et al., 2011). In HUVECs, ADM inhibits VEGF-stimulated ICAM-1, 
VCAM-1, and E-selectin mRNA expression through a phosphatidylinositol 3'-
kinase/Akt pathway, and reduces VEGF-induced endothelial adhesiveness for 
leukocytes (Kim et al., 2003). However, controversial results are shown in the 
studies from Hagi-Pavli and colleagues: ADM up-regulates ICAM-1 expression 
in oral keratinocytes via a cAMP- and NFκB-involved pathway, explaining the 
immunostimulatory role of ADM in oral muocsa and skin (Hagi-Pavli et al., 
2005). In addition, ADM is shown to induce cell surface expression of the 
adhesion molecules E-Selectin, VCAM-1, and ICAM-1 on HUVEC in a cAMP-
dependent manner (Hagi-Pavli et al., 2004).  
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In the Microarray analysis on HUVECs of the present study, down-regulation of 
adhesion molecules, such as ICAM-1, VCAM-1 and E-selectin, is observed 3 
hours after ADM administration. However, in the TaqMan®-QRT-PCR analysis, 
which provides more precise results than the microarray analysis, this 
observation on gene regulation of ADM under basal condition as well as after 
TNFα stimulation could not be confirmed. TNFα stimulation induces up-
regulation of ICAM-1, VCAM-1 and E-Selectin, facilitating adhesion of 
neutrophils to endothelium and transmigration to inflamed tissue sides. Either 
long-term or short-term administration of ADM showed no effect on the TNFα-
induced increase of ICAM-1, VCAM-1 and E-Selectin. The same was observed 
for the protein expressions of ICAM-1, VCAM-1, and E-selectin on cell surface: 
TNFα increases protein expression of adhesion receptors on cell surface, which 
is not influenced by ADM.  
 
Moreover, in the leukocyte transmigration assay, short term administration of 
ADM was already sufficient to inhibit leukocyte transmigration, while long term 
administration of ADM had no additional effects (data not shown). Therefore, it 
can be assumed that the effects of ADM on leukocytes transmigration are 
mostly based on its direct action on the dynamic regulation of this process 
rather than regulation of gene expression of adhesion molecules. 
6.1.3. Effects of ADM on endothelial cytoskeleton and junctions 
6.1.3.1. Effects of ADM on endothelial cytoskeleton 
Endothelial cell contractility driven by the mechanochemical interaction between 
actin and myosin is of vital role in regulating vascular contact integrity. The 
contractility is characterized by the formation of stress fibers, bundles of actin 
filaments associated with nonmuscle myosin II (Wojciak-stothard & Ridley, 
2002), and triggered by the phosphorylation of MLC, inducing myosin-actin 
cross-bridge cycling.In a simplified view contraction leads to dissociation of VE-
cadherin (which is anchored to the actin cytoskeleton) from its adjacent partner 
thus forming inter-endothelial gaps (Garcia et al., 1995). In the present study, 
ADM was shown to prevent thrombin- induced stress fiber formation and 
retraction of cell mass toward the center and prevented endothelial barrier 
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disruption, visualized by preserved VE-Cadherin lining at the cell borders. 
Consistent with these immunofluorescence study observations, ADM abolished 
the thrombin-induced MLC phosphorylation, indicative of reduced actomyosin 
based cellular contractility. The observation that ADM significantly relaxed 
endothelial contractility is in line with previous reports (Hippenstiel et al., 2002). 
However, in the endothelial cells with disrupted actin cytoskeleton triggered by 
cytochalasin D, ADM still remained its barrier protective effects, correlated with 
the increased TEER, reduced macromolecular permeability, as well as linear 
VE-cadherin distribution at the cell borders. This data implicate that the effects 
of ADM regulating endothelial barrier function in endothelial cells are at least 
partly cytoskeleton-independent.  
6.1.3.2. Effects of ADM on endothelial cell-cell junctions 
Amounting data from the literature reveal a fundamental role of ADM in 
regulating the organization of junctional proteins in particular supporting the 
ability of VE-cadherin to associate with peripheral cortical actin even after 
stimulation with thrombin, hydrogen peroxide and S. aureus α–toxin 
(Hippenstiel et al., 2002; Brell et al., 2005; Hocke et al., 2006). Moreover, 
concerning the blood brain barrier function, in primary brain microvascular 
endothelial cells of rats, ADM is shown to up-regulate expression of claudin-5 
(Honda et al., 2006). Additionally, in a recent study in lymphatic endothelial 
cells, ADM stimulation causes a reorganization of the tight junction protein ZO-1 
and the adherens protein VE-cadherin at the plasma membrane, independently 
of changes in junctional protein gene expression (Dunworth et al., 2008).  
 
The stability of VE-cadherin-catenin complex is dependent on its tyrosine 
phosphorylation status. Increased phosphorylation is correlated with the 
decreased adhesion. The vascular endothelial protein tyrosine phosphatase 
(VE-PTP), an endothelial membrane protein associated with VE-cadherin is 
known as an important regulator of this tyrosine phosphorylation thereby 
interfering with endothelial permeability and granulocyte extravasation in vitro 
and in vivo (Nottebaum et al., 2008; Broermann et al, 2011). Docking of 
neutrophil granulocytes or lymphocytes to TNFα-stimulated endothelial cells 
was shown to dissociate VE-PTP from VE-cadherin, thus leading to vascular 
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leakage (Nottebaum et al., 2008). Down-regulation of VE-PTP expression 
increased endothelial cell permeability, enhanced leukocyte transmigration, and 
inhibited VE-cadherin-mediated adhesion (Nottebaum et al., 2008). In the 
present CoIP study, ADM was demonstrated to strengthen the association of 
VE-cadherin to VE-PTP, which might explain the stabilization of ADM on basal 
barrier function. However, ADM could not completely abolish the VEGF or 
lymphocyteinduced dissociation of the VE-PTP/VE-cadherin complex. Notably, 
the present study highlights at the first time that ADM stabilizes the VE-cadherin 
junctional complex via its action on the VE-PTP/VE-cadherin association.  
6.2. Cellular signalling of ADM: the cAMP-dependent pathway 
ADM is a member of the CGRP super family and exerts its biological actions 
through binding to a CRLR/RAMP-2 and -3 receptor complex. RAMPs are 
essential for translocation of CRLR from the endoplasmic reticulum to the cell 
surface and regulate receptor specificity, ligand affinity, and receptor 
desensitization (McLatchie et al., 1998). The CRLRs and RAMPs are reported 
to play a role in the development and integrity of vasculature (Dackor et al., 
2006). Despite different tissue distribution of RAMPs isoforms, there are still no 
pharmacological differences between ADM-1 and -2 receptors to be observed 
so far. However, large tissue-specific analysis of the human and mouse 
transcriptomes shows that expression of RAMP2 is among the top 10 genes 
correlated with the expression pattern of CRLR, suggesting that most CRLR is 
coupled to RAMP-2 as a functional ADM receptor (Su et al. 2002; Gibbons et 
al., 2007). CRLR belongs to the super family of seven transmembrane GPCR 
and undergoes conformational changes resulting in coupling to cholera toxin-
sensitive Gs protein, activating adenylate cyclase and thus increasing second 
messenger cAMP (Mittra et al., 2006; Shimekake et al., 1995). 
6.2.1. The cAMP signaling in endothelial barrier function 
The intracellular second messenger cAMP is involved in a multitude of 
biological functions, ranging from metabolism, gene expression, cell division 
and growth, cell differentiation and apoptosis, as well as secretion and 
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neurotransmission. A large number of studies extensively document that 
stimulation of cAMP signaling stabilizes endothelial barrier function (Stelzner et 
al., 1989). However, several studies show the divergent effect of cAMP in 
endothelial monolayers of coronary artery origin (e.g. rat, swine, and guine pig) 
(Hempel et al., 1996; Noll et al., 1996; Watanabe et al., 1992), as well as in 
microvessels from the coronary system (Huxley et al., 1997), in hamster cheek 
pouch (Gawlowski & Duran, 1986), and adipose tissue (Sollvei & Fredholm, 
1981). In the study of Bindewald and colleagues, using adenosine analogs, beta 
receptor agonists and FSK the opposite response to cAMP in microvascular 
coronary endothelial cells (destabilization) and macrovascular aortic endothelial 
cells (stabilization) are observed and further analyzed (Bindewald et al., 2004). 
In both endothelial cells, contractile elements have identical response to cAMP, 
reducing phosphorylation status of MLC via activation of MLCP. However, in 
coronary endothelial cells, but not in aortic endothelial cells, an additional 
cAMP-mediated effect, delocalization of VE-cadherin and paxillin from cellular 
adhesion complexes, overrules cAMP-mediated relaxation effect on contractile 
elements and provokes a divergent effect on endothelial barrier function. This 
effect was most likely due to the loss of matrix adhesion rather than to the loss 
of intercellular barrier integrity and the in vivo-relevance is not established yet. 
 
In the present study, the cAMP elevating agent FSK like ADM showed in lung 
microvessel endothelial cells and umbilical venous endothelial cells 
concordantly stabilizing effects on barrier function, as reflected by increased 
electrical resistance, decreased endothelial permeability, and inhibited 
extravasation of granulocytes. Similar effect on endothelial barrier function was 
also observed by using unspecific PDE inhibitor IBMX (data not shown). The 
effects of FSK could be synergistically increased by IBMX (data not shown), 
underlining the robustness of pulmonary microvascular and umbilical vein 
endothelial cells as in vitro-model for the barrier stabilizing effect of cAMP in 
endothelial cells of different origins. 
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6.2.2. Correlation of ADM effects with cAMP signaling 
Driven by the fact that FSK, a direct activator of adenylate cyclase, although 
inducing much higher cAMP levels than ADM was less effective with respect to 
permeability it has been discussed that ADM may cause its effect also via 
cAMP-independent signaling  (Hippenstiel et al., 2002). However, the precise 
correlation of increased cAMP levels with their effects on endothelial barrier 
functions was not established in the studies. For this purpose, the 
pharmacology of ADM and FSK was re-evaluated, and their effects were 
quantified by using the lowest effective doses and pEC50 values. Throughout 
all the tested models, ADM and FSK showed qualitatively identical effects: both 
of them activated cAMP signaling pathways demonstrated by the activation of 
PKA and Epac/Rap1. Furthermore, both ADM and FSK were capable of 
increasing electrical resistance, decreasing macromolecular permeability, and 
inhibiting transendothelial migration of leukocytes. On a molar basis 
equivalently active doses (either with respect to pEC50 or minimal effective 
dose), FSK and ADM differed from each other overall by the same factor 
(~1000) in different models. This finding points at cAMP as the common 
signaling pathway in regulating barrier function.  
 
When changes of cAMP (∆cAMP over baseline) induced by equally effective 
doses of ADM and FSK were compared it was demonstrated that FSK requires 
3-5-fold higher cAMP concentration than ADM to achieve comparable effects on 
endothelial barrier function and activation of downstream events. The question 
was raised whether this quantitative difference of ADM and FSK is due to the 
different distribution of induced cAMP in endothelial cells. In a report by Rich 
and colleagues, a compartmentalized model of cAMP distribution is proposed 
that distinguishes between the microdomain and cytosol compartments (Rich et 
al., 2000). By using the cyclic nucleotide-gated (CNG) channels as cAMP 
sensors, which allow the real-time localized measurement of cAMP 
concentration in single cells, it was demonstrated that cAMP produced by 
transmembrane adenylate cyclase accumulates near membrane surface, and 
its further diffusion into cytosol is suggested to be hindered by the endoplasmic 
reticulum (ER) and plasma membrane invaginations such as caveolae (Rich et 
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al., 2000). The microdomain compartment of cAMP and its restricted diffusional 
access to the cytosol facilitate rapid and efficient activation of downstream 
events and also facilitate differential regulation of cellular targets (Rich et al., 
2000). Cyclic AMP gradients with decreasing concentrations from the 
subplasma membrane space toward the cell center have protective effects with 
respect to endothelial barrier function (Sayner et al., 2011). In contrast, reverse 
cAMP gradients with increasing concentrations in cytosol alter cytoskeleton and 
cell shape, leading to cell rounding and thus disruption of endothelial barrier 
function (Hong et al., 2005; Dal Molin et al., 2006). Edema factor of Bacillus 
anthracis activates a calcium- and calmodulin-dependent soluble adenylate 
cyclase, catalyzing the production of cAMP at the peri-nuclear region, which 
ultimately leads to the formation of transendothelial cell tunnels, barrier break 
down and edema (Maddugoda et al., 2011). Both FSK and ADM activate 
transmembrane G-protein coupled adenylate cyclase and induce microdomain 
compartment of cAMP, protecting endothelial barrier function. However, location 
of ADM receptor (CRLR and RAMP2/3) might be in close proximity to the target 
proteins, allowing that induced compartmentalized cAMP more sufficiently 
activate downstream signaling. This could explain the rather low difference of 
factor 2 to 3 between the cAMP levels needed for establishing equivalent 
effects by ADM and FSK, respectively. Notably all effects of ADM could be 
mimicked by use of FSK and moreover much higher efficacy in most assay 
systems was obtained upon dose escalation of FSK. This was clearly correlated 
to the much higher cAMP levels that were induced after FSK dose escalation, 
while induction of cAMP was saturated on a rather low level after escalation of 
ADM concentrations. This might be due to the limited number of ADM receptors 
of the cell surface limiting the signaling input. On the other hand this finding 
strongly supports the concept that all barrier protective effects of ADM are 
related to signaling via cAMP. 
6.3. Impacts of PKA and Epac/Rap1 on ADM signalling  
In eukaryotic cells, cAMP mediates its biological function via two ubiquitously 
expressed intracellular cAMP receptors, the classic protein kinase A (PKA) as 
well as the recently discovered exchange protein directly activated by cAMP 
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(Epac). Data of the present study show that ADM like FSK activates both 
pathways: activation of PKA pathway demonstrated by phosphorylation status 
of vasodilator stimulated phosphoprotein (VASP) as well as activation of 
Epac/Rap1 detected by use of a Rap1-pulldown assay. In order to find out to 
what extent the individual pathways contribute to the anti-edematous and anti-
inflammatory effects of ADM, the pathways were dissected by use of pathway 
specific cAMP mimetics, “007” for the Epac/Rap1 pathway and Benz-cAMP for 
the PKA pathway. In the present study, specificity of tool compounds for their 
corresponding pathways was demonstrated: Benz-cAMP specifically activated 
PKA pathway demonstrated by phosphorylation status of VASP in HUVECs and 
phosphorylation status of CREB in luciferase transfected CHO cells, while “007” 
specifically activated the Epac/Rap1 pathway detected by use of Rap1-pulldown 
assay but not vice versa. 
 
The coexistence of two cAMP effectors, PKA and Epac, allows a more precise 
and integrated control of cAMP-mediated signaling in a spatial and temporal 
manner (reviewed by Cheng et al., 2008). Firstly, PKA and Epac pathways can 
play distinct roles in a variety of biological processes. Epac but not PKA can 
mediate the prostanoid-mediated anti-proliferative effects (Haag et al., 2008). 
Epac/Rap1 pathway is exclusively involved in cAMP-mediated regulation of 
monocyte adhesion and chemotaxis (Lorenowicz et al., 2006). PKA is 
exclusively involved in the PGE2-induced inhibition of collagen I expression, 
while inhibition of fibroblast proliferation is exclusively mediated by Epac1 
(Huang et al., 2007). PKA activation but not Epac, has inhibitory effect on 
contractile activity of lung fibroblasts (Kamio et al., 2007). Secondly, Epac and 
PKA may play opposing physiological roles in different cell types (Mei et al., 
2002). Thirdly and most frequently, PKA and Epac signaling are interconnected 
in many cellular processes (Bos, 2006). The cAMP-activated signal pathways 
are interconnected in the regulation of endothelial barrier function. However, the 
exact crosstalk between both signaling is still not well understood. Particularly, 
the impacts of PKA and Epac/Rap1 signaling in ADM signaling are unknown 
and therefore are intensely investigated in the present study.  
DISCUSSION   125 
6.3.1. Impacts of cAMP signaling on anti-edematous effects of ADM 
In the present in vitro-study, both pathways were demonstrated to be equally 
involved in effects on regulating permeability, characterized by increased 
electrical resistance and reduced macromolecular permeability. Consistently, 
both pathway activators prevented vascular basal permeability and also hyper-
permeability induced by histamine in vivo. This finding was consistent with the 
previous studies that both PKA and Epac/Rap1 pathways exhibited permeability 
stabilized function (Birukova et al., 2010; Aslam et al., 2010).  In human 
pulmonary artery endothelial cells (HPAEC), agents like Prostaglandin E2 
(PGE2), prostacyclin, and atrial natriuretic peptide (ANP), are shown to induce 
cAMP elevation and subsequently stabilize pulmonary endothelial barrier 
function through both PKA and Epac pathways (Birukova et al., 2007; Birukova 
et al., 2008). Rac GTPase is further identified as a convergence point of PKA 
and Epac/Rap1 induced endothelial barrier protection (Birukova et al., 2010). 
Both PKA and Epac can activate Rac-specific GEFs, Tiam1 and Vav2, and 
converge on Rac activation, resulting in enhancement of cortical actin and 
adherens junctions. Down-regulating Epac, Rap1, Tiam1 and Vav2 by using 
SiRNA technique, as well as inhibiting PKA activity by PKI, all decrease Rac1 
activation and cAMP-mediated endothelial barrier enhancement (Birukova et al., 
2010). However, in the present study, both pathway activators were shown to 
synergistically enhance endothelial barrier function in vitro. In the Miles assay 
although both compounds effectively prevented histamine-induced 
hyperpermeability even no further additive effect was achievable upon 
combination of the used doses which might be explained by having reached the 
maximum achievable effect with the doses used. However, the synergistic effect 
of PKA and Epac/Rap1 activators in vitro suggested that both pathways do not 
regulate barrier function by simply converging in a Rac-dependent mechanisms.  
Indeed, PKA was reported to reduce endothelial MLC kinase activity, leading to 
decreased MLC phosphorylation and relaxed cellular contractility in a Rac-
independent manner (Birukova et al., 2004a; Yuan et al., 1997). Through 
phosphorylation on VASP, PKA could cause structural relaxation of the actin 
cytoskeleton linked to tight junctions via VASP-ZO-1 complex, thus stabilizing 
endothelial barrier function (Comerford et al., 2002). On the other hand, 
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Epac/Rap1 might directly enhance barrier function in a way of Rap1-dependent 
assembly of adherens junction and tight junction complexes in epithelial cell 
lines (Takai & Nakanishi, 2003; Birukova et al., 2010).   
6.3.2. Impacts of cAMP signaling on effects of ADM regulating 
granulocyte extravasation 
In the present study, ADM was demonstrated to inhibit granulocyte 
extravasation via its receptor activation and accumulation of intracellular cAMP. 
However, while the PKA activator Benz-cAMP inhibits leukocyte transmigration, 
which is comparable with the effect of ADM, “007” is shown to have no effect in 
this process. Even the combination of Benz-cAMP and “007” had no additional 
inhibitory effects on granulocyte extravasation, as compared to single treatment 
with Benz-cAMP. In a previous study, activation of Rap1 GTPase was reported 
to inhibit granulocyte transmigration by improving endothelial barrier function, 
whereas inhibiting Rap1 activity led to increased leukocyte transmigration 
(Wittchen et al., 2005). Notably, in the in vitro-leukocyte transendothelial 
migration assay used in the study by Wittchen et al., differentiated HL-60 cell 
lines instead of freshly isolated human PMNs were used for transmigration 
through the HUVECs monolayer, which might explain the different results. In 
line with this finding, a PKA inhibitor abolished the inhibitory effect of ADM on 
granulocyte transmigration, while the PKA inhibitor alone had no effects on 
granulocyte transmigration. These data are in support of a crucial role of PKA 
signaling in ADM-mediated regulation of leukocyte transmigration.  
 
For the paracellular transendothelial migration of neutrophils, the sequential 
opening and re-annealing of endothelial cell-cell junctions are required. 
Neutrophils release granular contents containing digestive enzymes and 
produce cytotoxic agents (e.g. reactive oxygen species and cytokines), inducing 
junction dissociation triggered by phosphorylation, actin stress fiber formation, 
and actomyosin contraction, subsequently causing endothelial 
hyperpermeability (Yuan et al., 2012). This mechanical disruption of endothelial 
barrier function was initially believed necessary for this process.  However, this 
conventional concept, the coupling between granulocyte transmigration and 
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endothelial hyperpermeability, has been recently challenged and discussed 
(reviewed by He, 2010; Yuan et al., 2012). The process of a neutrophil moving 
through two adjacent endothelial cells was demonstrated not to be 
accompanied with tracer protein leakage (Lewis and Granger, 1988). Both 
neutrophil and endothelial cell membranes were observed to remain in close 
contact during transmigration process using an immunofluorescence 
microscopic approach (Carman et al., 2007; Carman and Springer, 2004). 
Recently, granulocyte transmigration and endothelial hyperpermeability were 
shown to be temporally separated in aseptic cutaneous wounds: 
hyperpermeability preceded transmigration by several hours, and vascular 
permeability increased approximately threefold faster as compared to the rate of 
PMN influx (Kim et al., 2009). Indeed, in the present study, although PKA and 
Epac/Rap1 pathway differently influence granulocyte transmigration, both 
pathway activators were shown to attenuate PMN-induced endothelial 
hyperpermeability in the same manner (detected in ECIS model).  
 
Adherence of neutrophils induces increase of intracellular calcium concentration 
and activation of MLC kinase in endothelial cells (Saito et al., 1998). 
Subsequently, the signaling activates endothelial contractile apparatus and 
causes paracellular gap formation, being a key determinant of leukocyte 
transendothelial migration in response to inflammation (Garcia et al., 1998).  
MLC kinase phosphorylates MLC on serine 19, which subsequently facilitates 
the interaction of myosin with actin, leading to the actomyosin based contractile 
response. In our study, the MLCK inhibitor (ML-9) and the intracellular calcium 
chelator (BAPTA/AM) were shown to sufficiently inhibit leukocyte transmigration. 
In addition to MLCK, Rho kinase on one hand phosphorylates MLC on serine 19, 
and on the other hand phosphorylates the myosin –binding subunit (MBS) and 
inactivates MLC phosphatase, being also crucial in regulating the 
phosphorylation status of MLC (Kawano et al., 1999; Amano et al., 1996). 
BAY77-7549, a potent and highly selective Rho kinase inhibitor (Kast et al., 
2007) was shown to inhibit leukocyte transmigration. These data were 
consistent with the previous findings, suggesting that neutrophil-dependent 
activation of cellular contractility, indicated by phosphorylation status of 
endothelial MLC, could be a key determinant to regulate transendothelial 
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migration of leukocytes (Saito et al., 2001; Saito et al., 1998). In the present 
study, PKA activation was shown to reduce the phosphorylation status of MLC, 
whereas Epac/Rap1 activation was shown to have no effects on the same. 
However, the different data were reported by Birukova et al: phosphorylation of 
MLC was decreased by both PKA and Epac/Rap1 pathway activators (Birukova 
et al., 2010). It is of note that in their study human pulmonary artery endothelial 
cells instead of HUVECs were used to analyze the contractile apparatus. In 
another study using HUVECs, PKA activation but not Epac/Rap1 was also 
demonstrated to inhibit thrombin-induced phosphorylation of MLC and MLCP 
regulatory subunit MYPT1, partly via inhibition of the RhoA/ROCK pathway 
(Aslam et al., 2010). It is still unknown why PKA and Epac differently regulate 
contractile apparatus of endothelial cells from different origins. However, 
leukocyte adhesion and inflammatory hyperpermeability mainly occur in the 
postcapillary venules. Therefore, the endothelial contractility in HUVECs might 
be more predictive for the extravasation of PMN in vivo. In summary the data 
provide evidence that inhibition of leukocyte extravasation after cAMP signaling 
is linked to the contractile apparatus of the endothelial cell via PKA activation 
and subsequently reduced phosphorylation of the myosin light chain. 
Furthermore, these data underscore the concept that endothelial 
hyperpermeability and PMN transmigration are independently regulated 
processes and that hyperpermeability is not a prerequisite for transmigration 
because effective inhibition by activation of the Epac/Rap1 pathway is 
completely insufficient to inhibit PMN transmigration. 
6.4. Role of cortactin in cellular signalling of ADM 
Cortactin is one of the most important cytoskeletal components, and is identified 
as an F-actin binding protein and Src substrate. It is an 80 to 85 kDa actin-
binding protein involved in cortical actin assembly and dynamic actin 
rearrangement (Ammer & Weed, 2008). Cortactin is ubiquitously expressed with 
the exception that in leukocytes the cortactin-related protein hematopoietic cell-
specific Lyn substrate 1 (HS1) is expressed instead (Kitamura et al., 1989). The 
multidomain scaffold protein structure of cortactin facilitates multiple signals at 
locations of rapid actin rearrangement, such as sites of leukocyte adhesion and 
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transmigration. Cortactin stimulates actin polymerization by binding to the 
Arp2/3 complex in the cortical actin networks. The tyrosine residues 421, 466, 
and 482 within this proline-rich region of murine cortactin are identified as 
important targets of Src tyrosine kinases (Huang et al., 1998). Mutation of 
tyrosine residues with phenylalanine was previously shown to impair endothelial 
cell migration, which demonstrated the importance of tyrosine phosphorylation 
of cortactin in cytoskeletal regulation (Huang et al., 1998). 
Initially, cortactin was observed as a regulator of dynamic cytoskeletal 
remodeling involved in cell mobility. Recently, the role of endothelial cortactin in 
leukocytes transmigration and barrier integrity has been recognized 
increasingly. Following leukocyte adhesion or upon antibody-induced clustering 
of E-selectin or ICAM-1, cortactin was previously identified to become tyrosine 
phosphorylated and associated with adhesion molecules in human endothelial 
cells (Durieu-Trautmann et al., 1994; Adamson et al., 1999; Tilghman & Hoover, 
2002). This study suggested the role of cortactin in leukocyte transmigration by 
regulating adhesion molecule clustering on endothelial cells. Furthermore, 
silencing of cortactin by small interfering RNA (siRNA) was observed to inhibit 
leukocytes transmigration through HUVEC monolayer, accompanied by 
reduced accumulation of ICAM-1 at sites of neutrophil attachment (Yang et al., 
2006 a, b; Schnoor et al., 2011). In vivo, neutrophil extravasation into the TNF-
stimulated cremaster was inhibited in cortactin-deficient mice, which was 
caused by enhanced rolling velocity and reduced adhesion in postcapillary 
venules (Schnoor et al., 2011). More in-depth, cortactin supported neutrophil 
rolling via β2-integrin ligands instead of endothelial selectins, and cortactin 
facilicited firm adhesion via reduced ICAM-1 clustering around neutrophils 
(Schnoor et al., 2011).  
In line with the previous reports, silencing of cortactin by SiRNA in vitro was 
shown to increase endothelial permeability and reduce leukocyte 
transmigration. The cortactin knockdown-induced hyperpermeability could be 
reversed by ADM, suggesting that the cortactin-independent pathway was partly 
involved in ADM signaling on regulating endothelial permeability. In contrast to 
endothelial permeability, down-regulation of cortactin expression decreased 
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transendothelial migration of human neutrophils and abolished the inhibitory 
effect of ADM. These data suggest for the first time a crucial role of cortactin in 
ADM signaling to regulate granulocyte extravasation. Again these findings are 
in line with the concept that ADM influences endothelial permeability by both 
actin-dependent and actin independent pathways while its effects on PMN 
transmigration are solely dependent on actin modulating effects. 
6.5. Therapeutical potential of ADM for inflammatory diseases 
ADM is a multifunctional peptide which is able to act as an autocrine, paracrine, 
or endocrine mediator in many important and interrelated biological functions 
under normal and pathological conditions. Our present preliminary data 
evidences the beneficial effects of ADM during inflammatory processes, 
suggesting its pharmacological potency to treat human inflammatory diseases. 
Despite the wide expression of ADM throughout different organs and tissues, 
the receptor of ADM is demonstrated to be highly expressed in microvessels of 
lungs (Harel et al., 2008). Due to its specific receptor distribution ADM might be 
in particular of benefit for patients with acute lung inflammatory diseases (e.g. 
ALI or ARDS). ADM has been tested in several small clinical trials in humans for 
its potent hypotensive effects (Del Bene et al., 2000; Nagaya et al., 2000; Oya 
et al., 2000; Lainchbury et al., 1997; Lainchbury et al., 2000; Meeran et al., 
1997). All these studies demonstrated the safety of the endogenous peptide 
ADM in humans, being at significant advantage as compared to the direct 
adenylate cyclase activator (forskolin) with strong anti-inflammatory effects in 
vitro. The colforsin daropate hydrochloride (water-soluble forskolin derivative) 
has been approved in Japan as positive inotropic and vasodilatory compound to 
treat ventricular dysfunction in patients undergoing coronary artery bypass 
grafting (Kikura et al., 2004). However, due to unspecific effects of cyclic AMP, 
a number of side effects were observed in clinical trials, including 
tachycardia/palpitations, premature ventricular constriction, headache, hot 
flushes, as well as abnormal laboratory results (elevated LDH level, proteinuria, 
thrombocytopenia).  Based on these considerations, the development of ADM 
as an orphan medicinal product to treat life-threatening ALI is currently 
supported by the recent positive opinion of the Committee for Orphan Medicinal 
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Products of the European Medicines Agency (see the report from European 
Medicines Agency, EU/3/10/744). 
. 
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8. APPENDIX 
Compounds Function Structure 
BAPTA/AM Intracellular calcium 
chelator 
[1,2-Bis(2-aminophenoxy)ethane-N,N,N,N’-
tetraacetic acid tetrakis(acetoxymethyl ester)]  
 
BAY77-7549 Rho kinase inhibitor [6-chloro-N4-{3,5-difluoro-4-[(3-methyl-1H-
pyrrolo[2,3-b]pyridin-4-yl)oxy]-phenyl}pyrimidine-
2,4-diamine] 
 
Benz-cAMP PKA activator [N(6)-benzoyl-adenosine-3',5'-cyclic 
monophosphate] 
 
FSK (forskolin) Adenylate cyclase [(3R, 4aR, 5S, 6S, 6aS, 10S, 10aR, 10bS)- 
6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-
oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl 
acetate] 
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IBMX Unspecific PDE 
inhibitor 
[3-Isobutyl-1-methylxanthine] 
 
ML-9 MLCK inhibitor [1-(5-Chloronaphthalene-1-sulfonyl)-1H-hexahydro-
1,4-diazepine hydrochloride] 
 
Rp-8-Br-cAMP PKA-inhibitor [8- Bromoadenosine- 3', 5'- cyclic 
monophosphorothioate, Rp- isomer] 
 
W54011 C5a antagonist [N-((4-Dimethylaminophenyl)methyl)-N-(4-
isopropylphenyl)-7-methoxy-1,2,3,4-
tetrahydronaphthalen-1-carboxamide, HCl] 
 
“007” Epac/Rap1 activator [8-(4-Chlorophenylthio)- 2'- O- methyladenosine- 
3',5'- cyclic phonophosphate] 
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